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Thesis Abstract 
 
Background:  The mood stabilizer lithium has long been reported to be associated with 
reduced suicide risks, but many studies reporting associations between lithium and 
reduced suicide risks also have been nonrandomized and lacked adjustment for many 
potential confounders, active controls, uniform follow-up, or intent-to-treat samples.  
Concerns also have been raised that medications being considered as potential suicide 
preventative might increase risks of nonsuicide mortality while reducing risks of suicide.  
 
Methods:  Three studies of Veterans Health Administration (VHA) patients were 
conducted combining high-dimensional propensity score matching with intent-to-treat 
analyses to examine the associations between lithium and valproate and one-year suicide 
and nonsuicide mortality outcomes.   
 
Results:  In intention-to-treat analyses, initiation of lithium, compared to valproate, was 
associated with increased suicide mortality over 0-365 days among patients with bipolar 
disorder (Hazard Ratio (HR) 1.50 [95% Confidence Interval 1.05, 2.15])  Nonsuicide 
mortality among VHA patients with or without bipolar disorder was not significantly 
associated with the initiation of lithium compared to valproate   ( HR 0.92 [0.82-1.04]).  
Rates of treatment discontinuation, however, were very high (≈ 92%).  Longitudinal 
analyses revealed that the increased suicide risks associated with  initiating lithium 
among patients with bipolar disorder occurred exclusively after discontinuation of lithium 
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treatment.  In secondary analyses restricted to patients still receiving their initial 
treatment, there was no difference in suicide risk between the initiation of lithium or 
valproate.  
 
Conclusions:  Significantly increased risks of suicide were observed at one year among 
VHA patients with bipolar disorder initiating lithium compared to valproate, related to 
risks observed after the discontinuation of lithium treatment  Since these studies are 
nonrandomized, confounding may account for some or all of our findings, including the 
risks observed after lithium discontinuation.  Nevertheless, these results suggest that 
health systems and providers consider steps to minimize any potential lithium 
discontinuation-associated risk.  Approaches might include educating patients about 
possible risks associated with discontinuation and closely monitoring patients after 
discontinuation if feasible.  Given the obvious importance of any substantive difference 
between lithium and valproate in suicide or nonsuicide mortality risk, our studies also 
suggest that further research is needed, especially research that can further minimize the 
potential for confounding.   
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CHAPTER I 
 
 
Introduction 
 
 
The problem of suicide in the returning military is extremely well-recognized.1  
What particular interventions exist that may be effective for dealing with this important 
public health issue is far less well-known.  In fact, little is known about effective 
interventions to prevent suicide in any population.  For instance, there is only a single 
medication, clozapine, which has a United States Food and Drug Administration (FDA) 
indication for the reduction of suicidal behavior.  Unfortunately, clozapine is one of the 
most toxic and closely-regulated medications in all of medicine.  (In fact, some 
commentators have even voiced concerns that the use of clozapine to prevent suicidal 
behavior might increase mortality from its physical adverse effects approximately as 
much as it would decrease mortality by reducing suicide 2).  A handful of 
nonpharmacologic interventions against suicide have also been developed, 3 but, as 
evidence improves, the effectiveness of some of these interventions also has been called 
into question.  For example, one popular set of public-health oriented interventions, 
labeled “means restriction” has been found effective in some studies 4 but not others.5  
Finally, many of the nonpharmacologic interventions provided in clinical settings (e.g., 
particular psychotherapies6, 7) are also highly resource-intensive, requiring specialized 
training and sophisticated implementation.  
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In addition to that paucity of rigorous evidence concerning pharmacological and 
non-pharmacological interventions to address suicide risk, concerns have recently 
increased that several psychiatric medications intended to treat psychiatric conditions 
(antidepressants and anticonvulsants),8, 9 may actually increase, rather than decrease, the 
risk of suicidal ideation or behavior.   
*** 
Among the candidate pharmacological interventions currently available that lack 
FDA indications to reduce suicide or suicidal behavior, the medication that is best 
supported by existing evidence is lithium.  Ever since a well-publicized meta-analysis 
(primarily of observational studies) was completed 15 years ago reporting that lithium 
appeared to be associated with uniquely large reduction in suicide risk ( 5.6 to 8.6-fold 
reduction in risk),10 many psychiatrists have been aware of the possibility that lithium 
treatment might reduce suicidal behavior and death by suicide.  Treatment guidelines 
even went so far as to highlight this possibility.11  Subsequently, in data less appreciated 
by many psychiatrists, a meta-analysis of limited randomized evidence also observed a 
significant association of lithium treatment with reduced suicidal behavior and death by 
suicide.12  However, these studies in general have not focused on Veterans, and this 
evidence base, while encouraging, is beset with a number of limitations.   
One of the biggest concerns for the meta-analysis including observational findings 
is the conceivable (and perhaps even probable) possibility that until very recently patients 
started on lithium treatment might have been at lower risk of suicide than comparator 
medications, given that lithium may in certain circumstances increase risks of self-harm 
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upon overdose.13, 14  Thus, this meta-analysis, since it includes a number of 
nonrandomized studies from early in the use of lithium, likely summarizes study findings 
that are biased in favor of finding protective associations for lithium.  In keeping with this 
possibility, effect sizes have declined with subsequent updating of this meta-analyses.15  
 This meta-analysis helped inspire a large, well-publicized cohort study in 2003 
published in the Journal of the American Medical Association (JAMA).16  This study 
found lithium to be associated with significantly lower risk of suicide than valproate, with 
a large effect size (HR = 0.37, 95% CI 0.16, 0.91, p=0.03).  Lesser but still significant 
associations were observed for lithium compared to valproate for reduced suicide 
attempts requiring hospitalization (HR=0.59, 95% CI 0.43-0.83, p=0.002) or emergency 
room visits (HR=0.56, 95% CI 0.45-0.71, p<.001).  
This study, however, also contains the potential for numerous possible biases, 
including poorly-described covariates, a lack of information concerning the initial 
imbalances in many of these covariates among treatment groups, and, potentially most 
importantly, longer follow-up times for the lithium compared to the valproate treatment 
arm.16  This substantial difference in follow-up times likely resulted in a larger proportion 
of time at-risk for the lithium cohort accruing from the later stages of maintenance 
treatment.  Later stages of treatment, both through selection occurring during treatment 
and through the increasing passage of time from initial medication initiation (frequently 
observed to be a high-risk period for suicide or suicidal behavior17, 18) is likely to be a 
period of considerably lower suicide risk.  Permitting the lithium treatment arm to 
preferentially accrue longer follow-up time provides a comparison that is likely to be to 
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some degree biased.  One additional important aspect of JAMA cohort study was the 
observation, noted only extremely briefly, that suicide risk shortly after discontinuation 
of study medications was particularly pronounced.16  This is a concern because of 
literature suggesting prominent suicide and suicidal behavior risks occur shortly after 
lithium discontinuation,19-21 however it is unclear whether, while prominent, these risks 
are distinctive to lithium or are also associated with valproate discontinuation as well.22, 23   
Subsequent to the (primarily) nonrandomized study meta-analysis and the JAMA 
cohort study, a meta-analysis restricted to randomized clinical trials was published in 
2005.24  (This meta-analysis was subsequently revised in 2013,25 but the results are less 
succinctly summarized since no overall comparison of lithium to other active 
comparators is provided).  The original meta-analysis (2005) observed that lithium was 
significantly associated with a substantial reduction in suicide risk (HR = 0.26, 95% CI 
0.09, 0.77), although only 9 suicides were observed, including only 2 among patients 
receiving lithium.  
Most recently, a small randomized trial (n=49 patients randomized per treatment) 
designed specifically to examine the comparative effectiveness of lithium and valproate 
for suicidal behavior observed no significant different between the treatments, and only 
modest nonsignificant effect sizes (the time to first episode of suicidal behavior, or 
concerns about potential suicidal  behavior leading to a change in treatment, were 
approximately 16-25% lower in the lithium treatment arm).26  The 2013 meta-analysis 
combines these results with secondary findings from a recent trial examining the 
effectiveness of lithium and valproate in preventing mood episodes27 to give an overall 
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estimate for the difference in suicidal behavior risk between lithium and valproate 
treatment of OR = 0.64 (95% CI 0.30, 1.36, p=0.24).25   
*** 
One additional aspect of studies of suicide and suicidal behavior risk involves the 
concerns that have been raised that treatment studies of suicidal behavior may 
mischaracterize, to some degree, associations between treatments and suicide risk.  This 
is suggested in the pivotal trial observing efficacy for clozapine focused in preventing 
repeat suicidal behavior.28  While significant reductions in suicidal behavior was 
observed for patients treated with clozapine compared to olanzapine, doubt still exist 
about the overall effectiveness of this medicine to treat the most serious consequences of 
suicide behavior, death by suicide.  The reduction in risk of suicidal behavior did not 
appear to straightforwardly generalize to suicide, although numbers of suicides were very 
small (5 suicides were observed among patients initiating clozapine versus 3 suicides 
among patients initiating olanzapine).28 
Adding to this concern is the fact that generally only about half of suicides occur 
among individuals with prior suicidal behavior; this implies for half of suicide deaths the 
“pathway” to suicide death does not even include suicidal behavior.  Finally, certain risk 
factors for suicidal behavior have an opposite association for suicide risk.  Regarding 
gender, 3-4X as many women as men attempt suicide, but death by suicide is 3-4X as 
common in men versus women.  Similarly, with respect to age, suicide attempts are the 
most common in young people, but suicide deaths are most common in the elderly.  Even 
for lithium, some meta-analyses have observed that lithium appears to shift (decrease) the 
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ratio of suicides to suicide attempts, implying a greater association with reduced suicide 
than suicide behavior risks.29  Thus, concerns exist that investigating the more numerous 
(and convenient, for purposes of demonstrating statistical significance) events of suicidal 
behavior may convey an incomplete or potentially misleading picture of what 
interventions are the most likely to prevent death by suicide. 
 One final reason supports the investigation of death by suicide rather than, or in 
addition, to suicide attempts: the completeness of outcome data.  Events of suicidal 
behavior may fail to be documented in Veterans Health Administration (VHA) or any 
other non-universal health system records due to the receipt of out-of-system emergency 
care.  In contrast, deaths (by suicide or any other cause) are comprehensively recorded 
nationwide in the National Death Index, the accepted “gold standard” for mortality 
studies.   
*** 
The debates about clozapine mentioned above have highlighted another important 
issue in evaluating the ultimate clinical utility of any candidate suicide preventative:  the 
need to ensure that any intervention designed to prevent a relatively infrequent source of 
mortality, suicide, does not create risks for other causes of mortality that could easily 
outweigh any benefits in suicide risk reduction.  While suicide is a highly important, 
tragic, and potentially preventable cause of mortality (suicide currently ranks as the 10th 
leading cause of death in the United States), the incidence of suicide is much less 
frequent, on a population basis, than some other causes of death (most notably 
cardiovascular mortality).  Thus, comparatively small associations with increased 
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cardiovascular mortality associated with a candidate suicide preventative could easily 
more than counterbalance benefits resulting from even a substantial association with 
decreased suicide risk.  
Furthermore, the question of the potential associations of lithium (and comparison 
psychiatric medications) has its own independent scientific relevance.  Lithium is a very 
small ion (an alkali metal that is analogue to sodium and potassium) that penetrates 
almost all body tissues and has long been recognized to have potent biological effects.  
As early as 1892, experiments indicated that lithium can have profound influence on 
embryo development in sea urchins, and now it is recognized to influence development in 
a variety of organisms such as frogs and slime molds.30  It was later determined that 
lithium influences key second messenger systems such as phosphoinositides, and more 
recent investigations have found that lithium affects a host of other cellular targets as 
well.31  These cellular impacts likely lead to lithium’s well-known diverse impacts on 
physiology at the organ level.  These physiological effects range from the potentially 
beneficial (e.g., leukocytosis,32 reduced heart rate,33 and neurogenesis34) to the potentially 
hazardous (e.g., renal35, 36 and thyroid insufficiency,37 QTc prolongation,33 or 
arrhythmias38-40).   
 Trials designed to compare psychiatric interventions with a primary focus on 
suicide mortality, or even nonsuicide mortality, however, are exceedingly unlikely to 
occur.  First, mortality is not generally appreciated or thought about as a potential 
consequence of psychiatric treatment.  Thus it is unlikely that any trial focusing on such 
outcomes, at least as a primary outcome, will be acceptable to patient volunteers.  
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Moreover, many instances of poor outcomes in psychiatry (e.g., suicides or suicidal 
behavior) are preceded by clinical deterioration among patients (increased psychiatric 
symptoms, deteriorating psychosocial circumstances, and the initiation or worsening of 
substance abuse).  This potential foreshadowing raises the ethical responsibility during 
the trial to intervene (e.g., adding further medications, psychiatric hospitalization) to 
prevent the very outcome being studied.  In fact, modern clinical trials of suicidal 
behavior risks have used as the primary outcome both hospitalizations and/or other 
interventions (such as discontinuation, addition to, or change of the intervention 
medication) as part of a composite outcome.  Although highly necessary and desirable 
from an ethical and humane standpoint, it is well-recognized that these composite 
outcomes likely have a lack of comparability, to some important degree, with actual 
suicidal behavior or death by suicide.  The correlation of these composite outcomes with 
suicidal behavior or particularly death by suicide is particularly uncertain. 
 Thus, investigating the association of lithium and comparison medications of 
greatest public health interest on the outcomes of greatest public health interest (death by 
suicide and from all other causes), a major element of any evidence base is likely to be 
rigorously-conducted, extremely large-scale observational studies.  The next section 
describes some of the important challenges and opportunities of such research and the 
major approaches adopted in these studies to address these issues.  
*** 
 Although advances in nonrandomized comparative effectiveness research have 
been burgeoning over the past few years, fueled in part by major funding and 
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organizational initiatives focusing on this important field of health care research, it is 
well-known that nonrandomized studies of interventions have a greater potential for bias 
than randomized studies, and even than nonrandomized studies which are not 
investigating interventions.  This is due to the difficult-to-address phenomenon of 
confounding by indication.  In general, important clinical decisions made by providers 
and patients are likely to be influenced by factors that may potentially impact risk for 
outcome, and thus potentially bias the results of studies.  This poses a dual challenge.  
The first is, rather than address just a few pertinent risk factors (e.g., age, gender, race), 
as might be done in a prognostic or descriptive epidemiological study, a host of 
potentially clinically relevant risk factors may need to be examined, adjusted for, or 
controlled to ensure that confounding by indication is not overly biasing results.  These 
additional factors for consideration include, but are not limited to indicators of the 
severity the patient’s diagnoses/conditions, as reflected by the presence or absence of 
recent hospitalizations, current and recent medications taken for those conditions, the 
numbers and types of medical or psychiatric specialists recently seen, recent diagnostic 
tests received, as well as indicators of general mental and nonmental health care 
utilization and other demographics (e.g., rural versus urban residence, marital status, 
etc.).  
Among recent analytic innovations to attempt to address confounding by 
indication, an recently proposed approach likely to be particularly suited for application 
to rich observational datasets is the high-dimensional propensity score.  Introduced in 
2009, this method attempts to more fully address potential confounding by substantially 
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increasing the number of covariates that conceivably can be included in a model.  Many 
analytic methods are limited in the number of covariates that can be included through the 
number of outcome events.  However, propensity scores, by modeling the influence of 
outcome-associated measured covariates on exposure, rather than outcome, provide a 
mechanism to control for 10X or even 100X more covariates than past approaches.  
High-dimensional propensity scores formalize this approach by deliberately attempting to 
have this more numerous collection of covariates incorporate a broader range (i.e., 
dimensions) of potential confounding as well.  The initial manuscript describing this 
method included a number of covariates in each of 5 covariate dimensions.   While most 
analyses were restricted to 200 to 500 covariates, already a large number, one comparison 
in this initial manuscript included 4989 covariates in the model.41   
In addition, this technique gains added power when combined with matching or 
weighting methods.  These methods, especially propensity score matching, provide closer 
balance in the included covariates than methods that stratify on a limited number of 
categories (e.g., quintiles) 42 or incorporate the propensity score as a regression covariate.  
In addition, matching and weighting also have the beneficial property that these methods 
mimic in some ways the control of covariates obtained in a randomized trial.  The 
balance in pertinent covariates can be presented and readily grasped in a “Table 1” 
describing the treatment groups.  A very important limitation is, however, in contrast to a 
randomized trial, this balance only pertains to the measured covariates (and is sensitive to 
considerations of how completely they are measured and/or how correctly they are 
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modeled), and not to unmeasured covariates.  (Successfully randomized trials balance 
both measured and unmeasured covariates).   
The development and use of high-dimensional propensity scores has not been 
without controversy, especially concerning how variables to be included are selected.  In 
general, the high-dimensional propensity score leans in the direction of data-driven, 
rather than theory-driven, criteria for inclusion of covariates.  While this may seem 
attractive to some, these data-driven efforts have included tendencies to weight 
imbalances in prevalence between the treatment arms in variable selection (rather than 
simply prioritizing covariates based on their association with outcomes, rather than 
treatment exposure).  This approach of selecting covariates for inclusion based on part 
with their association with treatment exposure may introduce biases in the estimate of 
outcome risks.  In fact, it has recently been recognized that such a variable selection 
strategy has the potential to enhance a potential limitation distinct to propensity scores, 
the phenomenon of “bias amplification” (or the term we prefer, confounding 
amplification).43-47  Confounding amplification refers to the tendency as a propensity 
score becomes progressively more predictive of treatment exposure for the method to 
actually enhance, or increase, differences in unincluded confounders.  Stated another 
way, while the intent of high-dimensional propensity scores are to incorporate greater and 
greater confounding information into the score, leaving less confounding “unincluded,” at 
the same time the propensity score will be operating to enhance whatever small or large 
residual confounding after the large number of included covariates are brought into 
balance.  This potential inherent limitation to propensity scores may be especially 
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relevant to studies in which the likelihood of some unmeasured confounding is high, such 
as studies of mental health interventions.   
*** 
In addition to investigating the application and findings resulting from application 
of high-dimensional propensity scores to the rich VA clinical databases, the studies 
described here also incorporate several other important methodological enhancements 
compared to previous studies.  The most important of these enhancements include the 
quantification of intent-to-treat and “former user” risks.  Intent-to-treat estimates, still not 
routinely used for nonrandomized studies, perform two extremely valuable functions: 1) 
they help make effect estimates from nonrandomized studies more directly comparable to 
findings from randomized trials, and 2) they ensure that any risks arising after treatment 
discontinuation are considered in judgments of treatment effectiveness.  (As indicated 
above, previous research is suggestive that such risks may exist).  Risks observed among 
“former users” in the survival analyses refers to the risk observed for some patients after 
they discontinue their initiated treatment until they resume either treatment.  These risks, 
observed during a period of non-exposure to treatment, can serve as a useful index 
suggesting the amount of residual baseline confounding or confounding arising from 
selection of patients to discontinue treatment.48, 49  
An additional valuable facet to the studies described below is that temporal 
changes in confounding by indication, coupled with the restriction of our study to a more 
recent time period than most prior literature (1999-2008) is expected to provide a useful 
contrast to prior literature in an analytic sense.  Since our studies were restricted to the 
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period subsequent to or coincident with the publication of the meta-analyses, cohort 
studies, and treatment guidelines supporting lithium’s potential effectiveness versus 
suicide and suicidal behavior, the pattern of confounding may be substantially different in 
this study from much of the previous evidence.  (Even the 2003 cohort study was 
restricted to the period 1995 to 1999, before this literature had emerged and during a 
period in which valproate use might have been reserved for those who were most 
treatment-refractory).  While confounding by indication is never advantageous, the fact 
that confounding by indication may have reversed from prior periods so that higher risk 
patients were preferentially has some advantages.  If a comparable beneficial association 
between lithium and suicide risk can be observed comparable to what has been observed 
in past studies, then confidence would increase that at least some of this association is 
genuine may be increased given that the direction of bias deemed likely would have 
biased against observing this association, or at least favored this association less than 
previous literature.  
 There are other more basic aspects to study design that may have methodological 
advantages compared to prior studies, such as the use of incident-user samples,50 and 
modelling of potential baseline confounders in flexible forms (i.e., approaches which do 
not assume linearity) that also allow risks to vary substantial over time in the period 
preceding treatment initiation.  Also of importance is the focus on a fixed, uniform 
follow-up period after treatment initiation of likely clinical relevance: the first year after 
initiation.  The first six months to one year after treatment initiation is likely to be the 
focus of any clinical intervention particularly designed to address short-term suicide risk.  
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Finally, the studies reported here also have the methodological advantage of examining 
lithium use in two contexts: one in which confounding by indication may be highly 
prominent (suicide), and a second (nonsuicide mortality) where at least direct, conscious 
confounding by indication engendered by prescriber behavior would be expected to be 
more limited or potentially even minimal.  
This set of studies sought to apply the techniques of high-dimensional propensity 
scores, intent-to-treat estimates, and related techniques, to the crucial question of 
preventing suicide in Veterans.  These studies include a preliminary examination of the 
larger question of determining whether any suicide prevention benefits of a candidate 
intervention such as lithium are outweighed by mortality risks from other causes.  In the 
chapters that follow, we describe the implementation and findings of three studies 
designed to evaluate whether lithium is associated with reduced risks for suicide and to 
further investigate its association with other causes of mortality.  These studies are 
intended to both incorporate a sophisticated awareness of the potential limitations of 
nonrandomized treatment studies while advancing the evidence base concerning whether 
lithium should be considered as a candidate intervention to reduce suicide.  
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CHAPTER II 
 
 
Suicide Risk in Veterans Health Administration Patients with 
Mental Health Diagnoses Initiating Lithium or Valproate 
 
 
Abstract 
 
 
Background:  Lithium has been reported in some, but not all, studies to be associated 
with reduced suicide risk.  
 
Methods:  Intention-to-treat, high-dimensional propensity score-matched cohort study of 
one-year suicide mortality in Veterans Health Administration patients (n = 
21,194/treatment) initiating lithium or valproate from 1999-2008.  One-year suicide 
mortality was examined among all patients initiating lithium or valproate (intention-to-
treat analysis) who were matched on 934 propensity score covariates ranging from 
demographics, diagnoses, inpatient and outpatient encounters, current and recent 
medications, and indicators of recent suicidal behavior.  
 
Results:  No significant difference in suicide was observed over 0-365 days in the 
primary intent-to-treat analysis (lithium/valproate conditional odds ratio (cOR) = 1.22, 
95% CI 0.82, 1.81; p = 0.32), when individuals were still receiving their initial lithium or 
valproate treatment (cOR = 0.86, 0.46, 1.61; p = 0.63) or after such treatment had been 
discontinued/modified (OR = 1.51, 95% CI 0.91, 2.50; p = 0.11).  Significantly increased 
suicide risks in the first 0-180 days of follow-up were observed in secondary analyses of 
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individuals after discontinuation of their initial lithium, compared to valproate, treatment 
(OR = 2.72, 95% CI 1.21, 6.11; p = 0.015). 
 
Conclusions:  We detect no significant differences in one- year suicide risk between 
patients initiated on lithium compared to valproate.  However, we did observe an 
increased suicide rate shortly after individuals discontinued initial lithium compared to 
valproate, treatment.  The implications of this secondary finding would differ depending 
on whether the increased risk upon discontinuation relates more to risks associated with 
discontinuation of lithium versus valproate, or to the characteristics of the patients 
initiating and subsequently stopping each treatment (confounding).  Further research is 
needed to determine initiating lithium therapy may reduce suicide risk during active 
treatment, increase risk upon discontinuation, or both.  In the meantime, these results 
suggest that health systems and providers should consider approaches to minimize any 
potential lithium discontinuation-associated risk, including educating patients about 
possible risks associated with discontinuation and closely monitoring patients after 
discontinuation. 
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Introduction 
 
Reducing suicide is both an international priority and a particular need for 
Veterans.1  The mood stabilizer lithium has been reported to be associated with uniquely 
large reductions in risks of suicide and suicidal behavior.15, 16, 29  Many studies, however, 
have been nonrandomized and contained substantial methodological limitations, lacking 
adjustment for many potential confounders, active controls, incident-user designs, 
uniform follow-up, or intent-to-treat samples.14  A meta-analysis of 32 randomized trials 
of lithium reported significant reductions of suicide risk with lithium,12 as did a recent 
trial of lithium augmentation,51 but these findings were based on an extremely small 
number of outcomes (i.e., only 2 suicides total among patients receiving lithium).  
In contrast, other nonrandomized studies22, 52 and a recent small randomized trial 
of suicidal behavior53 report smaller, nonsignificant reductions in suicide or nonfatal 
suicidal behavior associated with lithium in comparison to another commonly-used mood 
stabilizer, valproate.  While nonrandomized studies provide the large sample sizes needed 
to determine associations between treatments and suicide, concerns exist that prior 
nonrandomized studies may have been confounded through preferential prescription of 
lithium to patients at low13 or lower14 risk of suicide.  Prescriber behavior may have 
changed substantially over the past 15 years, however, given well-publicized meta-
analyses,10, 20 treatment guidelines,11 and high-profile studies16 reporting that lithium 
treatment may be associated with distinct reductions in suicide risk.   
Using data from this more recent period, we sought to address confounding 
through methods intended to approximate some of the strengths of randomized trials.  In 
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addition to adopting a fixed follow-up time, these methods included: 1) matching patients 
based on a “high-dimensional” propensity score42 designed to be particular 
comprehensive in including information on potential confounders available from VHA 
administrative and clinical databases,41 and 2) deriving intent-to-treat and post-
discontinuation risk estimates.48  Propensity score matching can permit an unusually large 
number of covariates to be controlled, creating treatment groups closely similar in 
prevalence for numerous covariates (similar to a trial).  Intent-to-treat estimates ensure 
that confounding arising after treatment initiation from difference in the patients 
discontinuing each treatment to be controlled, and also have the advantage of ensuring 
that risks arising after treatment discontinuation are considered in judgments of treatment 
effectiveness.  Combining data from this more recent epoch of care with these 
methodological approaches, we conducted the largest cohort study to date examining 
whether suicide risk differs between patients initiated on lithium compared to valproate.  
 
Methods 
 
Data Sources 
Demographic, inpatient and outpatient mental and nonmental health treatment 
records, and outpatient pharmacy prescription data was obtained from the Veterans 
Health Administration (VHA) National Psychosis and Depression Registries54 (linked, 
de-identified healthcare databases of all VHA patients since 1997 with at least one 
psychotic or depressive disorder diagnosis).  This study was approved by the Institutional 
Review Boards of the Bedford and Ann Arbor Veterans Affairs Medical Centers. 
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Study Cohort 
Incident users (≥ 6 months of no lithium or valproate use) with recent VHA 
utilization (past year and a previous year) were identified among all patients with mood 
or psychotic disorders within the past 30 days receiving at least one outpatient 
prescription for lithium or valproate from April 1999 to December 2008.  These broad 
diagnostic inclusion criteria (Appendix 1-1) were chosen to maximize statistical power, 
given the comparatively few suicides expected, even in a large cohort, over a fixed one-
year follow-up period, and to facilitate the evaluation of lithium and valproate as widely-
useful suicide preventatives.  Prior research suggests that any effectiveness of lithium 
against suicide is not restricted to patients with bipolar disorder.51, 55  At least 89% of our 
cohort of the ultimate propensity score-matched cohort had an affective disorder 
(Appendix 1-1).  Individuals with potentially nonpsychiatric indications for treatment 
were excluded (epilepsy, cluster or migraine headache, or neuropathy diagnoses in the 
past 30 days; dementia medication use in the past 180 days; cancer, dementia, skull 
fracture diagnosis, traumatic brain injury diagnosis or treatment; home care or hospice 
care in the past year; or any nursing home residence or inpatient rehabilitation in the past 
2 years).  Patients were also excluded if they had started their mood stabilizer on an “as 
needed” basis or both mood stabilizers simultaneously (Appendix Figure 1-1).  
 
Exposure Determination 
Receipt of lithium or valproate was determined by outpatient prescription fills.  
For the primary “intent-to-treat” analysis, all individuals initiating treatment were 
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followed until end of follow-up (365 days), suicide, or death from other causes.  
Secondary analyses examined briefer follow-up times and/or stratified follow-up time by 
whether individuals were still receiving initial treatment.  Individuals were identified as 
“still receiving initial treatment” if they had not switched to or added the other treatment, 
nor discontinued the initial treatment (a ≥ 15-day gap between outpatient prescriptions, 
adjusted for early refills).  All other follow-up time was classified as occurring during the 
period when individuals had “stopped/modified” initial treatment.  Since this 
stopper/modifier group included individuals subsequently resuming either treatment, we 
secondarily analyzed suicide risks for individuals over 0-180 days that had stopped initial 
treatment and not resumed either treatment before suicide, other mortality, or the end of 
follow-up.  Risks observed after treatment discontinuation may reflect risks related to 
discontinuation of the medication (e.g., “rebound” mania or depression), but may also 
reflect differences in baseline risk between the treatment groups (i.e., confounding) still 
remaining in the analysis, or differences in selection occurring during follow-up.48  
 
Outcome 
Date and cause of death (suicide) was obtained from National Death Index files56 
for 1999-2009 using previously established definitions (International Classification of 
Diseases, Tenth Revision codes X60–X84, Y87.0, and U03).57 
 
Propensity Score Modeling 
An extensive set of 934 baseline covariates was derived (Table 2-1 and Appendix 
1-2) from VHA databases reflecting demographics, diagnoses, general VHA mental and 
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nonmental health healthcare utilization,41 hospitalizations, clinic use, diagnostic testing, 
current and recent prescriptions (Appendix 1-3), diagnosed suicide attempts and injuries, 
regional (state-level) suicide risk, and prior mood stabilizer treatment, often modeled 
over several time periods or with flexible forms (multiple indicator variables).  This 
approach follows the general aims of “high-dimensional” propensity score 
methodology,41, 58 but did not include automated variable generation or selection.  
Instead, a number of covariates in each utilization/diagnosis/medication domain were 
generally included, since the full determinants of suicide risk are not well understood, 
although covariates with a substantial association with treatment exposure were 
individually evaluated and removed if they were judged unlikely to be confounders.  
(Inclusion of variables that are substantially associated with exposure but are not 
confounders can actually increase confounding from uncontrolled factors).43, 44, 46, 59    
 
Statistical Methods 
The propensity score was calculated by logistic regression (c statistic=0.69).  We 
then 1:1 matched patients initiating lithium and valproate using propensity score calipers 
of 0.03 (0.2 standard deviations of the propensity score logit)60, 61 achieving 98.7% 
matching of lithium-initiated patients.  Balance in the prevalence of covariates between 
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Table 2-1.  Summary of Variables Included in the Propensity Score  
(Prevalence of each balanced within a standardized difference of <0.018 in final matched cohort) 
Type of Patient 
Characteristic Covariates Included 
General Covariates 
Demographics 49 Total Covariates including: Age (5-year categories), Sex, self-reported Race, 
Ethnicity, Marital Status, Income, Disability Status, Distance to VHA facility, 
Urban/Rural hospital location, and Year of Medication Start  
Psychiatric Covariates 
Presenting 
Diagnosis 
9 Variables, including Bipolar I, Bipolar II, Bipolar NOS, Major Depression, 
Depression NOS, Schizophrenia, Schizoaffective Disorder and Other Psychoses 
General Utilization 74 Covariates, including Total VA Mental Health (MH) Provider Visits x 6 time 
periods, Total MH hospitalizations x 2 time periods, Total Current MH 
Medications, Recently Discontinued MH medications, and Possibly Discontinued 
MH medications, and Total Diagnostic Interviews, Total Medication Management 
Visits, Total Individual Psychotherapy Visits, Total Group Psychotherapy Visits (all 
x 2 time periods) 
Comorbid Diagnoses 46 Covariates including PTSD, Other Anxiety Disorders, Adjustment Disorders, 
Personality Disorders, Somatoform Disorders, Impulse Control Disorders, Sleep 
Disorders, Eating Disorders, Sexual Disorders, Delusional Disorder, ADHD, 
Development Disorders, Cognitive Disorder NOS, and Dissociative Disorder 
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Table 2-1.  (continued) 
Comorbid Substance 
Abuse Diagnoses 
41 Covariates, including 4 Covariates (Abuse, Dependence, Remission from 
Abuse, and Remission from Dependence for each of the following: Alcohol, 
Amphetamines, Cocaine, Marijuana, Opioids, Sedatives, Other), with other 
covariates for Hallucinogen Abuse/Dependence/Remission, Combined Drug 
Dependence and Remission from Combined Drug Dependence, with and without 
opioids, Unspecified Dependence, and Alcohol intoxication and Alcohol or Drug 
psychoses 
Suicide Attempt 
Diagnoses 
9 Covariates, designating if Suicide Attempt diagnosed during NonMental Health 
(NonMH) hospitalization, MH hospitalizations, or as Outpatients, x 3 time periods 
(0-30d, 31-180d, 181-365d).  
Hospitalizations 10 Covariates, including whether Inpatient on Start Date, Within last 7 days, 8-30 
days, 31-180 days, and 181-365 days, Type of Latest Hospitalization (Psychiatric, 
Substance Abuse, Residential/Day program, Domiciliary), and whether any 
hospitalizations in last year involved an AMA discharge 
Specific Outpatient 
Utilization 
48 Covariates (all modeled as 0 visits, 1 visits, or 2+ visits): General Mental 
Health clinic, Psychiatry visits, Psychotherapy visits, Substance Use Disorder 
visit, Primary Care Mental Health clinic, Health Care for Homeless Veterans, and 
Substance Abuse and non-Substance Abuse visits, x 2 time periods (0-180 days 
and 181-365 days) 
Current Medications 24 Covariates, including Olanzapine, Risperidone, Quetiapine, Ziprasidone, 
Aripiprazole, Clozapine, First Generation Antipsychotics, Other Mood Stabilizers, 
SSRIs, SNRIs, Bupropion, Mirtazapine, TCAs, MAOIs, Benzodiazepines, other 
Hypnotics, Stimulants, Substance Abuse treatments, and other medications 
Recent Medications 
 
24 covariates, designating prescription received in last 180 days for same 
medication categories as “Recent Medications” but no prescribed supply 
extending to Lithium/Valproate start date  
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Table 2-1.  (continued) 
Prior Treatment 
History 
Prior treatment with Any Mood Stabilizer, Prior treatment with Lithium or Valproate 
Geographic Suicide 
Risk 
5 variables designating quintiles of Age-Adjusted State Suicide Rates (2000-2007) 
NonPsychiatric Variables of Possible Particular Relevance to Suicide Risk 
Nonpsychiatric 
Diagnoses 
7 covariates, including any Acute Injury, any Fracture, Blood Vessel injury, 
Internal injuries, Open Wounds, Poisoning, Inhalation/Drowning/Asphyxiation 
injury 
Nonpsychiatric 
Utilization 
6 covariates, including Pain Clinic visits (0, 1, 2+) x 2 time periods 
Nonpsychiatric 
Medications 
4 variables, including current Opiate Pain Medicine, recent Opiate Pain Medicine, 
and 2 types of overdose antidotes 
Also Included: 
Numerous covariates designating Nonpsychiatric Diagnoses, Nonpsychiatric Hospitalizations, 
Nonpsychiatric VHA Utilization (General and Specific), Nonpsychiatric Medications (current and recent), 
and Nonpsychiatric Diagnostic Tests. 
3 covariates recording prior VHA pharmacy use (any prior use, use in the last 180 days, and use in the 
last 365 days) were also included to help balance the extensiveness of pharmacy records among 
recipients. 
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the treatment groups were assessed using standardized differences (Table 2).  
Standardized differences are equivalent to Cohen’s d effect sizes, with a difference of ≥ 
0.10 often considered as indicating significant imbalance.42   
For the analyses of the intent-to-treat cohort or of individuals still receiving initial 
treatment, we used conditional logistic regression, whereas for individuals stopping or 
modifying treatment, ordinary logistic regression was used since matching was not 
rigorously preserved.   
Several additional secondary analyses were conducted, including comparing the 
prevalence between the treatment groups of diagnostically-coded suicidal ideation 
(V62.84, a code for suicidal ideation only available for the years 2005-2008) in the 30 
days prior to treatment initiation among the patients for whom this information was 
available (< 50% of the full sample).  We also compared the suicide risk associated with 
the treatment groups prior to matching, conducted a Cox regression analysis, and 
conducted a sensitivity analysis matching the sample with an alternative propensity score.  
All analyses were performed using SAS, version 9.3, except the standardized difference 
calculations (Microsoft Excel 2007). 
 
Results 
A 1:1 propensity-score matched cohort of 42,388 patients (including 102 suicides 
over 365 days of follow-up) was derived from 93,335 incident users of lithium or 
valproate meeting inclusion/exclusion criteria (Appendix Figure 1).  Patients initiating 
lithium and valproate were generally balanced even prior to matching on a wide variety 
of psychiatric and nonpsychiatric diagnoses, outpatient and inpatient utilization, and 
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medication covariates: only 17 (1.8%) of 934 covariates exhibited initial standardized 
differences of ≥0.10 between treatment groups.  Table 2-2 demonstrates the close balance 
achieved after propensity score matching between treatment groups for these 17 initially-
imbalanced covariates plus 14 established suicide risk factors.62-66  Similarly close 
balance after matching was observed for all other covariates (none of the 934 covariates 
had a standardized difference of even 0.018 after matching).  Despite the general balance 
in most covariates observed between the treatment groups prior to matching, propensity 
score matching led to a substantial reduction in the observed treatment effect estimate 
(initial 0-365 day Odds Ratio [OR]=1.45 [lithium/valproate], versus 0-365 day 
Conditional Odds Ratio (cOR)=1.22 after propensity score matching).   
The treatment groups also displayed very substantial, but highly similar, rates of 
stopping or modifying initial treatment:  47% of patients initiated on both lithium and 
valproate were still receiving their initial treatment at 90 days, 24% at 180 days, and only 
8% at 365 days (Appendix Table 1-1). 
Table 2-3A and 2-3B provides results for these extensively-matched treatment 
groups over the first year after medication initiation.  No significant difference was noted 
in the primary outcome (intent-to-treat 0-365 day cOR 1.22, 95% Confidence Interval 
[CI] 0.82, 1.81; p=0.32).  In addition, no significant difference was noted in a secondary 
analysis among patients during the period within the first year in which they were still 
receiving initial treatment (cOR 0.86, 95% CI 0.46, 1.61; p=0.63), an effectiveness  
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Table 2-2.  Characteristics of Patients Initiating Lithium and Valproate (Propensity-score 
Matched Sample) 
Patient 
Characteristica 
Lithium 
(n=21194) 
Valproate 
(n=21194) Standardized 
Difference N (%) N (%) 
 Demographics 
Age ≥50 years oldb 10244 48.3 10156 47.9 0.008 
SEX (Female)c 2894 13.7 2934 13.8 0.005 
RACE, White 16748 79.0 16793 79.2 0.005 
RACE, Black 2825 13.3 2770 13.1 0.008 
Married 7416 35.0 7298 34.4 0.012 
STATE SUICIDE RATE, 3rd quintile 3305 15.6 3251 15.3 0.007 
 Presenting Diagnosis
d  (Past 30 days) 
BIPOLAR I DISORDER 9562 45.1 9683 45.7 0.011 
BIPOLAR DISORDER,  
   Not Otherwise Specified (NOS) 1643 7.8 1661 7.8 0.003 
DEPRESSIVE DISORDER, 
    Not Otherwise Specified (NOS) 4214 19.9 4129 19.5 0.010 
SCHIZOPHRENIA  924 4.4 949 4.5 0.006 
OTHER PSYCHOSIS  252 1.2 255 1.2 0.001 
 Additional Psychiatric Diagnoses (Past Year) 
POST-TRAUMATIC STRESS 
DISORDER (PTSD) 4842 22.8 4749 22.4 0.010 
Alcohol Dependence 4426 20.9 4478 21.1 0.006 
 Recent Suicidal Behavior Diagnoses (past 30d, by location where diagnosed) 
NonMental Health Hospital- 
Diagnosed 28 0.13 24 0.11 0.005 
Mental Health Hospital-Diagnosed 30 0.14 32 0.15 0.002 
Outpatient Visit-Diagnosed 144 0.68 147 0.69 0.002 
 Recent Suicidal Behavior Diagnoses  (past 31-180d, by location where diagnosed) 
NonMental Health Hospital- 
Diagnosed 43 0.20 43 0.20 0.000 
Mental Health Hospital-Diagnosed 31 0.15 29 0.14 0.003 
Outpatient Visit-Diagnosed 90 0.42 82 0.39 0.006 
 Possible Suicidal Behavior-Related Diagnoses (past year) 
Any Acute Injury 3872 18.3 3884 18.3 0.001 
 Recent Discharge from Psychiatric Hospitalization 
Discharged in past 7 days 2232 10.5 2219 10.5 0.002 
Discharged in past 8-30 days 863 4.1 881 4.2 0.004 
Discharged in past 31-180 days 2024 9.5 2063 9.7 0.006 
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Table 2-2.  (continued) 
Current Psychiatric Medications 
OTHER MOOD STABILIZERS(S)  2891 13.6 2854 13.5 0.005 
SSRI antidepressant 7615 35.9 7666 36.2 0.005 
SNRI antidepressant  1988 9.4 2019 9.5 0.005 
Past Treatment History 
PRIOR MOOD STABILIZER 7503 35.4 7530 35.5 0.003 
Diagnoses, Nonpsychiatric (past year) 
MILD LIVER DISEASE 1747 8.2 1719 8.1 0.005 
Outpatient Utilization, Nonpsychiatric (past 180d) 
GASTROENTEROLOGY  
CLINIC, 1+ visits 
1102 5.2 1077 5.1 0.005 
Current Medications, Nonpsychiatric 
THIAZIDE DIURETIC  1499 7.1 1492 7.0 0.001 
ACE INHIBITOR  2764 13.0 2736 12.9 0.004 
NSAIDS 3491 16.5 3522 16.6 0.004 
a Patient Characteristics listed in ALL CAPITAL LETTERS are the 17 characteristics with a ≥ 0.10 Initial 
Standardized Difference (although these differences are far less after the propensity-score matching). 
b Age presented in this format (<50 years vs. ≥50 years old) to streamline its presentation within this 
Table.  Age was actually modeled using 11 indicator variables reflecting age groups from < 35 years old 
in 5-year intervals to ≥80 years old. 
c The proportion of females in the cohort is low because the Veteran sample is predominantly male. 
d Percentages for Indicating Diagnoses do not add up to 100%.  Some diagnoses were not substantially 
imbalanced and therefore not included in the Table, although they were included in the propensity score 
and matched upon (e.g. Major Depression, Bipolar II Disorder, Schizoaffective Disorder, and ≥2 Indicating 
Diagnoses in past 30 days).  
 
COVARIATES in ALL CAPITAL LETTERS designate those with an initial imbalance ≥ 0.10 
standardized difference prior to matching 
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Table 2-3.  Suicide Deaths and Rates over Time by Mood Stabilizer Treatment 
Table 2-3A. Primary Analysis (Intent-to-treat, 0-365 days) 
 All Patients Initiating Treatment (Intent-to-Treat Cohort)   
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Conditional 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-365 
days 21194 56 7.27 21194 46 5.98 
1.22a        
(0.82-1.81) 1.22 
Table 2-3B. 0-365 day Findings Stratified by Initial Treatment Status  
 During Exposure to Initial Treatmentb   
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Conditional 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-365 
days 21194 18 6.71 21194 21 7.68 
0.86c     
(0.46-1.61) 0.87 
 During Period After Stopping/Modifying Initial Treatmentd   
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-365 
days 19494 38 7.58 19362 25 5.05 
1.51e    
(0.91-2.50) 1.50 
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Table 2-3.  (continued) 
a p=0.32. 
b The counts of patients “During Exposure to Initial Treatment” include all the propensity score-matched patients, since 
all patients accrued at least some follow-up time in that status.  Counts of suicide deaths among these patients indicate 
suicide deaths occurring on a day in which the patient was classified as still receiving initial treatment.  That is, these 
counts represent suicide deaths occurring during the period covered by a prescribed supply of medication (without any 
co-prescription of the other medication), or during the gap(s) permitted after the prescription had ended, up until the day 
that the first gap of 15 or more days had occurred. 
c p=0.63. 
d The count of patients “During Period After Stopping/Modifying Initial Treatment” indicates all the patients who reach 
that status by the end of the follow-up period, since all such patients accrued at least some follow-up time during which 
they were not still receiving their initially assigned treatment.  That is, this is a count of patients modifying their initial 
treatment by switching to or augmenting with the other medication or discontinuing their initial treatment, either 
temporarily or permanently.  Counts of suicide deaths among these patients among these patients indicate suicide 
deaths occurring on a day after the patient had exited “still receiving initial treatment” status, whether by discontinuing 
or modifying their initial treatment. 
e p=0.11.  
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measure traditionally reported in many nonrandomized studies of lithium.  Finally, 
increased suicide risks during the 0-365 day period were observed, although not 
statistically significant, among patients once they had stopped or modified lithium, 
compared to valproate, treatment (Odds Ratio (OR) = 1.51, 95% CI 0.91, 2.50, p = 0.11). 
Additional secondary analyses (Table 2-4A and 2-4B) indicated an increased 
intent-to-treat risk of suicide of among patients initiating lithium over 0-180 days that 
was marginally statistically significant (Conditional Odds Ratio (cOR) = 1.56, 95% CI 
0.92, 2.69, p = 0.08), in association with significantly elevated risk of suicide among 
patients after stopping or modifying lithium, compared to valproate, treatment during this 
period (Odds Ratio (OR) = 2.72, 95% CI 1.21, 6.11, p = 0.015).  The differing risk of 
suicide between individuals stopping/modifying lithium treatment and 
stopping/modifying valproate treatment over 0-180 days was associated almost 
exclusively with those stopping, rather than modifying, treatment (Table 4, Footnote i: 
OR = 3.61, 95% CI 1.34, 9.73, p = 0.011).   
Figure 2-1 presents the intent-to-treat survival curve for suicide for the lithium 
and valproate treatment groups.  Because of nonproportional hazards (the crossing of the 
survival curves at approximately 90 days), the interpretation of the survival analysis 
(Appendix 1-4) is less straightforward than, but generally consistent with, the logistic 
regression results.  Table 5 indicates that recent suicidal ideation, as reflected by 
diagnostic code, was significantly more prevalent among patients initiating lithium than 
among those initiating valproate (OR = 1.30, 95% CI 1.09, 1.54, p = 0.003) for the 
19,411 patients for whom these data were available. 
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Table 2-4.  Suicide Deaths and Rates over Time by Mood Stabilizer Treatment over Briefer Time 
Periods (0-90 and 0-180 days)  
TABLE 2-4A. Intent-to-Treat Analyses 
 All Patients Initiating Treatment (Intent-to-Treat Cohort)   
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Conditional 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-90  
days 21194 18 9.35 21194 19 9.87 
0.95a      
(0.50-1.81) 0.95 
0-180 
days 21194 39 10.2 21194 25 6.54 
1.56b     
(0.94-2.58) 1.56 
TABLE 2-4B. Findings Stratified by Initial Treatment Status  
 During Exposure to Initial Treatment   
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Conditional 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-90  
days 21194 15 10.0 21194 17 11.3 
0.88d      
(0.44-1.77) 0.88 
0-180 
days 21194 17 7.99 21194 17 7.93 
1.00e      
(0.51-1.96) 1.01 
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Table 2-4.  (continued)  
 
During Period After Stopping/Modifying Initial Treatmentf 
  
 Patients Initiating Lithium Patients Initiating Valproate   
Follow-up 
Time 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Patients, 
No. 
Suicide 
Deaths, 
No. 
Rate 
(per 106 
person-
days) 
Odds Ratio 
(95% CI) 
Rate 
Ratio 
0-90  
days 11227 3 6.98 11185 2 4.75 
1.49g      
(0.25-8.95) 1.47 
0-180 
days 16138 22 13.0 15958 8 4.78 
2.72h,i      
(1.21-6.11) 2.72
 
a p=0.87. 
b p=0.08. 
c See Table 3, Footnote b. 
d p= 0.72 
e p>0.99. 
f See Table 2-3, Footnote d. 
g p=0.66. 
h p=0.015 
i Risks observed in patients stopping or modifying initial treatment were almost exclusively observed in patients 
stopping treatment (rather than modifying treatment or discontinuing and later resuming either treatment):      
Patients Stopping Lithium: Suicides = 18; Suicide Rate (per 106 person-days) = 18.3.  
Patients Stopping Valproate:  Suicides = 5; Suicide Rate (per 106 person-days) = 5.09.   
This yields an odds ratio of 3.61 (95% CI 1.34, 9.73) and a rate ratio of 3.60. 
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Figure 2-1.  365-day Survival Curve of Suicide by Treatment (Intent-to-Treat Analysis) 
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Table 2-5.  Presence of V-code (62.84) denoting Suicidal Ideation in the 30 days prior to Lithium or 
Valproate Initiation (2005-2008) 
 
 Patient Characteristic 
Patients 
Initiating Lithium 
Patients 
Initiating 
Valproate 
Odds Ratio 
(95% CI) P value 
Suicidal Ideation  305 237 1.30 
(1.09-1.54) 
0.003 
No Suicidal Ideation 9478 9391 
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Discussion 
 
This manuscript reports the largest study, to our knowledge, examining lithium’s 
association with suicide risk, and the first to use two design elements (propensity score 
matching and intent-to-treat analysis) intended to help nonrandomized studies better 
approximate findings from randomized trials.  Lithium treatment, compared to valproate 
treatment, was not associated with reductions in suicide risk among VHA patients with 
mental health diagnoses over the first year of treatment, either in the primary intent-to-
treat analyses or in secondary analyses of patients actively receiving their initial 
treatment.    
This study’s findings diverge from past meta-analyses.12, 15  Several potential 
reasons suggest themselves.  First, follow-up was only continued for one year (some 
studies have specifically reported that treatment with lithium for > 1 year was required to 
observe significant reductions in suicide risk).67-69  A second reason may relate to 
characteristics of this sample (a Veteran sample with high rates of treatment 
discontinuation).  High rates of treatment discontinuation would be expected to be 
especially influential in an intent-to-treat design, since effect estimates would 
substantially reflect risks observed during periods of nonexposure after discontinuation of 
treatment.  Furthermore, in naturalistic studies high rates of discontinuation can 
complicate interpretation of risks even among patients apparently receiving active 
treatment, since it cannot be clearly ascertained whether or when patients prescribed 
medication consume it.  Outcomes for patients who do not start a received prescription or 
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terminate it early may be ascribed to active treatment, but actually relate to the risks 
associated with nonexposure or treatment discontinuation.  Alternatively, some prior 
studies reporting large associations between lithium treatment and reduced suicide risk 
may have been biased by inadequately controlled initial confounding or differences in 
selection occurring during treatment.13, 14  
However, two other possibilities deserve consideration, since they are consistent 
with important elements of our data and would have implications for patients, providers, 
and healthcare systems.  Both relate to the statistically significantly increased suicide 
risks observed among patients discontinuing lithium at 0-180 days.  Risks among patients 
discontinuing treatment may result from several causes, including: 1) genuine new risks 
produced by medication discontinuation, and 2) intrinsic, non-treatment-related 
differences in suicide risk between the treatment groups (i.e., baseline confounding not 
resolved by the propensity score matching).  A third potential cause, differing tendencies 
between the treatment groups for high-risk patients to discontinue treatment (through 
self- or provider-based selection), may also contribute to these risks but appears unlikely 
to explain the entirety of our findings (Appendix 1-5A).  If risks observed after lithium 
discontinuation relate directly to discontinuing lithium, this finding would appear 
consistent with a substantial literature documenting pronounced suicide risks upon 
lithium discontinuation (e.g., suicide rates up to 14-fold greater than the rates observed 
during the prior lithium treatment).13, 20, 21  However, most of these studies were 
uncontrolled.  The only two prior studies directly comparing lithium and valproate 
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observed similar, not different, suicidal behavior risks among patients discontinuing 
either treatment.22, 23  
The substantial increased risks observed among patients discontinuing lithium 
over 0-180 days could also reflect potential confounding remaining after propensity score 
matching48, 49 (i.e., patients initiating lithium being at higher intrinsic suicide risk).  If 
active lithium treatment was associated with reduced suicide risks, then those reduced 
risks might largely counterbalance confounding in the analyses of the intent-to-treat 
cohort and of the patients still receiving initial treatment, leaving such confounding to be 
revealed primarily after treatment discontinuation.  It is unclear whether much 
confounding persists in our analysis, given the approximate initial balance observed in 
numerous measured factors and the further balance achieved after propensity score 
matching.  Several lines of evidence suggests, however, that if any substantive 
confounding does exists, it likely biases against lithium.  The effect of further increasing 
covariate balance through propensity score matching was to noticeably reduce initial 
effect estimates associating lithium with increased suicide risk.  This suggests the initial 
imbalance in propensity score covariates, although generally small, biased associations 
towards observing higher risks for lithium.  In addition, our data, while extensive, does 
not include information on several important risk factors (suicidal planning, means, 
recent stressors, and psychiatric symptoms, and, for some individuals, information on 
suicidal ideation).  Our analysis of diagnostically-coded suicidal ideation found modest 
but significantly higher rates among patients initiating lithium, even after the propensity 
score matching.   
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A role for chance is also important to consider in interpreting our findings, since a 
substantial number of comparisons were examined and only three statistically significant 
associations were observed: among patients discontinuing lithium compared to valproate 
over 0-180 days (Table 4), among all patients initiating lithium compared to valproate 
from 91-180 days, and among patients discontinuing lithium compared to valproate over 
91-180 days (Appendix 1-4).  Nevertheless, while our primary findings over 0-365 days 
indicate no statistically significant differences between the treatments, results from even a 
study of this size do not preclude potential clinically meaningful differences existing 
between the treatments below the power of this study to detect.  The significant risks in 
patients discontinuing initial lithium treatment over 0-180 days generally suggests some 
degree of nonequivalency between the treatments, with lithium being associated with 
distinct risks upon discontinuation compared to valproate and/or (if some or all of the 
risks associated with lithium discontinuation reflect confounding), with more positive 
benefit against suicide than suggested by our findings, especially during active treatment.  
Several study limitations should be noted.  Data limitations include gaps in 
prescription records for inpatients or patients receiving care outside the VHA, and 
potential errors in measurement of covariates.  Analytic limitations included the absence 
of rematching/reweighting of patients during follow-up.  This limitation precluded 
analysis of whether differences exist between the treatment groups during follow-up in 
either the initiation of, or persistence with, treatment with other psychiatric medications 
(e.g., antidepressants or antipsychotics).  This study was a study of typical care, rather 
than being restricted to monotherapy, unlike some recent studies.22, 23  Given that other 
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psychiatric medications may influence suicide risk,70, 71 strategies such as marginal 
structural models which reweight patients during follow-up should be considered in the 
future (Appendix 1-5A).  However, numerous classes of psychiatric medications 
prescribed at and before lithium or valproate initiation were very closely balanced 
between the two treatment groups, thus likely producing close similarity in concomitant 
medications, at least early during follow-up.  The absence of rematching/reweighting also 
precluded a determination of whether patients experiencing ongoing or emergent suicidal 
ideation or behavior during follow-up were more likely to be discontinued from one of 
the two treatments.  
In addition, serum medication levels would have provided information beyond 
simply prescription data about medication persistence, if these had been available.  Study 
findings might have been influenced by the considerable diagnostic heterogeneity of this 
patient cohort, although each individual diagnosis was closely balanced in prevalence 
among lithium and valproate recipients and almost 90% of our sample had mood disorder 
diagnoses (Appendix 1-1).  Our focus upon suicide mortality (comprehensively 
documented nationwide, even for patients who leave VHA care) improved outcome 
ascertainment compared to nonfatal suicidal behavior, but unfortunately limited statistical 
power.  Generalizability to non-VHA patients, to patients with the excluded medical 
conditions (e.g., cancer, head injury, or seizures), and to cohorts with differing rates of 
treatment discontinuation or that are treated for longer than one year is uncertain.  
Propensity score methods may also potentially inadvertently amplify any 
remaining confounding, primarily if variables are included that are substantially 
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associated with treatment (i.e., lithium or valproate initiation) but not outcome (i.e., 
suicide).46, 59  How much of a bias is typically produced is controversial.46, 72  
Nevertheless, the differences between treatment groups in baseline suicidal ideation 
diagnoses suggests some unaddressed confounding may remain in this study, and our 
particular implementation of propensity score matching included extensive variables in 
some domains (e.g., medical diagnoses) in which only a subset of variables may have 
been strongly related to suicide risk.  (However, Harris and Barraclough found that 90% 
of the medical diagnoses they reviewed were significantly associated with suicide risk).64  
To reduce the potential for amplification of remaining confounding (also termed 
“residual confounding”), we actively made judgments concerning inclusion/exclusion of 
the covariates that are of most concern (i.e., covariates with substantial associations with 
treatment).  In addition, extremely few propensity score covariates (< 2%) exhibited an 
initial substantial association with treatment (≥ 0.1 initial standardized difference), 
suggesting that few variables were included that would contribute substantially to 
residual confounding amplification.  Furthermore, a sensitivity analysis targeting this 
concern by removing a large number of variables (approximately half of the total) with 
the weakest apparent associations with suicide produced only modest effect estimate 
changes (Appendix 1-6).  Most importantly, the direction of change in the 0-365 day 
effect estimates from the unmatched (OR = 1.45) to the matched sample (cOR = 1.22) 
strongly suggests that overall confounding was most likely reduced by the propensity 
score matching, not amplified (Appendix 1-5B).  Therefore, any amplification of residual 
confounding appears to be sufficiently minor that the propensity score methodology still 
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produced an important reduction in overall confounding.  When comparing this study to 
other studies, however, it is important to note that residual confounding amplification 
could have potentially enhanced, to at least a slight degree, an apparent bias in this study 
against observing a protective association for lithium treatment against suicide risk.  
Nevertheless, our findings generally agree with the most recent randomized and 
nonrandomized studies.  With one exception73 recent nonrandomized studies of suicide or 
suicidal behavior risk have observed nonsignificant (and typically modest) differences 
between lithium and valproate, or lithium and anticonvulsants in general.22, 23, 74-77  
Recently, a small but methodologically-rigorous trial focused on suicidal behavior 
prevention53 observed only nonsignificant differences in suicidal behavior between 
lithium and valproate.  Results from this trial (involving 2.5 years of follow-up) and the 
BALANCE trial27 (involving 2 years of follow-up) were combined in an updated 
randomized trial meta-analysis25 which estimated that lithium treatment was associated 
with a nonsignificant reduction in nonfatal suicidal behavior compared to valproate (OR 
= 0.64, 95% CI 0.30, 1.36, p = 0.24).  These findings appear broadly consistent with this 
study, in that all three studies observed nonsignificant intent-to-treat differences between 
lithium and valproate.  The central estimate for lithium’s effect size, however, did differ 
in direction between the three studies (nonsignificantly decreased suicidal behavior risk 
in the trials versus nonsignificantly increased suicide risk in this study).  This difference 
might simply be due to chance, residual confounding (possibly augmented by residual 
confounding amplification), differences in follow-up time (one year versus 2-2.5 years), 
or differences in outcome (suicide versus suicidal behavior).  However, this difference 
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could also reflect a “two-sided” nature to lithium’s association with suicide risk.  That is, 
some degree of decreased suicide/suicide behavior-related risk may be associated with 
active lithium treatment (and thus contributing more greatly to the trial intent-to-treat 
estimates, which had much higher treatment persistence rates), combined with some 
degree of increased risk associated with lithium discontinuation (which would thus 
contribute more greatly to the intent-to-treat estimates in our study).  This possible “two-
sided” association between lithium and suicide risk would be also consistent with the 
significant differences in baseline suicidal ideation diagnoses between the treatment 
groups observed in this study (suggesting some residual confounding and thus a greater 
benefit to active lithium treatment than indicated) and the timing of the emergence of 
significant risks after lithium discontinuation (suggesting risks associated with 
discontinuation itself) (Appendix 1-5E). 
Clearly, our findings illustrate a need for further research (Appendix 1-7).  Until 
such research resolves whether the increased risks observed in patients discontinuing 
lithium relate specifically to lithium discontinuation, prudence suggests patient and 
provider education about the possible risks of lithium discontinuation and close 
monitoring of patients discontinuing lithium (and, potentially valproate22, 23 when 
feasible.  Such monitoring is already recommended to limit mood episode recurrences.78  
In addition, healthcare systems, providers, and patients should strive to maximize 
persistence with lithium treatment once initiated.  When discontinuation does occur, there 
may be value to facilitating a gradual discontinuation of lithium by patients when 
appropriate.79, 80 
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Conclusions 
In summary, this study did not observe significant benefits for lithium in 
preventing suicide compared to valproate among Veterans Health Administration patients 
over the first year of treatment.  This study is notable, however, for high rates of 
discontinuation of both lithium and valproate, and for the finding of increased suicide risk 
among patients discontinuing lithium over 0-180 days.  If such increased risk largely 
reflects confounding still persisting in the analysis, such confounding could conceal a 
clinically meaningful suicide preventative effect for lithium.  Alternatively, some or all of 
the risk among patients discontinuing lithium could represent genuinely greater risks of 
suicide related to lithium, compared to valproate, discontinuation.  Until further research 
more fully clarifies the relationships between lithium treatment, discontinuation, and 
suicide, patients initiating lithium should be educated concerning the possible risks 
associated with lithium discontinuation and the need to maximize persistence with 
lithium treatment, and receive close monitoring after discontinuation if feasible.  Further 
research incorporating intent-to-treat approaches is clearly needed, given the possible 
beneficial or hazardous effect sizes still compatible with this study’s results, the pressing 
need for interventions against suicide, and the broad potential use of lithium. 
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Chapter III 
 
 
Nonsuicide Mortality Associated with Lithium and Valproate 
Treatment of US Veterans Health Administration Patients 
with Mental Disorders 
 
 
Abstract 
 
Background/Aims:  To assess associations between lithium, valproate, and nonsuicide 
mortality.  
 
Methods:  Intention-to-treat, high-dimensional propensity score-matched incident-user 
cohort study of Veteran’s Health Administration (VHA) patients with mood or psychotic 
disorders newly initiating lithium or valproate from 1999-2008 using Cox regression  
(n=21, 288/treatment).  
 
Results:  Matching produced treatment groups closely similar in every one of an 
extensive set of measured covariates (all standardized differences < 0.019).  Significant 
differences between lithium and valproate were not observed for our primary, intent-to-
treat analysis over 0-365 days (HR = 0.92, 95% CI 0.82, 1.04).  Lithium initiation was 
associated with significantly reduced nonsuicide mortality in the intent-to-treat cohort for 
the secondary endpoint of 0-90 days (HR = 0.67, 95% CI 0.51, 0.87).  In other secondary 
analyses, a sizeable reduction in mortality was observed during active treatment with 
lithium across all time periods studied (e.g., 365-day HR = 0.62, 95% CI 0.45, 0.84), but 
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significantly increased risks were observed among patients discontinuing lithium by 180 
days (HR = 1.54, 95% CI 1.01, 2.37).    
 
Conclusions:  Patients initiating lithium had did not have substantially lower nonsuicide 
mortality than patients initiating valproate for our primary endpoint of 0-365 days.  In 
secondary analyses, lower hazards of nonsuicide mortality were observed for patients 
initiating lithium compared to valproate over 0-90 days (intent-to-treat analysis).   
Consistently lower nonsuicide mortality was among patients maintaining treatment, but 
elevated risk among patients discontinuing treatment by 180 days.  While residual 
confounding or selection effects cannot be excluded, this study suggests potential benefits 
to enhancing lithium treatment persistence and monitoring of patients discontinuing 
lithium, and identifies important needs for further research.  
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Introduction 
 
While a substantial literature exists concerning the potential association of lithium 
with reduced suicide mortality, very few studies have examined lithium’s potential 
influence on nonsuicide mortality.  Many organ systems are exposed to lithium,81, 82 and 
lithium produces diverse physiological effects.  Some of these effects are potentially 
beneficial (e.g., leukocytosis,32 reduced heart rate,33 and neurogenesis34), while others are 
potentially hazardous (e.g., renal35, 36 and thyroid insufficiency,37 QTc prolongation,33 or 
arrhythmias38-40).  A limited number of studies, primarily83-90 but not exclusively12 
nonrandomized, have examined associations between lithium treatment and nonsuicide 
mortality.  These studies are consistent with the possibility that lithium might reduce 
mortality risk in psychiatric patients.  Determining the effects upon nonsuicide mortality 
of lithium or other psychiatric treatments is clearly important, especially since patients 
with serious mental illness are at particular risk for premature mortality.91-94  
We conducted a nationwide cohort study of the United States (US) Veterans 
Health Administration’s (VHA) detailed clinical databases, employing two methods 
intended to increase the likelihood that observational studies will yield results similar to 
randomized trials: high-dimensional propensity score matching and intent-to-treat 
estimates.  High-dimensional propensity score matching permit inclusion of particularly 
detailed information concerning potential confounding while facilitating the assessment 
of the balance in these potential confounders that is achieved between treatment groups.  
Intent-to-treat estimates enhance interpretation of results by allowing assessment of 
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whether benefits during active treatment are negated by risks upon discontinuation.  
Employing these approaches, we investigated whether initiation of lithium was associated 
with reduced nonsuicide mortality compared to initiation of valproate, a treatment which 
has largely replaced lithium in many countries.95-98 
 
Methods 
 
Data Sources 
Demographic characteristics, inpatient and outpatient mental and non-mental 
health treatment records, and outpatient pharmacy prescription data was obtained from 
the VHA National Psychosis and Depression Registries.54  (These registries are linked, 
de-identified healthcare databases of all VHA patients nationwide since 1997 with at least 
one psychotic or depressive disorder diagnosis).  This study was approved by the 
Institutional Review Boards of the Bedford and Ann Arbor Veterans Affairs Medical 
Centers. 
 
Study Cohort 
 
Incident users50 (≥ 6 months of no lithium or valproate use but with recent VHA 
utilization) receiving at least one outpatient prescription for lithium or valproate from 
April 1999 to December 2008 were identified (Appendix 2-1).  A broad cohort of patients 
with mood or psychotic diagnoses in the 30 days prior to medication initiation was 
examined since the limited prior literature concerning lithium and mortality is not 
restricted to bipolar disorder (Appendix  
2-2).12, 84, 86, 90  
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Patients with possible non-psychiatric indications for valproate or lithium 
(epilepsy, migraine or cluster headache, or neuropathy diagnoses in the past 30 days; 
dementia medication use in the past 180 days; cancer, dementia, skull fracture diagnosis, 
traumatic brain injury diagnosis or treatment, home care, or hospice care in the past year; 
or any nursing home residence or inpatient rehabilitation in the past two years) were 
excluded.  Patients were also excluded if they initiated lithium or valproate on an “as 
needed” basis, both medications simultaneously, or resided outside the United States. 
 
Exposure Determination 
Receipt of lithium or valproate was defined by a fill of an outpatient prescription 
for these medications.  For the intent-to-treat analysis, all patients filling an initial 
outpatient prescription were followed until end of follow-up (i.e., 90, 180, or 365 days) or 
death. 
Secondary analyses stratified follow-up time by whether patients were still 
receiving initial treatment.  Patients were considered “as-initially-treated” until a ≥15 day 
gap occurred between outpatient prescriptions (adjusting for early refills), or upon 
initiation of the other mood stabilizer (i.e., lithium or valproate).  Patients were 
considered “former users” for the period of time after initial treatment discontinuation 
until follow-up time was censored upon subsequent treatment resumption or switching (to 
the other treatment), death, or the end of follow-up.  Given that this “former user” follow-
up period is free from exposure to either medication studied, former users have been 
advanced as a possible index of the potential biasing effects of residual baseline 
confounding and/or selection occurring during treatment.48, 49  However, risks among 
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former users can be more fully conceptualized as representing the combined effects of 
residual confounding and selection along with any persistence of effects from active 
treatment, and any risks produced upon treatment discontinuation (Appendix 2-3).  These 
“discontinuation-associated risks” would include effects such as “rebound” mania or 
depression. 
 
Outcome 
Date and cause of death was obtained from National Death Index files for 1999-
2009.56  This study was limited to nonsuicide mortality, with follow-up time for patients 
dying of suicide censored at suicide death. 
 
Propensity Score Modeling  
 
948 covariates derived from VHA databases were included in an initial propensity 
score model generally following the “high-dimensional” propensity score approach41, 58 
(Appendix 2-4).  These covariates included potential risk factors for both non-suicide and 
suicide mortality99 (including demographic characteristics, diagnoses, general VHA 
mental and non-mental health services utilization,41 hospitalizations, clinic use, 
occurrence of diagnostic testing, current and recent prescriptions, recent injuries and 
diagnosed suicide attempts, and state-level and VHA-hospital subsystem mortality 
risk100) (Appendices 2-5 and 2-6), often with multiple indicator variables to allow for 
nonlinear covariate-mortality relationships.  An “outcome-focused” propensity score was 
then derived limiting covariates to the 523 covariates with substantial associations with 
outcome101 (i.e., +/- 20% change in nonsuicide mortality).102  Further details of how this 
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covariate restriction was implemented are provided in Appendix 2-6.  This outcome-
focused propensity score, intended to limit unintended amplification of confounding 
which remained uncontrolled, 46, 59, 101 provided the basis for the results reported here.  
Results from analyses using the initial propensity score are provided in Appendix 2-7.  
The results from the two models are generally similar but differ in a few important 
details, such as the time periods for which significant associations are detected.  
  
Statistical Methods 
The propensity score was calculated using logistic regression.  Patients initiating 
lithium and valproate were 1:1-matched (Appendix 2-8) using calipers of 0.2 standard 
deviations of the propensity score logit,60,61 resulting in 99.3% matching of lithium-
initiated patients.  Balance in covariates between treatment groups was assessed using 
standardized differences (equivalent to Cohen’s d effect sizes, with a difference of > 0.10 
indicating significant imbalance).42   
Statistical significance was determined using techniques that reflected matching 
(stratified Cox regression with sandwich variance estimators) for the primary intent-to-
treat analyses and the secondary as-treated analyses.  Ordinary Cox regression was used 
for the secondary former user analysis (since matching was not preserved for this 
analysis).  All analyses except standardized differences performed using SAS, version 
9.3.  Standardized differences were calculated using Microsoft Excel 2010.  
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Results 
 
The incident user cohort of 93,162 patients initiating lithium or valproate was 
generally balanced (standardized difference < 0.10)42 between the treatment groups in 
virtually all non-mental health and mental health covariates even prior to matching.  After 
matching, substantial additional balance was achieved between treatment groups 
(n=21,288 patients per group).  As an end result, high-dimensional propensity score 
(hdPS) matching achieved a very close balance (standardized differences <0.019) for 
each one of the 523 covariates included in the outcome-focused analysis.  Table 3-1 
indicates the standardized differences in the matched cohort for two categories of 
covariates: 1) those few variables with a substantial imbalance (≥ 0.10 standardized 
difference) between treatment groups initially, and 2) a number of additional covariates 
with well-established or highly plausible relationships with nonsuicide mortality.  These 
additional covariates include age, sex, disability status, recent number and types of 
hospitalizations, and particular diagnoses, medications, and attendance at certain 
outpatient clinics.  Comparison of the unmatched and hdPS-matched effect estimates 
indicate that hdPS-matching reduced effect sizes in a direction consistent with reducing 
baseline confounding biasing against valproate (Appendix 2-9). 
Impersistence with treatment was very common even within 180 days, but rates of 
treatment impersistence were highly similar between the treatment groups:  76.4% of 
patients initiating lithium and 75.4% initiating valproate did not persist with initial 
treatment for 180 days (Appendix 2-10). 
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Table 3-1.  Characteristics of Patients Initiating Lithium and Valproate  
                   (Propensity-score Matched Sample) 
Patient 
Characteristic 
Lithium 
(n=21288) 
Valproate 
(n=21288) Standardized 
Difference N (%) N (%) 
INITIALLY SUBSTANTIALLY IMBALANCED COVARIATES 
(Initial Standardized Difference ≥ 0.10) 
Sex (Female)
a
 2932 13.8 2952 13.9 -0.003 
Bipolar I Disorder, past 30d 9630 45.2 9719 45.7 -0.008 
Other Psychosis, past30d 251 1.2 261 1.2 -0.004 
Post-Traumatic Stress Disorder (PTSD), 
past year
 4858 22.8 4849 22.8 0.001 
Other Mood Stabilizer(s), current  2963 13.8 2894 13.6 0.006 
Prior Mood Stabilizer Treatment 7573 35.6 7473 35.1 0.010 
Mild Liver Disease, past year 1495 8.4 1708 8.0 0.015 
ACE Inhibitor, current 2772 13.0 2765 12.9 0.001 
SELECT ADDITIONAL VARIABLES WITH LESSER INITIAL IMBALANCES 
Age, 65-79
b 
1358 6.4 1359 6.4 0.000 
Age, 80+
b 
164 0.8 154 0.8 0.005 
Married 7455 35.0 7370 34.6 0.008 
Disability (51-100%) 5473 25.7 5481 25.7 -0.001 
Charlson Comorbidity Index, 
past year, 1+ 
7601 35.7 7468 35.1 0.013 
Myocardial Infarction, past year 235 1.1 243 1.1 -0.004 
Diabetes (Uncontrolled), past year 2722 12.8 2691 12.6 0.004 
Arrhythmia, past year 860 4.0 856 4.0 0.001 
Chronic Obstructive Pulmonary Disease, 
past year 
2968 13.9 2934 13.8 0.005 
Total Nonpsychiatric Medications, 
current, 5+ 
5670 26.6 5589 26.3 0.009 
Beta-Blockers, current 2757 13.0 2713 12.7 0.006 
Opioid Pain Medication, current 2409 11.3 2374 11.2 0.005 
Antiplatelet Agent, current 221 1.0 218 1.1 0.001 
Warfarin, current 200 0.9 187 0.9 0.006 
Nonpsychiatric  
Hospitalizations, past year, 1+ 
1842 8.7 1781 8.4 0.010 
Latest Discharge from Medical ICU  330 1.6 323 1.5 0.003 
Latest Discharge from Neurology 54 0.3 54 0.3 0.000 
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Table 3-1.  (continued)      
Nonpsychiatric Discharge, Against 
Medical Advice (AMA), past year 
207 1.0 203 1.0 0.002 
General Surgery, past 180d,
c
 1+ 705 3.3 697 3.3 0.002 
Nonpsychiatric Visits, last 7d,
c
 1+ 4479 21.0 4426 20.8 0.006 
Specialty Visits, past 180d,
c
 1+ 3720 17.5 3619 17.0 0.013 
Cardiology clinic, past 180d,
c
 1+ 594 2.8 599 2.8 -0.001 
Pain clinic, past 180d,
c
 1+ 447 2.1 467 2.2 -0.006 
Chaplain Service, past 180d,
c
 1+ 547 2.6 540 2.5 0.002 
Nuclear Medicine, past year, 1+ 837 3.9 812 3.8 0.006 
Alcohol Dependence 4440 20.9 4449 20.9 -0.001 
Heroin/Opiate Dependence 824 3.9 810 3.8 0.003 
a
 The sex ratio of our sample differs substantially from that of bipolar disorder in the general population because 
our sample is a Veteran sample, primarily made up of male individuals.  It is particularly important to note that the 
hdPS-matching procedure did not substantially change the prevalence of male or female sex in the final study 
cohort compared to the initial sample, or the prevalence of any of the other included covariates.  Rather, the 
matching procedure led to the selection of a set of patients initiating valproate who were very similar to those 
initiating lithium.  For instance, in the original study cohort prior to matching 13.9% of patients initiating lithium 
and 9.4% of patients initiating valproate were female.  In the final cohort, 13.7% of patients initiating lithium and 
13.7% of patients initiating valproate were female. 
b
 Age presented in this format (65-79 years old and 80+ years old) because these were the age groups with highest 
mortality.  Age was actually modeled using 11 indicator variables reflecting age groups from < 35, 35--39, 40-44, 
45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, and 80+ years old. 
c 
“d”= days; e.g. 30d = 30 days. 
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Overall survival was greater among patients initiating lithium, with 274 deaths 
over 365 days observed among the lithium intent-to-treat cohort, compared to 296 deaths 
among the valproate intent-to-treat cohort.  Greater differences (71 versus 101 deaths, 
respectively) were observed between the as-treated cohorts.  Survival curves for the 
intent-to-treat and as-treated analyses are provided in Figures 3-1A and 3-1B. 
Table 3-2 provides the primary, intent-to-treat analysis results, indicating that 
lithium was associated with substantially reduced mortality risks over 0-90 days (hazard 
ratio (HR) = 0.67, 95% CI 0.51, 0.87), the period of greatest medication persistence, but 
not 0-180 days (HR= 0.97, 95% CI 0.82, 1.15) or 0-365 days (HR = 0.92, 95% CI 0.82, 
1.04).  Secondary analyses by treatment status (Table 3-3) reveal large and significant 
associations with nonsuicide mortality during active lithium treatment compared to 
valproate treatment over all time periods.  Hazard ratios were consistently and 
considerably lower during the period of likely active use of lithium compared to likely 
active use of valproate (as-initially- treated hazard ratios ranging from HR = 0.59, 95% 
CI 0.42, 0.84, to HR = 0.62, 95% CI 0.45, 0.84).  However, significantly increased 
nonsuicide mortality was also observed among lithium former users (n = 54) than 
valproate former users (n=35) over 0-180 days (HR = 1.54, 95% CI 1.01, 2.37), although 
not for other time periods.   
Table 3-4 indicates no significant intent-to-treat associations existed between 
treatment and specific categories of causes of death at 365 days.  The mortality categories 
with associations closest to statistical significance, however, were cardiovascular disease 
(CVD) and deaths from all other causes.  Upon further examination, these categories  
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Figure 3-1A.  Survival curve of lithium and valproate treatment, intent-to-treat cohort 
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Figure 3-1B.  Survival curve of lithium and valproate treatment, as-initially-treated patients 
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Table 3-2.  Risk of Nonsuicide Mortality (Intent-to-Treat Cohort) 
Time Period Hazard Ratio (Lithium/Valproate) 
0-90 Days 
0.67
a
 
(0.51-0.87) 
0-180 Days 
0.97
b
 
(0.82-1.15) 
0-365 Days 
0.92
c 
(0.82-1.04) 
a 
Based on 48 deaths / 1934388 person-days for lithium and 72 deaths / 1933337person-days for valproate; p = 0.003 
b 
Based on 128 deaths / 3839959 person-days for lithium and 132 deaths / 3838384person-days for valproate; p = 
0.73 
c
 Based on 274 deaths / 7733701 person-days for lithium and 296 deaths / 7729420 person-days for valproate; p = 
0.17    
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Table 3-3.  Risk of Nonsuicide Mortality (Stratified by Exposure Status) 
Time Period 
Hazard Ratio 
(Lithium/Valproate) 
During Initial Exposure 
(As-Initially-Treated) 
During Subsequent 
Nonexposure 
(Former Users) 
0-90 Days 
0.59
a
 
(0.42, 0.84) 
0.88 
(0.45-1.74) 
0-180 Days 
0.59
b
 
(0.42, 0.82) 
1.54
c
 
(1.01-2.37) 
0-365 Days 
0.62
d
 
(0.45, 0.84) 
1.02 
(0.79-1.32) 
a
 p = 0.004  
b
 p = 0.002  
c
 p = 0.045  
d
 p = 0.002 
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Table 3-4.  Risk of Nonsuicide Mortality by Cause (Intent-to-Treat Cohort) 
Cause of Death 
Intent-to-Treat 
Hazard Ratio (Lithium/Valproate) 
Cardiovascular (CVD) 
(n=171 deaths) 
0.86 
(0.70-1.06) 
Injury 
(n=105 deaths) 
0.94 
(0.72-1.24) 
Cancer 
(n=54 deaths) 
1.25 
(0.85-1.83) 
Stroke 
(n=21 deaths) 
1.20 
(0.66-2.18) 
All Other Causes 
(n=231 deaths) 
0.87 
(0.71-1.05) 
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were also the only categories to have significant (All other Causes, HR = 0.50, 95% CI 
0.28-0.91) or borderline significant (CVD, HR = 0.60, 95% CI 0.36-1.01) associations 
among as-initially-treated individuals. 
 
Discussion 
 
In a nationwide cohort study of 42,576 VHA psychiatric patients initiating lithium 
and valproate, no significant difference in mortality risk over 0-365 days was observed in 
our primary, intent-to-treat analysis.  However, interpretation of this finding is 
complicated by the fact that high rates of treatment impersistence were observed among 
individuals initiating either lithium or valproate.  By 365 days, 92% of patients had 
discontinued their initial treatment, and approximately 75% had discontinued their 
treatment by 180 days.  Such high rates of treatment impersistence make detecting intent-
to-treat differences between treatments more unlikely.  In contrast, significant intent-to-
treat associations of lithium initiation with lower mortality risks were observed over 0-90 
days.  This is the period during which treatment persistence was highest, and the 
likelihood of detecting intent-to-treat differences expected to be the greatest.  However, 
this period is also the time during which any initial confounding is expected to be the 
most pronounced.103  
Although our high-dimensional propensity score successfully achieved close 
balance on a large number and variety of important potential confounders, some degree 
of remaining confounding remains plausible (Appendix 2-11).  Risk estimates indicating 
greater mortality risk among patients initiating valproate in the unmatched sample 
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(Appendix 2-9) become less pronounced after hdPS-matching, suggesting that overall 
confounding initially biases against valproate.  Intent-to-treat estimates are important not 
only because they are the preferred effect estimates in randomized trials, but also because 
in both randomized and nonrandomized studies, they remove the possibility of 
confounding arising after treatment initiation.  As a result, the firmest conclusion that can 
be reached from our intent-to-treat analyses is that initiating lithium may be associated 
with reduced mortality, given the 0-90 day secondary intent-to-treat findings, if baseline 
residual confounding is minimal or modest.  However, this intent-to-treat association is 
not maintained over longer follow-up, either due to the high rates of treatment 
discontinuation, the 0-90 day findings being a chance result, or, possibly, due to the 
occurrence of greater mortality risks associated with lithium than valproate 
discontinuation. 
Our secondary (“as-initially-treated” and “former user”) findings are consistent 
with both an association between active lithium treatment and reduced mortality risk, and 
an association between lithium discontinuation and increased mortality risk, compared to 
valproate.  Among patients who persisted with initial treatment, strong associations were 
observed between lithium, compared to valproate, treatment and reduced mortality across 
all time periods.  Even if confounding biasing against valproate exists, the intent-to-treat 
estimate both over 0-90 days (central estimate HR = 0.67) and the “as-initially-treated” 
effect estimate (central estimate HR = 0.59 to 0.62) are of such size to raise at least some 
question whether residual confounding could plausibly explain this entire association.  
Equally important to recognize, however, is that if any confounding does exist and it 
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generally bias against valproate, this suggests the increased mortality risk associated with 
patients discontinuing lithium from 0-180 days may be even greater than indicated. 
Although not focused upon here, another potential contributor to the “as-initially-
treated” and “former user” findings is differences between the treatment groups in which 
patients are selected during follow-up to discontinue versus remain on their treatment.  A 
substantial contribution from differential selection during follow-up is consistent with 
some, but not all, of the study findings (Appendix 2-13).  Thus, a potential integration of 
our findings is suggested in which some degree of mortality benefits during active 
lithium treatment are counterbalanced by some degree of mortality risks during 
discontinuation of lithium treatment, compared to valproate treatment.  Assessing the 
precise likelihood of this scenario, however, or whether lithium initiation is associated 
with net benefit or harm over the first 365 days of treatment, is difficult.   
In spite of these uncertainties, one clear clinical recommendation can be made: 
once initiated, persistence with lithium treatment should be monitored and if clinically 
indicated, maintained.  Regardless of whether the predominant association of lithium 
treatment (compared to valproate) with mortality is one of lower mortality risks during 
active treatment or higher mortality risks during lithium discontinuation, in either case 
maximizing persistence with lithium treatment would be of clear benefit (Appendix 2-
14). 
Our results are generally consistent with a limited prior literature.  A clinical trial 
meta-analysis of both placebo and comparator-controlled trials reported significant 
reductions in overall mortality with lithium treatment (HR = 0.42, 95% CI 0.27, 0.81).  
64 
 
 
However, the randomized trial results from comparator-controlled trials are informed by 
just 4 deaths among lithium recipients and 12 among comparator recipients (Reference 
20, Figures 2 and 4).  Nonrandomized studies of lithium’s effects on nonsuicide mortality 
are few but generally indicate reduced risks with active lithium treatment, although they 
typically lack active comparators, intent-to-treat designs, or detailed controls for 
confounding.83-90  Our study is, to our knowledge, the first nonrandomized active-
comparator study to include an examination of nonsuicide mortality risks associated with 
lithium discontinuation.  Nevertheless, the results here are consistent in a general sense 
with limited prior uncontrolled studies, which observed that lithium discontinuation is a 
high-risk period for overall mortality.104, 105  This study’s findings potentially could also 
be broadly consistent with prior randomized106 and nonrandomized79, 107 literature 
indicating that lithium discontinuation substantially increases risks of mood episodes.  
Finally, our conclusions concerning the importance of persistence with lithium treatment 
are generally consistent with multiple prior studies reporting substantial lithium treatment 
impersistence.108-114   
Study limitations include our lack of inpatient prescription information, lack of 
serum medication levels as an alternative method to assess persistence with treatment, 
and the inherent inability to completely model potentially important covariates such as 
hospitalizations (Appendix 2-15).  A few variables found important in past mortality 
studies (income and race) which are sometimes poorly measured in VA data were not 
included in the outcome-focused propensity score.  While available medical information 
was extensively represented, this information was only present for treatment received at 
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the VHA.  Although we employed multiple methods to attempt to balance the treatment 
groups in VHA medical utilization (including indicators such as the presence and number 
of recent nonpsychiatric medications, overall visits, and specialist visits a patient 
received), this lack of outside healthcare data may be particularly important for patients 
receiving emergency care (which is more likely to occur at the nearest available hospital) 
or for older patients with Medicare.  We also did not rebalance our treatment groups 
during follow-up for time-varying factors such as medications received through methods 
such as marginal structural models, although the treatment groups were closely balanced 
on a very extensive set of psychiatric and nonpsychiatric medications present at treatment 
initiation.  Given that a very large majority of patients had stopped or modified their 
initial treatment by 365 days, we did not examine patient outcomes occurring over >365 
days from treatment initiation.  Nevertheless, to the degree that either lithium or valproate 
is associated with health risks or benefits that accrue over > 1 year of treatment, the 
impact of these risks and benefits upon mortality will not be reflected in this study.  
Patients with several major mental health diagnoses were included to achieve 
sufficient power (e.g., depression, bipolar, and psychotic diagnoses).  Although the 
psychiatric diagnoses were each balanced closely between treatments by hdPS-matching, 
this may have introduced some heterogeneity in the associations between treatments and 
mortality.  Suicide deaths, which some studies have reported as strongly influenced by 
lithium treatment16, 29 and/or its discontinuation,20 may have been miscoded to some 
extent as accidents/injuries, resulting in an outcome not completely specific for 
nonsuicide mortality.  Studies of overall mortality have also been criticized in general for 
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their lack of specificity.115  However, an overall nonsuicide mortality focus for this study 
appears appropriate, given that lithium and valproate affect so many organ systems that a 
priori cause-specific hypotheses are difficult.   
Our study examines a U.S. Veteran sample, and as such its generalizability to 
non-Veteran samples may be uncertain.  For instance, 86% of our sample is male.  
Perhaps less obviously, the intent-to-treat estimates that are essential for developing a full 
view of the possible risks and benefits of treatment produce important additional 
limitations to generalizability.  For the intent-to-treat estimates to likely generalize to 
other patient samples, that patient sample would need to exhibit a similar rate of 
treatment persistence.  The treatment impersistence rates observed here, however, 
appears to be quite consistent with those observed in the only other incident cohort from 
a broad sample of United States patients that we were able to identify.  Johnson and 
McFarland reported a median time to discontinuation of the first episode of treatment 
with lithium of only 72 days in a U.S. Health Maintenance Organization sample.113  
Finally, although work in propensity score methodology has been steadily advancing, it 
has not been definitively determined whether outcome-focused propensity scores should 
be favored over larger propensity scores in all circumstances.  Reassuringly, the results 
given here for the outcome-focused model and in Appendix 2-7 for the initial model are 
generally consistent in many aspects.  These aspects include significant intent-to-treat 
difference between lithium and valproate at 90 days and substantial effect sizes for as-
treated and former users that are almost uniformly consistent with the outcome-focused 
model in the direction of effects, although not always identical in significance.   
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In our judgment, this study clearly establishes high-priority clinical and research 
agendas.  The data from this study clearly suggests a need for clinical systems and 
providers to encourage patients to continue with their lithium treatment.  A limited 
literature exists concerning psychosocial interventions that might help accomplish this 
task.116  In addition, two trials that have included group psychoeducation with an 
emphasis on educating patients on the importance of medication treatment and/or 
adherence for successful management of bipolar disorder have shown superior outcomes 
to standard care.117, 118  Our data also supports monitoring patients closely upon 
discontinuation when feasible, a practice already recommended in some guidelines to 
limit mood episode recurrence.78  Finally, some approaches such as gradual 
discontinuation79 have been proposed to limit the adverse psychiatric effects of lithium 
discontinuation.   
From a research perspective, this study establishes a need for further research to 
elucidate the balance of risks and harms associated with lithium initiation.  These studies 
might include the use of instrumental variables to reduce confounding from imperfectly 
measured or unmeasured factors (if valid instruments can be identified), and/or marginal 
structural models to reduce the impact of differential selection during treatment on the 
secondary (i.e., “as-initially-treated” and “former users”) analyses.  Marginal structural 
models would also allow the impacts of additional treatments commenced during follow-
up to be evaluated.   
Whether any mortality differences between lithium and valproate are primarily 
due to their direct psychiatric effects (stabilizing mood), indirect effects on physical 
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health (e.g., mood stability possibly leading to better adherence to medical treatment), or 
direct effects on physical health (both medications affect many organ systems) remains to 
be elucidated.  The plausibility of differences in psychiatric effectiveness contributing to 
nonsuicide may be supported by some recent randomized27 and nonrandomized119 studies 
that have reported greater efficacy or effectiveness for lithium that valproate for bipolar 
disorder.  In the BALANCE trial, the valproate treatment arm underperformed both the 
lithium-valproate combination and the lithium alone treatment arms.27  In Denmark, 
lithium was found to be associated with fewer subsequent psychiatric hospitalizations 
than valproate.119  A few other interventions targeting mental health have been associated 
with changes in overall mortality,120 but others have not.121   
 
Conclusions 
This cohort study of U.S. Veterans Health Administration patients observed 
significantly reduced nonsuicide mortality among all patients initiated on lithium 
compared to valproate over 0-90 days but not beyond this period.  Furthermore, 
significant associations were observed in opposite directions in secondary analyses: 
reduced mortality associated with individuals receiving lithium treatment, and increased 
mortality associated with individuals discontinuing lithium treatment (over 0-180 days), 
relative to valproate.  This pattern suggests a dual aspect to the associations of lithium 
and valproate treatment with mortality: associations in a beneficial direction associated 
with active lithium treatment that potentially exceed or are exceeded by counterbalancing 
by mortality associations in a harmful direction associated with lithium discontinuation.  
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Intrinsic uncertainties common to nonrandomized studies (e.g., confounding), despite our 
efforts to minimize them, preclude a definitive judgment of whether lithium initiation 
was associated with net mortality benefit or net harm compared to valproate initiation.  
One clear and important clinical conclusion nevertheless emerges: once lithium treatment 
has been initiated, patients and providers should strive to maximize persistence with 
lithium treatment when feasible and clinically indicated.  Such a conclusion results 
regardless of whether lithium is associated with benefits during active treatment or harms 
after discontinuation.  In addition, given the problem of premature mortality in patients 
with serious mental illness,91-94 the potential mortality differences between lithium and 
valproate should immediately receive greater research attention.  
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CHAPTER IV 
 
 
Suicide Risk in Veteran Health Administration Patients with 
Bipolar Disorder Initiating Lithium or Valproate 
 
 
Abstract 
 
 
Objective:  Past literature has reported sizable associations between lithium treatment 
and reduced suicide risk in patients with bipolar disorder, but these studies have often 
lacked extensive controls for confounding, intent-to-treat designs, active comparators, 
and/or fixed and equal follow-up time between treatments.  
 
Method:  Intention-to-treat, high-dimensional propensity score-matched incident-user 
cohort study of Veteran’s Health Administration (VHA) patients with bipolar disorder  
newly initiating lithium or valproate from 1999-2008 using Cox regression (n=11, 
298/treatment).  
 
Results:  Matching produced treatment groups closely similar in every one of an 
extensive set of measured covariates (all standardized differences <0.024).  Initiation of 
lithium treatment was associated with significantly higher risk of suicide than valproate 
initiation over the first year of treatment (0-365 day HR = 1.50, 95% CI 1.05, 2.15, p = 
0.008) in our primary analysis.  However, secondary analyses indicated that no increase 
in suicide risk was associated with patients still receiving their initial lithium treatment 
(365 day HR = 1.0, 95% CI 0.52, 1.92).  In contrast, an increased risk of suicide was 
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observed subsequent to the discontinuation of lithium, compared to valproate, treatment 
although this association was only significant at 0-180 days (HR = 6.10, 95% CI 1.37, 
27.3, p = 0.018).  
  
Conclusions: Over the first 12 months after treatment initiation in this large, extensively-
matched cohort study of VHA patients, lithium initiation was associated with higher 
suicide risks than valproate initiation.  This association was largely observed among 
patients discontinuing lithium, compared to discontinuing valproate, treatment.  High 
rates of treatment impersistence also meant that the intent-to-treat effect estimate 
predominantly reflects associations that were observed after treatment discontinuation.  
Several lines of evidence suggest some residual confounding may exist biasing towards 
observing higher suicide risks among patients initiating lithium.  Nevertheless, our 
findings indicate a need for caution concerning employing lithium as a suicide 
preventative among bipolar patients, a need to educate patients and providers about 
potential risks associated with lithium discontinuation, and a need to develop approaches 
to maximize persistence with lithium treatment and minimize risks upon discontinuation. 
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Introduction 
 
 
Reducing suicide is both a national priority and a particular need for Veterans.1  
The mood stabilizer lithium has long been reported to be associated with uniquely large 
reductions in risks of suicide and suicidal behavior.15, 16, 29  Many studies, however, have 
been nonrandomized and lacked intent-to-treat designs, extensive controls for 
confounding, active comparators and/or restrictions to incident-users.14  Evidence from 
randomized trials is extremely limited (e.g., a meta-analysis of 32 trials included just 2 
suicides among patients assigned lithium), but consistent with large, significant 
reductions in suicide risk (OR = 0.26).12   
In contrast, recent nonrandomized studies22, 23, 74-76 and a small randomized trial of 
suicidal behavior53 report smaller, nonsignificant reductions in suicide or nonfatal 
suicidal behavior associated with lithium in comparison to another commonly-used mood 
stabilizer, valproate.   
While nonrandomized studies can provide the large sample sizes desirable in 
studies of rare events such as suicide, concerns exist that earlier studies may have been 
confounded by prescription of lithium to patients preferentially at lower suicide risk.13, 14   
Over the past 10-15 years, however, prescriber behavior may have changed given well-
publicized meta-analyses,10, 20 treatment guidelines,11 and high-profile studies16 that have 
reported lithium treatment to be associated with distinct reductions in suicide risk.   
Focusing on this more recent time period, we conducted an important follow-up 
study to our investigation examining lithium and valproate treatment and suicide risks 
among Veterans Health Administration patients (Chapter 2).  One limitation of this prior 
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study was that a heterogeneous cohort of patients with bipolar disorder, depression or 
other severe mental illness was examined, with the intention of maximizing statistical 
power to observe associations over a uniform, one-year period after treatment initiation.  
This study focuses the examination of suicide risks only among individuals with a 
diagnosis of bipolar disorder, the principal psychiatric patient group receiving lithium or 
valproate.  
Similar to our prior study (Chapter 2), a nationwide cohort study of lithium and 
valproate recipients was conducted that was designed to approximate some aspects of 
randomized trials by: 1) matching patients based on a high-dimensional propensity 
score42 and 2) deriving intent-to-treat risk estimates.48  High-dimensional propensity 
score matching allows treatment groups hundreds of measured covariates to be closely 
balanced between treatment groups (similar to a trial).  Intent-to-treat estimates also 
ensure that any differences in the risks arising after treatment discontinuation are 
included when evaluation the comparative effectiveness of two treatments.  Intent-to-treat 
estimates also removes confounding arising after treatment initiation from differential 
selection of patients to continue or discontinuation treatment, although bias can still arise 
if treatment modification is present.    
Using these methods we evaluated whether suicide risk differed between patients 
with bipolar disorder initiated on lithium compared to valproate. 
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Methods 
 
Data Sources 
Demographic characteristics, inpatient and outpatient mental and non-mental 
health treatment records, and outpatient pharmacy prescription data was obtained from 
the VHA National Psychosis Registry (a linked, de-identified healthcare databases of all 
VHA patients with at least one psychotic or bipolar disorder diagnosis).  This study was 
approved by the Institutional Review Boards of the Bedford and Ann Arbor Veterans 
Affairs Medical Centers. 
 
Study Cohort 
Incident users (≥ 6 months of no lithium or valproate use) with recent VHA 
utilization receiving at least one outpatient prescription for lithium or valproate from 
April 1999 to December 2008 were identified having a diagnosis of bipolar disorder 
(Bipolar I, II, or NOS) within 30 days prior to medication initiation.  Patients were 
excluded if they possessed potential nonpsychiatric indications for valproate or lithium, 
initiated mood stabilizer on an “as needed” basis, or both mood stabilizers 
simultaneously.  
 
Exposure Determination 
Receipt of lithium or valproate was determined by outpatient prescription fills.  
For the intent-to-treat analysis, all patients filling an initial outpatient prescription were 
followed until end of follow-up or death.  Secondary analyses stratified follow-up time by 
whether patients were still receiving initial treatment.  Patients were considered “as-
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treated” until a ≥ 15-day gap occurred between outpatient prescriptions (adjusting for 
early refills) or upon initiation of the other medication.  “Former users” consisted of 
patients after initial treatment discontinuation until follow-up time was censored upon 
treatment resumption or switching, death, or end of follow-up.  This nonexposed “former 
user” group has been proposed as a potential index of residual confounding and/or 
selection during treatment under certain conditions,48, 49 however, it most accurately 
represents the combined effects of residual confounding, selection during treatment, 
persistence of any active treatment effects, and discontinuation-associated risks (e.g., 
rebound mania, anxiety, etc.).   
 
Outcome 
Date and cause of death was obtained from National Death Index files for 1999-
2009.56    
 
Propensity Score Modeling  
Over 900 covariates, including a large number of potential psychiatric and 
nonpsychiatric risk factors for suicide from numerous administrative data domains, were 
derived from VHA databases (Chapter 2).  Our approach generally followed the “high-
dimensional” propensity score method,41, 58 except variables were individually 
constructed and evaluated, instead of using automated variable construction and selection 
procedures.    
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Statistical Methods 
The propensity score was calculated using logistic regression.  Patients initiating 
lithium and valproate were then 1:1-matched using calipers of 0.2 standard deviations of 
the propensity score logit,60, 61 resulting in 97.4% matching of lithium-initiated patients.  
Balance in covariates between the treatment groups was assessed using standardized 
differences (equivalent to Cohen’s d effect sizes, with a difference of ≥ 0.10 considered 
as indicating significant imbalance).42   
Statistical significance was determined using analytic methods reflecting 
matching (stratified Cox regression with sandwich variance estimators), except for 
analyses of “former users” (for which non-stratified Cox regression was used, since 
matching was not preserved).61  The primary analysis examined intent-to-treat 
associations between treatments over 0-365 days.  Secondary endpoints examining intent-
to-treat treatment-risk associations over 0-90 days and 0-180 days.  All analyses were 
performed using SAS, version 9.3, except the calculation of standardized differences, 
performed using Microsoft Excel 2010. 
 
Secondary analyses 
In addition to the secondary time periods examined for the intent-to-treat 
analyses, other secondary analyses were also conducted.  The association between the 
treatments and suicide risk was examined among patients who were still receiving their 
initial treatment over 0-90 days, 0-180 days, or 0-365 days.  Follow-up time for these “as-
initially-treated” analyses was censored once ≥ 15 day had transpired from the end date 
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of their most recent prescription of the initiated mood stabilizer (lithium or valproate), at 
which point they were considered to have stopped treatment.  Follow-up time was also 
censored immediately if they received a prescription for the other mood stabilizer, if they 
died from nonsuicide causes, at the end of follow-up.  The association between initiation 
of lithium and valproate and suicide risk was also evaluated for patients who had stopped 
their initial treatment.  Follow-up time for these “former users” analyses commenced on 
the 15th day after their last prescription fill of their initial treatment, and was censored 
immediately upon either resumption of the initiated treatment or switching to the other 
treatment, death from other causes, or the end of follow-up.  
In addition, we also compared the suicide risk associated with the treatment 
groups prior to matching.  Finally, the prevalence of diagnostically-coded suicidal 
ideation (V62.84, a code for suicidal ideation only available from the years 2005-2008) in 
the 30 days prior to treatment initiation was compared between the treatment groups 
among the patients for whom this information was available (< 50% of the full sample). 
 
Results 
 
 
The two treatment groups were highly similar in virtually all measured covariates 
even prior to matching.  Only 7 of 917 (0.8%) covariates had an initial standardized 
difference (i.e., prior to matching) of ≥ 0.10, including only three covariates directly 
related to mental health (Table 4-1).  The largest initial standardized difference was only 
0.17.  Table 4-1 demonstrates how the hdPS-matching functions to bring covariates, even
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Table 4-1.  Baseline Covariates by Treatment, Before and After Propensity-Score Matching 
 
Patient 
Characteristic 
Unmatched Sample (Prior to Matching) Matched Sample (After Matching) 
Lithium Valproate Standardized 
Difference 
Lithium Valproate Standardized 
Difference N % N % N % N % 
COVARIATES WITH SUBSTANTIAL INITIAL IMBALANCES
a 
Current Other 
Mood Stabilizer 
1934 16.2 3062 10.9 0.156 1799 15.4 1792 15.4 0.002 
History of past 
Mood Stabilizer 
4770 39.9 9279 32.9 0.145 4576 39.3 4616 39.6 -0.007 
State-level 
Suicide Risk, 
quintile 4 
1649 13.8 2948 10.5 0.102 1555 13.35 1542 13.24 0.003 
Liver Disease, 
Mild 
1049 8.8 1306 4.63 0. 166 898 7.7 896 7.7 0.001 
Current Thiazide 
Diuretic 
732 6.1 2765 9.8 -0.137 719 6.2 731 6.3 -0.004 
Current ACE 
Inhibitor 
1404 11.7 4379 15.5 -0.111 1380 11.9 1364 11.7 0.004 
Current NSAID 1846 15.4 5504 19.5 -0.108 1812 15.6 1848 15.9 -0.008 
SELECT ADDITIONAL COVARIATES OF INTEREST 
Age, 65-79 yob 789 6.59 2173 7.71 -0.043 778 6.68 778 6.68  0 
Age, 80+ yob 102 0.9 251 0.9 -0.004 99 0.8 99 0.8  0 
Sex (Female) 1766 14.8 3374 12 0.082 1687 14.5 1710 14.70 -0.006 
Post-Traumatic 
Stress Disorder 
(PTSD) 
2305 19.3 6442 22.8 -0.088 2250 19.3 2266 19.5 -0.004 
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Table 4-1.  (continued) 
Depression NOS 345 2.9 1066 3.8 -0.050 338 2.9 345 3.0 -0.004 
Alcohol 
Dependence 
2625 21.9 6619 23.5 -0.037 2537 21.8 2625 22.5 -0.018 
Psychiatric 
Hospitalization, 
past 7 days 
1419 11.9 4226 15.0 -0.092 1391 11.9 1374 11.8 0.005 
Psychiatric 
Hospitalization, 
last year 
9149 76.5 20565 72.9 0.081 8916 76.5 8933 76.7 -0.003 
Current SSRI 3643 30.4 9584 33.9 -0.074 3553 30.5 3549 30.5 0.001 
Current SNRI 709 5.9 1575 5.6 0.015 687 5.9 679 5.8 0.003 
Current 
Olanzapine 
1118 9.3 3009 10.7 -0.043 1098 9.4 1062 9.1 0.011 
Current Clozapine 6 0.05 10 0.04 0.001 6 0.05 6 0.05 0.000 
Recent Other 
Mood Stabilizer 
1488 12.4 2854 10.1 0.073 1400 12.0 1404 12.1 -0.001 
Any acute injury 2179 18.2 5238 18.6 -0.009 2081 17.9 2074 17.8 0.002 
NonFatal Suicide 
Behavior (NFSB), 
NonMHdx, 
past30dc 
15 0.13 52 0.18 -0.015 15 0.1 14 0.1 0.002 
NFSB, MHdx, past 
30dc 
19 0.16 43 0.15 0.002 19 0.2 21 0.2 -0.004 
NFSB, Outptdx, 
past 30dc 
79 0.66 218 0.77 -0.013 75 0.6 77 0.7 -0.002 
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Table 4-1.  (continued) 
NFSB, NonMHdx, 
past 31-180 daysc 
18 0.15 27 0.10 0.016 16 0.1 16 0.1 0.000 
NFSB, MHdx, past 
31-180 daysc 
18 0.15 32 0.11 0.010 18 0.2 13 0.1 0.012 
NFSB, Outptdx, 
past 31-180 daysc 
38 0.32 107 0.38 -0.011 38 0.3 39 0.3 -0.002 
a 
Substantial Initial Imbalance refers to a standardized difference in prevalence between the lithium and valproate treatment groups of ≥ +/- 0.10.  
b 
Age is presented in this format to simplify presentation.  In actuality, age was modeled with 11 indicators. 
c 
NFSB= Non-fatal suicide behavior; NonMHdx= Diagnosis code entered during nonmental health hospitalization; MHdx= Diagnosis code entered 
during a mental health hospitalization; Outptdx= Diagnosis code entered during an outpatient encounter. 
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when initial imbalances are modest, into closer balance in the matched sample (often into 
extremely close balance).  After matching, every one of the 917 covariates was closely 
balanced between treatment groups to a standardized difference of ≤0.024 (and >87% of 
the covariates within a standardized difference of 0.001).   
 The intent-to-treat survival curve for our matched cohort is presented in Figure 4-
1.  
 Table 4-2 provides the results from our primary, intent-to-treat analysis.  
Significantly increased hazards of suicide death associated with initiation of lithium 
treatment were observed over 0-365 days (HR = 1.50, 95% CI 1.05, 2.15, p = 0.026).  In 
addition, when secondary endpoints of 0-90 days and 0-180 days were examined, 
significantly increased hazards of suicide death were also observed at 180 days (HR = 
1.87, 95% CI 1.17, 2.97, p = 0.008).   
Table 4-3 provides hazard ratios for our secondary “as-initially-treated” and 
“former users” analyses.  No significant differences were observed in suicide risk among 
patients during the time in which they received initial lithium or valproate treatment.  In 
contrast, substantially elevated risk were observed among former users of lithium at 180 
days (HR = 6.10, 95% CI 1.37, 27.2, p = 0.018).  This association was not significant 
over 0-365 days, results were no longer significant at 365 days (HR = 2.05, 95% CI 0.88, 
4.79, p = 0.098) although a p value <0.10 was observed.  
Table 4-4 presents the prevalence of diagnostically-coded suicidal ideation 
between treatments for the 10,608 patients for whom this data was available (patients 
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Figure 4-1.  Survival Curves, 0-365 days, Intent-to-Treat Cohort 
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Table 4-2.  Risk of Suicide Death by Treatment (Intent-to-Treat Cohort) 
Length of Follow-up 
Number of Suicides 
Intent-to-Treat 
Hazard Ratio 
[Lithium/Valproate] 
(95% Confidence Interval) Lithium Valproate 
0-90 days 13 11 
1.18 
(0.67-2.09) 
0-180 days 28 15 
1.87a 
(1.17- 2.97) 
0-365 days 39 26 
1.50b 
(1.05-2.15) 
a p=0.008 
b p=0.026 
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Table 4-3.  Risk of Suicide Death by Treatment and Treatment Status  
                   (As-Initially-Treated versus Former User) 
Length of Follow-
up 
As-Initially-Treated Former User 
Number of 
Suicides 
Stratified 
Hazard Ratio 
(Li/Val) 
(95% CI) 
Number of 
Suicides Hazard Ratio 
(Li/Val) 
(95% CI) Li VAL Li VAL 
0-90 Days 12 10 
1.0 
( 0.5-2.0) 
1 1 
0.92 
(0.06-14.7) 
0-180 Days 13 11 
1.0 
(0.52-1.92) 
12 2 
6.10 
(1.37-27.3)a 
0-365 Days 15 15 
1.0 
(0.52-1.92) 
16 8 
2.05 
( 0.88-4.79)b 
a p=0.018 
b p=0.098 
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Table 4-4.  Presence of V-code (62.84) denoting Suicidal 
Ideation in the 30 days prior to Lithium or Valproate 
Initiation
a 
 
 
 Patient Characteristic 
Patients 
Initiating 
Lithium 
Patients 
Initiating 
Valproate 
Odds 
Ratio 
(95% CI) 
Suicidal Ideation  176 122 1.47
a 
(1.16-
1.86) No Suicidal Ideation 5103 5207 
a for the portion of the cohort initiating treatment in 2005-
2008 
b p=0.0012 
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initiating treatment from 2005-2008).  A diagnosis code for suicidal ideation had been 
entered for the patients initiated on lithium than valproate significantly more often in the 
30 days prior to initiation of treatment (OR = 1.47, 95% CI 1.16, 1.86, p = 0.001). 
 
Discussion 
 
In this extensively-matched nationwide cohort of 23, 298 Veterans Health 
Administration patients with bipolar disorder initiated on lithium or valproate, initiation 
of lithium treatment was associated with increased risk of suicide at 180 and 365 days in 
intent-to-treat analyses.  The high rates of treatment impersistence observed, however, 
means that the majority of days in the intent-to-treat estimate related to the period after 
initial treatment with lithium or valproate has ceased.  As a result, the intent-to-treat 
results can be expected to reflect residual confounding to a greater extent than usual.   
Furthermore, our secondary analyses indicate that some or most of the association 
between lithium initiation and increased suicide risk appears to be explained by 
substantially increased risk for suicide in patients who discontinued lithium compared to 
valproate.  In contrast, active treatment with lithium was not significantly associated with 
increased or decreased suicide risk.  Two important conclusions suggest themselves when 
these results are considered as a whole.  First, the possibility that initiating lithium may 
pose a suicide hazard to some patients who discontinue it even within the first year of 
treatment needs increasingly thorough research and clinical consideration.  The 
occurrence of such risks upon discontinuation is consistent with past findings indicating 
that the period post-lithium discontinuation may pose distinct suicide, suicidal behavior, 
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or mood episode risks.  Second, the conclusion cannot be reached that active lithium 
treatment was not associated with reduced risks of suicide in this patient cohort, 
potentially even by a substantial, clinically-meaningful amount.  Residual confounding in 
this study appears to bias against finding protective associations between lithium 
treatment and suicide, thus weakening any inferences concerning the presence or size of a 
protective association between active lithium treatment and suicide risks.  Making further 
progress regarding possible confounding, however, will likely require either different 
study designs or different patient cohorts with lesser confounding.   
These two conclusions regarding possible discontinuation-associated risks and 
residual confounding biasing against lithium were also the principal conclusions of our 
earlier study (Chapter 2).  This earlier study included most of the bipolar individuals 
examined here along with patients with other mood and psychiatric disorders who were 
receiving lithium or valproate.  However, these conclusions are reinforced and 
strengthened by these specific results, which show directionally similar, although even 
more extreme, patterns of risk over the study period.  
The judgments concerning residual confounding also are reinforced by the 
apparent greater degree of channeling of patients with bipolar disorder with recently-
diagnosed suicidal ideation to preferentially receive lithium (OR=1.47) than for the 
cohort as a whole (OR=1.30) (Chapter 2).  Finally, the substantially increased risks of 
suicide observed at 180 days have even more of an “emergent quality” in this study (i.e., 
a greater change in the risk among former users than observed over 0-90 days) than the 
prior study of the whole cohort (Chapter 2).  Although some caution is warranted since 
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the confidence intervals for the estimates of risk in patients after discontinuing treatment 
over 0-90 days and 0-180 days overlap, this suggestion of emergent risks are more 
consistent with risks that are associated with discontinuation (an event that takes time to 
occur), and is less consistent with confounding (at least with fixed confounding or with 
time-varying confounding that is most substantial close to initiation, a pattern suggested 
by some other suicide studies examining psychiatric medications.17, 122  
For these reasons we conclude that our findings in this study simultaneously 
suggest that some degree of residual confounding biasing against lithium likely exists, as 
well as some degree of greater suicide risks upon lithium, compared to valproate, 
discontinuation.  
The possibility of risks associated with lithium discontinuation appears consistent 
with several decades of research.  Since the early 1980s evidence has accumulated that 
discontinuation of lithium places patients at increased risk for mood episodes.  
Subsequent work has demonstrated that the time to mood episode relapse can be as brief 
as approximately two weeks (more precisely, 13-19 days)123 to 1-4 months,79, 107 and that 
associated risks are especially pronounced if the discontinuation is abrupt.79  One study 
reported that suicide risks were particularly prominent within only 30 days after 
discontinuing mood stabilizers, without specifying the specific risks observed with 
lithium, valproate, or carbamazepine discontinuation.16  To our knowledge, however, no 
study has systematically examined risk from discontinuation occurring shortly after 
medication initiation, a period in which patients may still be at heightened vulnerability 
for suicide in general.   
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Because of these findings consistent with possible discontinuation-associated 
risks, this study suggests a clear need exists for clinical systems and providers to 
encourage patients to continue with their lithium treatment once initiated.  
Educational/psychosocial interventions have been developed to promote adherence with 
treatment.116 117, 118  Clinical systems and providers also may need to take steps to 
minimize suicide risk in patients who stop lithium treatment, whether at their own 
initiative or as directed by their provider.  Available evidence suggests that when 
discontinuation occurs, it should be done gradually if possible.79  When feasible, 
increased clinical monitoring also should occur after discontinuation, as has been 
previously recommended for mood stabilizers to minimize risk of mood episode 
relapse.78  
Further assessment and/or research also may be needed concerning the more 
difficult question of whether lithium should be avoided in certain patients for whom risks 
of discontinuation appear high or adherence to follow-up monitoring likely to be low.  A 
recommendation not to initiation lithium in patients deemed likely to discontinue the 
treatment has been made 20 years, although it was based on the very limited randomized 
evidence available at that time.124  Finally, the fact that significantly increased intent-to-
treat risks are observed, despite the fact that some of these risks may result from 
confounding and that the risks appear associated with lithium discontinuation rather than 
during lithium treatment, should encourage added caution on the part of clinical systems 
considering whether to promote expanded use of lithium as a possible suicide 
preventative.   
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It is important to recognize that our findings do not necessarily suggest a lack of 
effectiveness for lithium against suicide during active treatment.  Residual confounding 
biasing against lithium would imply that the central HR of 1.0 observed for active lithium 
treatment may actually be a composite of some degree of protective association from 
lithium coupled with some degree of residual confounding in the opposite direction 
(biasing against lithium).  This bias against lithium is suggested both the suicidal ideation 
findings (more diagnoses in patients initiating lithium than valproate) and by comparison 
of matched versus unmatched effect estimates, which indicated greater risks associated 
with lithium treatment prior to matching (data not shown).  Furthermore, propensity score 
methods also may amplify to some degree whatever residual confounding exists after 
control of the measured covariates, and some degree of unmeasured confounding is 
plausible in our analyses.  Any such amplification is likely modest, however, given the 
low c statistic.  
A second reason exists to view our study as not necessarily indicating a lack of 
effectiveness for lithium against suicide during active treatment.  Both our study design 
and the very high rates of treatment discontinuation, makes it difficult to infer about 
suicide risk after 365 days (although we present some very limited data for the overall 
cohort in Chapter 3).  Some studies have specifically reported that treatment with lithium 
for >1 year was required to observe significant reductions in suicide risk.67-69 
Nevertheless, our results appear generally consistent with two recent randomized 
trials that had durations of 2-2.5 years.  Neither of these studies observed statistically 
significant reductions in suicide behavior amongst patients initiated on lithium.  It is 
91 
 
 
 
worth nothing, however, that both studies observed nonsignificant findings of effects that 
still were in the direction of reduced suicide risk.  The findings from these studies have 
been combined in a recent meta-analysis which derived a substantial, bust still 
nonsignificant, reduction in was associated with a nonsignificant reduction in nonfatal 
suicidal behavior compared to valproate (OR = 0.64, 95% CI 0.30, 1.36, p = 0.24).  
Treatment persistence was substantially lower in this study than those trials, perhaps 
contributing (given the likely direction of confounding) to the different direction of 
association observed in our study.  
The complications engendered by the possibility of residual confounding suggests 
that further research should either strongly consider study designs that can address 
unmeasured confounding (randomized trials and possibly instrument variable analyses) 
or perhaps focus on cohorts in which lithium is more universally used, such as some areas 
of Europe.    
This study has additional limitations.  These include the fact that information was 
available for VHA outpatient prescriptions only, serum medication levels were not 
available, suicide events were relatively few, and that there was an inability to control for 
some relevant confounders such as suicidal ideation, plans, and means, mental health 
symptoms, psychosocial stressors, and outpatient hospitalizations.  In addition, our design 
choice of not restricting the cohort to patients receiving monotherapy with mood 
stabilizers (lithium and valproate) helped preserve power and generalizability of findings, 
but would be expected to add uncertainties.  In particular, changes in other psychiatric 
medications over the one year of follow-up were not included in the analysis.  However, 
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the patient cohorts were closely balanced on a very wide variety of psychiatric 
medications or medication classes at study initiation.  Confounding amplification is also 
possible, although likely was fairly minimal given the very modest c statistic.  
Nevertheless, the potential for this study design to both remove more measured 
confounding than some other study designs, but also amplify residual confounding, 
should be kept in mind since several plausible confounders were not able to be included.   
Finally, generalizability of this sample outside other Veteran samples with similar 
sex distribution (predominantly male) and rates of Post-Traumatic Stress Disorder 
(PTSD) and substance use is uncertain.  In addition, generalizability of the intent- to-treat 
estimates is further limited by the fact they are most applicable to cohorts with similar 
rates of treatment discontinuation.   
  
Conclusions 
In this study of US Veterans with bipolar disorder, initiation of lithium, compared 
to initiation of valproate, was associated with significantly higher suicide risks over 0-
180 and 0-365 days in our primary, intent-to-treat analyses.  These analyses included the 
outcomes of all patients initiating treatment were considered regardless of whether they 
occurred during active treatment or after discontinuation any subsequent treatment 
discontinuation (>90% of patients discontinued had their treatment by 365 days).  
Significantly increased suicide risks were observed in secondary analyses associated with 
patients who had discontinued lithium, compared to valproate, treatment over 0-180 days, 
but not among patients receiving active lithium treatment.  Several lines of evidence 
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support the possibility of some residual confounding biasing against lithium; nonetheless, 
our findings suggests that clinical systems and providers should consider taking steps to 
minimize treatment discontinuation once lithium is started and increase the monitoring of 
patients after lithium discontinuation.  In addition, the likely presence of some residual 
confounding biasing against lithium largely precludes judgments about whether lithium 
has effectiveness against suicide in this cohort.  Given the lack of effective interventions 
against suicide, further research examining the balance of potential risks and benefits 
associated with the initiation of lithium treatment is clearly needed.  
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CHAPTER V 
 
 
Final Summary and Conclusions 
 
 
This set of studies has examined several important aspects of the question of 
whether the mood stabilizer lithium might serves as an effective suicide preventative in 
United States Veterans Health Administration (VHA) patients.  Lithium’s effectiveness 
for suicide prevention was examined among incident psychiatric users overall, as well as 
specifically among patients with bipolar disorder.  In addition, the question of whether 
any potential benefits of lithium versus suicide might be counterbalanced by increased 
mortality for other causes of death was also addressed.  Lithium’s association with both 
suicide and nonsuicide mortality has been examined in comparison to a popular and more 
commonly-used alternative treatment, valproate.  
*** 
In mental health research, nonrandomized comparative effectiveness research 
may be particularly needed to address questions regarding the association of psychiatric 
medications with irreversible or terminal endpoints.  Randomized trials examining such 
endpoints, at least as primary outcomes, are likely to either be judged unethical or 
unpopular with patients.  Some limited data regarding suicide and nonsuicide mortality 
does exists from randomized trials and is likely to continue to be accrued, but acquired 
and reported as “serious adverse events” rather than as study primary outcomes.  Our 
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study employed high-dimensional propensity scores, a recent innovation in 
nonrandomized comparative effectiveness studies, but one for which considerable 
validation data has been acquired.41, 125, 126  Furthermore, our studies mimicked 
randomized trials in a limited degree in producing groups of patients receiving either 
medication that were highly similar on numerous covariates and also through the use of 
intent-to-treat effect estimates. 
 Unfortunately, nonrandomized studies in mental health can be expected to be 
particularly challenging.  The likelihood of confounding, especially confounding due to 
unmeasured confounders, is especially high and difficult to predict.  Propensity score 
methods are able to balance measured factors included in the propensity model, but not 
unmeasured factors.  So many aspects central to mental health care are not routinely 
measured in administrative clinical datasets, or even recorded in chart documentation.  
The latter consideration means that even labor-intensive chart review is still unlikely to 
fully measure the factors that may contribute to confounding.  These unmeasured or 
incompletely measured elements include, for example, such important factors as outside 
hospitalizations, recent mental health symptoms and psychosocial stressors.  In addition, 
certain “measured covariates” in mental health may be very imperfectly measured or 
modelled, such as substance abuse.  Although diagnostic categories exist which 
differentiate substance abuse from substance dependence, for example, these categories 
almost certainly are highly imprecise measures of what is of most interest: the level of 
substance use or misuse occurring right at the time of treatment initiation.   
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As a result of these uncertainties, additional caution must be exercised in the 
interpretation of nonrandomized mental health treatment studies compared to other 
nonrandomized treatment studies.  The possibility of the residual confounding must 
always be a prominent consideration in the interpretation of nonrandomized mental 
health treatment studies.        
For certain outcomes, however, that are often not examined in mental health 
research, such as nonsuicide mortality, reasonable assumptions can be made that at least 
some direct forms of confounding are likely to be less prominent.  “Confounding by 
indication” refers to the tendency for providers to choose different treatments based on 
the patient’s condition, and can be alternatively termed, most briefly, as “channeling,” or 
perhaps most descriptively as “confounding by provider intention.”  “Confounding by 
indication,” is specifically likely to be reduced in studies of non-indicated uses or 
ancillary effects of mental health medications (such as their associations with nonsuicide 
mortality) compared to the confounding by indication that would exist for studies 
examining indicated uses of the medication.  Mental health prescribers are not tasked 
with primary responsibility for addressing a patient’s physical health.  Some degree of 
confounding by indication in studies of psychiatric medications and nonsuicide mortality, 
however, remains still feasible.  First, mental health providers do not ignore the physical 
health condition of their patients, it is simply not their primary focus.  Second, medical 
contraindications exist for mental health treatments (e.g., kidney- and cardiac-related 
contraindications for lithium, and liver or bone marrow- related contraindications for 
valproate), that plausibly could affect nonsuicide mortality risk.  Third, to the extent that 
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providers (or patients) believe one of the two medications to be more effective, then this 
medication might be preferred for those patients who are most severely mentally ill.  To 
the extent that severity of mental illness may impact mortality risk, this prescribing 
tendency, regardless of the actual effectiveness of the medication, would be expected to 
lead to some degree of nonsuicide mortality “confounding by indication.”  
*** 
Methodological Conclusions  
 
Part of the value of this study has been as a “testing ground” to determine whether 
a recent innovation, high-dimensional propensity scores, can be profitably applied the 
VHA’s large, extensive databases.  This set of studies has gone beyond a simple 
application of high-dimensional propensity score studies to integrate other innovations, 
such as the use of intent-to-treat, current user, and former user risks in an effort to 
enhance the inferences that can be made from nonrandomized studies.  This set of studies 
has demonstrated that: 
 
1) Implementation of a high-dimensional propensity score is feasible in VHA 
databases.  Our high-dimensional propensity score was not executed using the 
automated variable generation methods of the originally-proposed method.  Yet, 
in approximately a year of half-time programmer effort we were able to generate 
almost 1,000 propensity score variables that not only well represented the detail 
available in VHA databases, but also had likely a priori relevance.127  That is, 
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each variable chosen for inclusion was judged to have some non-negligible 
probability of being associated with mortality (either suicide or nonsuicide 
mortality).  Our judgments were borne out somewhat by the fact that when 
variables were excluded from our propensity score that were empirically observed 
to have a < 20% association with outcome in univariate comparisons, less than 
half the variables were excluded.   
In addition, we were able to identify opportunities to “semi-automate” 
certain important variables.  Most notably, this included using the first 2 digits of 
the VHA’s 3 digit “medication class codes” for generating our >100 nonmental 
health medication covariates based on current or recent but apparently 
discontinued use of medications.  Not only did this approach speed variable 
construction but using a more aggregated form of important covariates has been 
recently associated with better performance 128. 
 
2) Any confounding amplification is likely to be modest.  Although concerns about 
confounding amplification only began to be widely discussed after initiation of 
our project, through our consultation with Dr. M. Alan Brookhart we had already 
adopted an approach which appeared to keep any confounding amplification 
relatively modest.  Our approach scrutinized in particular those variables with a 
particularly strong association with exposure to assess further whether they were 
plausible confounders.  Of note, no variables were observed to meet Dr. 
Brookhart’s original criteria of concern: an odds ratio of exposure of ≥ 4.0. (In 
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fact, no covariates were observed that had even an odds ratio of exposure of ≥ 3.0.  
This is another potential indicator that our two treatment groups may not have 
been extremely confounded even prior to the application of the propensity score).  
Therefore, we extended this scrutiny to covariates with an odds ratio of exposure 
between 2.0 and 3.0.  This process led to the non-inclusion of a handful of 
variables that were judged to potentially likely not to have a genuine relationship 
with the outcome.  Most importantly, our c statistics for our propensity score 
models were relatively modest (the highest c statistics being in the range of 0.69-
0.70).  Recent simulation has suggested that propensity score models with 
explanatory power in this range have modest confounding amplification in the 
range of ≤ 60%, although the precise specifics of this simulation was based on R2, 
not c statistics.47  The possibility of some degree of confounding amplification 
reinforces the need to consider a role for residual confounding in our study, in 
spite of the extensiveness of our efforts to deal with measured confounding.   
 
3) Former user risks appear to have some distinct value in the interpretation of 
findings from nonrandomized studies (and presumably from randomized studies 
as well), although their interpretation is complex.  The most extreme 
demonstration of this value occurred during the interpretation of the intent-to-treat 
suicide risk results for the individuals with bipolar disorder alone.  Splitting the 
analysis into individuals receiving initial treatment and former users made it clear 
the entire association between lithium and increased risk related to risks among 
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patients who had stopped initial treatment.  In addition, there appears to be value 
for interpretation in separating “former users” – those individuals who are no 
longer exposed to either medication being studied from “resumers” – patients who 
resume either treatment, since nonexposed individuals have value as potential 
indicators of residual confounding at baseline or arising during treatment.48, 49   
It is interesting to note that depending on available sample size and 
number of outcomes, several additional categories of “former users” could be 
envisioned with progressively increasing stringency in their definition of 
“nonexposure.”  For instances, if sample size permits, it may prove valuable to 
examine a special class of former users which examines the follow-up time for 
individuals who have stopping their medication studied and not initiated any other 
psychiatric medication subsequent to this discontinuation.  Even more rigorous 
would be a requirement that “former users” not include any individuals who had 
started other psychiatric medications on or after the date of initiation of the 
medication under study.  In this case, the “former user” period would represent a 
period of nonexposure to any psychiatric medication which was not present at 
baseline.  Given still greater sample size, the most rigorous definition would be to 
examine only patients initiating psychiatric medication monotherapy involving 
the study medications; thus, the former user period would consist of follow-up 
time free of exposure to any psychiatric medication.  That design among other 
things, would prevent uncertainties arising from changes as seemingly as minor as 
possible dose increases of psychiatric medications being received concomitantly.  
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As the definition of “former user” becomes more restrictive, however (especially 
if a restriction to monotherapy is enforced), generalizability of the findings would 
become restricted.   
  
4) Stratification appeared to play a useful role in facilitating interpretation of our 
results, even with our limited power.  The clearest demonstration of the value of 
stratification arises by stratification of the follow-up period into multiple time 
periods (0-90 days, 0-180 days, and 0-365 days for all 3 studies, and, for the first 
suicide risk analysis, division into the mutually exclusive categories of 0-90, 91—
180, and 181-365 days as well).  In addition, our stratification of suicide risk by 
treatment by psychiatric diagnoses (bipolar disorder versus nonbipolar disorder) 
was also valuable.  The stratification of follow-up time permitted the detection of 
significantly elevated risks in former users over the 0-180 day period in all 3 
analyses which would have been missed with simply an examination of 0-365 
days.  Detection of this elevated risk had particular value in the nonsuicide 
mortality manuscript, since it occurred in the opposite direction of the significant 
associations of reduced nonsuicide mortality with lithium initiation in the intent-
to-treat analyses (0-90 days), and with still receiving lithium treatment in the 
current user analyses (all 3 time periods).  This suggests that simple confounding 
(i.e., in the same consistent direction), even if it varied in size, could not explain 
the entirety of both the 0-90 day findings suggesting potential effectiveness for 
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lithium and the 0-180 day former user findings suggesting possible distinct risks 
upon discontinuation.   
Our stratification by diagnoses yielded the observation that in the bipolar 
cohort both risks in former users and intent-to-treat risks were significant, and in 
the hazardous direction.  This suggests that the elevated risk in former users arises 
from either baseline confounding (which would then also be expected to be 
biasing the treatment effect estimates in the intent-to-treat and still receiving 
initial treatment cohorts) or from risks associated with discontinuation of the 
treatment, rather than from confounding arising after treatment initiation from 
selection occurring during follow-up (at least pertaining to risk for from non-
medication related outcomes, which would not affect ITT estimates).   
 
5) Examination of non-included factors can help provide insight into the likely 
direction of residual confounding.  For the suicide mortality analyses, a 
potentially important covariate was likely present for approximately half the 
sample:  suicidal ideation, as reflected by a diagnostic code (V62.84).  This 
covariate likely only represent a fraction of reported suicidal ideation (it was 
present in <2% of our sample in the 30 days prior to medication initiation), and 
the fact the code only came into existence in 2005 meant it could not be present 
for the approximately half of patients initiating medication prior to that time.  Yet, 
examining this covariate helped reinforce the possibility that some residual 
confounding biasing against lithium likely existed in our suicide risk studies:  for 
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both studies, significantly more patients initiating lithium had a V-code denoting 
suicidal ideation in the past 30 days than patients initiating valproate.  Not only 
might this imbalance account for some amount of residual confounding directly, 
this residual imbalance after propensity score matching potentially suggests that a 
similar imbalance may occur in other suicide-related risk factors, although this 
cannot be concluded with certainty.    
*** 
Comparative Effectiveness Conclusions 
This set of studies comparing lithium and valproate had several important and 
unexpected results.  First, at the most basic level, the high rate of treatment 
discontinuation we observed in this VHA sample poses a substantial practical barrier to 
any efforts to employ lithium for the purposes of influencing either suicide or nonsuicide 
mortality.  Approximately 75% of patients had discontinued (or been discontinued by 
their providers) their lithium or valproate treatment (at least temporarily) within 6 months 
of initiating treatment.  Our observed rates of treatment discontinuation were surprising 
to us for a medication intended to be a long-term treatment of a generally chronic 
condition.  However, the rates observed in this VHA sample were not very dissimilar 
from those observed in the only two other similar studies (i.e., studies examining broad 
samples of incident users) that we could identify.113, 114  
More importantly however, were the findings that these high rates of treatment 
discontinuation were coupled with intent-to-treat associations with suicide risk that either 
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favored lithium to only a fairly minimal, nonsignificant extent (for the cohort as a whole), 
or that significantly favored valproate (for individuals with bipolar disorder).  These 
intent-to-treat results suggest that it is possible lithium initiation among patients with 
bipolar disorder, at least over the first year of treatment, poses a net suicide hazard.  This 
is of particular concern since individuals with bipolar disorder are the core target group 
for psychiatric treatment with lithium.  Further examination of the results from 
individuals with bipolar disorders revealed that the significantly increase intent-to-treat 
suicide risks were associated almost exclusively increased suicide risks associated with 
individuals who had discontinued their initial lithium treatment.  The extent to which this 
increased risk after lithium discontinuation relates to residual confounding biasing against 
lithium, or risks produced upon lithium discontinuation that exceed risks produced upon 
valproate discontinuation, however, is unclear.   
Our intent-to-treat results are compatible, in the general sense of failing to 
establish a benefit for lithium in suicide prevention, with the only trial explicitly designed 
to compare lithium and valproate for suicidal behavior prevention.53  This study found no 
significance differences between lithium and valproate, and only modest nonsignificant 
differences, although the study was very small (49 patients in each arm).53   
The observation within all three studies that for at least one time period the risks 
associated with lithium discontinuation were significantly greater than risks associated 
with valproate discontinuation may be consistent with findings from almost 3 decades of 
research of distinctly increased risks for mood episode relapse shortly after lithium 
discontinuation.  Of note, as early as 1994 one commentator interpreted randomized 
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research reporting intent-to-treat outcomes as indicating that the risks of mood episode 
relapse exceeded the benefits of mood stabilization from active lithium treatment unless 
patients remained on lithium for at least two years.124   
Some studies have also reported increased risks of suicide upon lithium 
discontinuation.  To our knowledge, however, risks associated with discontinuation have 
not been previously reported to occur in relation to lithium discontinuation occurring 
after only as brief a course of treatment as examined here (≤ 180 days).  At a minimum, 
the set of studies described here puts the issue of potential discontinuation-associated 
risks front and center in assessments of whether to encourage the initiation of patients on 
lithium as a suicide preventative.  It also creates a need to consider strategies to minimize 
discontinuation, educate patients and providers about the risks of discontinuation, and to 
monitor patients after discontinuation.1   
The association of significantly lower nonsuicide mortality risks associated with 
lithium than valproate among patients still receiving initial treatment (and among the 
 
                                                          
 
1 Not explored extensively here is the additional implication from these findings that, to 
the extent that lithium has effectiveness against suicide, it is possible that this 
effectiveness will be greater in populations without bipolar disorder than those with 
bipolar disorder, since counterbalancing risks upon discontinuation may not be 
prominent.  This conclusion is suggested by the fact that the findings in the cohort with 
bipolar disorder are suggest lesser benefits and/or greater harms associated with lithium 
treatment than the findings for the cohort as a whole.  By implication, this suggests that 
some degree of greater benefits and/or lesser harms pertaining to suicide risks are likely 
to be associated with lithium treatment in individuals without bipolar disorder. 
106 
 
 
 
entire intent-to-treat sample of patients initiating lithium over the first 90 days of 
treatment), in combination with the significantly higher nonsuicide mortality risks 
observed among patients stopping lithium over 0-180 days, suggests that some degree of 
genuine nonsuicide mortality risk difference exists between lithium and valproate.  The 
overall direction of the association (i.e., whether lithium initiation is beneficial or 
detrimental) is not clear, and difficult to determine since such judgments depend on the 
level of unmeasured confounding.  
In addition, two primary insights concerning likely confounding also suggest 
themselves.  First, our studies suggested that the comparison between lithium and 
valproate initiators was relatively unconfounded by measured covariates.  In all the 
studies, only a handful of the >900 covariates in the propensity score differed by a degree 
typically seen as indicating substantial imbalance (i.e., a standardized difference of ≥ 0.1, 
a measure equivalent to the better-known Cohen’s d statistic).  For instance, in the bipolar 
disorder cohort, < 2% of covariates had an initial imbalance between the treatment groups 
of a standardized difference of ≤ 0.1.  This suggests that many types of information 
available clinically to providers did not appear to influence treatment choice (for 
instance, diagnoses, or the presence of a recent mental health or nonmental health 
hospitalizations).  It also is consistent with, although does not prove, the possibility that 
providers are substantially relying on their own preferences, based perhaps on training, 
marketing, or prior experience when recommending lithium or valproate treatment, rather 
than the patient’s condition.  If so, this circumstance would be beneficial for the purposes 
of a nonrandomized study, since it implies baseline confounding may be fairly minimal.  
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An apparent “provider preference” has been observed to be a major influence on 
prescription choice for other mental health medications and been exploited in certain 
circumstances as a candidate instrumental variable.129 
Second, despite our approach to minimize confounding amplification, and 
evidence suggesting initial overall confounding from measured factors may have been 
modest, the potential for at least some degree of residual confounding also appears 
substantial.  For both the suicide and nonsuicide mortality analyses, the modest c statistic, 
while desirable to minimize confounding amplification, intrinsically suggests that a 
substantial portion of the variance in receipt of lithium or valproate remains unexplained 
in the propensity score model.  Thus, while it is certainly true that much or most of this 
variance may relate to factors unrelated to outcome and thus not confounders (a prime 
example would be any provider preference for one medication over the other), the modest 
c statistic also implies ample opportunity exist for some predictors of exposure that are 
genuine confounders to have escaped modeling.  
 
*** 
 
In conclusion, despite well-known limitations of nonrandomized research 
concerning control of confounding, and the high probability that these limitations are 
likely to be particularly germane to nonrandomized mental health treatment research, this 
set of studies has made significant contributions to the scientific literature.  Through 
application of the high-dimensional propensity score, examination of intent-to-treat, 
current user, and former user risk, strategic use of stratification, and enhancement of the 
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analysis by examining important factors not able to be included in the propensity score, 
this set of studies has managed to arrive at several important conclusions.  The most 
notable conclusion concerns the imperative emerging from all three studies (and 
reinforcing previous findings) to plan ways to minimize and manage any potential risk 
related with the discontinuation of lithium.  A second prominent finding is that some 
degree of nonsuicide mortality risk difference may exist between lithium and valproate.  
Our nonsuicide mortality study therefore reinforces the need for the overall mortality 
impacts of psychiatric treatments to receive increased clinical and research attention.  
Finally, careful interpretation of the suicide risk studies reveals that although these 
studies do not directly support a sizeable benefit of active lithium treatment in reducing 
suicide risk, the possibility of a sizable benefit cannot be rigorously excluded.  A degree 
of confounding biasing against lithium in the suicide studies appears likely and 
potentially is substantial.  This set of studies therefore has produced a clear mandate for 
further research, and will hopefully inform multiple subsequent studies inside and outside 
the Veterans Health Administration. 
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Appendix 1-1.  Diagnostic Codes Included in the Cohort 
Since the databases used in this study were initially developed for use in tracking 
the care delivered to a broad collection of Veterans Health Administration (VHA) 
patients with depressive or psychotic disorders, a considerable range of diagnostic codes 
were available for inclusion during database construction.  To maximize power and 
because existing literature suggested than any suicide benefits from lithium might span a 
variety of diagnoses,51, 55 we decided to retain a broad group of eligible mood and 
psychotic diagnoses in the cohort.  Virtually all cohort members had received a diagnosis 
of bipolar I, bipolar II, or bipolar NOS, depression NOS, major depressive disorder, 
schizophrenia, schizoaffective disorder, or “other psychoses” (including Psychosis NOS) 
within the past 30 days, and the prevalence of these diagnostic categories were highly 
similar between the two matched treatment groups (i.e., within a standardized difference 
of <0.018).  Table 2-1 in Chapter 2 provides the data for the final prevalence for each 
treatment group of those diagnostic categories with initial substantial imbalances between 
the treatment groups.  
Specifically, patients could enter the cohort with receipt of at least one of a 
number of ICD-9 codes in the past 30 days prior to lithium or valproate initiation.  The 
most common codes by far were 296.0-296.99 and 311.  Much less common were 295.0-
295.9, 297.0-297.3, 297.8-297.9, 298.0-298.4, 298.8, 300.4, 301.12, 309.0-309.1, and 
293.83.  Only a few diagnoses predominated: bipolar disorder, major depression, and 
depression not otherwise specified; for instance, as Manuscript Table 1 indicates, less 
than 6% of patients in both treatment groups had a diagnosis of schizophrenia or “other 
psychoses.”  In addition, (not shown in Table 2-1) approximately 5% had schizoaffective 
disorder.  Thus, although our final cohort did include a few individuals with 
schizophrenia or “other psychoses,” the final diagnostic composition consisted of only 
11% of individuals with a psychotic disorder, and some of these individuals also had 
diagnoses of eligible mood disorders within the past 30 days.  Furthermore, although our 
entry criteria did permit some increased diagnostic heterogeneity compared to past 
studies, the propensity score-matching did produce an extremely similar prevalence of 
each diagnosis within the two treatment groups (i.e., within a standardized difference of 
0.018 for all diagnostic categories). 
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Appendix 1-2.  Additional Information Concerning Variables Included in the High-
Dimensional Propensity Score 
 
DEMOGRAPHICS AND YEAR OF ENTRY  
Demographics: Indicator variables were used for age (< 35 years old, ≥ 80 years old, and 
intervening 5-year age intervals), sex, and race/ethnicity as recorded in VA system. (Race 
information is relevant to studies of suicide risk because suicide rates vary widely based 
on race.  When information on race was missing it was imputed using methods 
previously developed).  In addition, indicator variables were also included for marital 
status (single/married/separated or divorced/widowed), income, disability status (as 
indicated by percent of “service connection” of a particular disability), distance to 
Veterans Health Administration (VHA) facility, urban/rural location of the facility where 
they are obtaining care, and fiscal year of medication start.  
UTILIZATION 
Utilization variables are derived from VHA clinic stop codes, a set of approximately 500 
codes used to categorize each outpatient encounter.  These codes result in classifying care 
provided into considerably broader categories of care than CPT codes used in “high-
dimensional” propensity scores ,41 reducing the need to consider whether codes should be 
aggregated or whether information is lost without such aggregation.127  
General Mental Health and NonMental Health Utilization:  We calculated the total 
number of VHA clinic stop codes relating to encounters with providers over specific time 
periods.  We then used indicator variables to indicate whether, and at what frequency 
mental health and nonmental health encounters had occurred over periods as brief as the 
last 7 days before medication initiation to longer time periods occurring over the previous 
two years.   
For general mental health utilization, we also constructed variables reflecting the 
total number of hospitalizations (as indexed by discharge dates), and variables dividing 
total MH provider visits into four subtypes (diagnostic interviews, medical management 
visits, and individual and group psychotherapy visits) over different time periods.  For 
general nonmental health utilization, we also included variable representing the number 
of nonmental health hospitalizations and the number of surgery clinic and specialist visits 
(based on stop codes) during particular time periods.  Also, variables were constructed 
reflecting the total ER/Urgent care visits, lab visits, and presence and absence of a flu 
shot in the last year (one possible indicator of preventative care). 
Lastly, for both general mental health and nonmental health utilization, we 
included indicator variables for the total number of mental health and nonmental health 
medications, divided into medications that people were receiving on the lithium/valproate 
start date, the number of medications that they had very recently been taking but for 
which an active prescription did not exist on the date of lithium/valproate start (termed 
“Possibly Discontinued”), and the number of medications recently received (within the 
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last 180 days) but not received in the last 30 days (“Recently Discontinued”).  The types 
of medication considered “mental health” is described under the subsection 
“Medications” below and in Appendix 1-3.  All other medication types were considered 
“nonmental health medications.” 
The distinction between “general/basic” utilization and more specific outpatient 
utilization is somewhat subjective.  For instance, we included the total number of lab 
visits under “general utilization” but included number of X-Rays, EKGs, and other 
diagnostic tests under “Non-Mental Health Diagnostic Tests.” 
 
Mental Health and NonMental Health Outpatient Utilization: Clinic stop codes were 
classified with indicator variables to reflect whether a patient had attended no visits of 
that type, a single isolated visit, or repeated visits (2 or more visits of that type) within a 
time period.  The two time periods examined were the last 180 days prior to 
lithium/valproate start, and the prior 181 to 365 days before lithium/valproate start.  For 
mental health outpatient utilization, visits were classified as occurring with psychiatrists, 
psychotherapists, in the general mental health clinic, primary care behavioral health 
clinic, substance use disorder clinic, or Health Care for Homeless Veterans clinic, with 
additional indicators for visits involving group treatment.  
A much greater variety of stop codes exists for nonmental health outpatient 
utilization.  We chose all stop codes appearing for ≥ 5% of either treatment group in 
either the last 180 days or days 181 to 365 prior to medication start and other, lower 
prevalence clinic stop codes thought a priori to be of importance as indicating potentially 
substantially compromised physical health (e.g., pacemaker clinic, etc.). 
In addition, nonmental health stop codes also were also used to construct the 
diagnostic testing module described below.   
Mental Health and NonMental Health Hospitalizations: The VHA uses approximately 
90 bedsection codes to classify hospitalizations by the type of care received.  The 30 
bedsections that relate to mental health hospitalizations were classified into 4 larger 
classes: Psychiatric-focused hospitalizations, Substance Abuse-focused, Residential/Day 
program, and Domiciliary Program (longer-term housing).   
Because suicide risks with relation to mental hospitalization appear to be time-
dependent, we focused on capturing timing of hospitalization and the nature of the most 
recent hospitalization.  We constructed multiple indicators to reflect the timing of the 
latest discharge date relative to medication initiation, as well as characterizing that latest 
hospitalization into one of the 4 classes of mental health hospitalizations.  
With regard to bedsection codes for NonMental health hospitalizations, a few 
codes were consolidated when counts were observed to be particularly low (e.g., 
dermatology bedsection discharges), but in most cases a simple indicator variable was 
developed to reflect either that the patient’s most recent hospitalization had been of that 
bedsection type, or that any of their hospitalization bedsections in the two years prior to 
medication start had been of that bedsection type.  These latter variables were constructed 
both as a measure of overall disease burden (of conditions of a severity requiring 
hospitalization), because for some progressive conditions earlier hospitalizations or 
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diagnoses can actually reflect worse health prognosis, 130 and because failing health is 
one risk factor for suicide.  These variables included ICU bedsections, “Step Down” 
Bedsections, Telemetry Bedsections, General Medicine Bedsections, Specialty Medicine 
(e.g., Neurology, Cardiology) Bedsections, Surgery Bedsections, etc. 
 
DIAGNOSES 
 
Comorbid Psychiatric and Nonpsychiatric Diagnoses and Indicating Diagnoses:  
Indicator variables were used to reflect a variety of specific psychiatric diagnoses given 
in the past year, based on ICD-9-CM.  We required all cohort members to have VHA 
service use in the last year as well as a prior year, so this time period maximized 
information about what diagnoses a patient likely actually had.  The one exception was 
diagnoses that served as an indication for treatment (mood or psychotic diagnoses), for 
which our criteria was more stringent: we required the diagnosis to be entered in the last 
30 days.  This was done in order to maximize the likelihood that this was the reason the 
patient was receiving lithium or valproate.  
Nonpsychiatric diagnoses are also of importance to address.  In a meta-analysis of 
literature up through 1993, Harris and Barraclough64 observed that 19 different 
nonpsychiatric illnesses were significantly associated with increased suicide risk.  
Nonpsychiatric diagnoses were aggregated into larger categories based on the comorbid 
illness categories that make up the Charlson Comorbidity Index and the Elixhauser 
Comorbidity Index, as per a classification procedure developed for use with 
administrative databases.131  For the Charlson index categories, the following 13 (out of 
the total 17) comorbidity categories were used:  Myocardial infarction, Congestive Heart 
Failure, Peripheral Vascular Disease, Cerebrovascular Disease, Chronic Obstructive 
Pulmonary Disease, Connective Tissue Disease, Peptic Ulcer, Mild Liver Disease, 
Moderate or Severe Liver Disease, Diabetes Mellitus without complications, Diabetes 
Mellitus with complications, Renal Disease, AIDS/HIV Infection.  
Elixhauser Comorbidity categories were also included, based on the same 
reference,131 when these categories were judged not to overlap with the Charlson index 
categories.  The eleven categories included were:  Arrhythmias, Weight Loss, 
Coagulopathies, Pulmonary Circulation Disease, Hypertension without Complications, 
Hypertension with Complications, Valvular Disease, Neurodegenerative Diseases, 
Hypothyroidism, Obesity, Anemia from Blood Loss, and Deficiency Anemia.   
Multiple indicators were also included to reflect total score on the Charlson 
Comorbidity Index, considering all diagnoses received in the past year.  
 In addition, indicators for other injury-related and a few specific diagnoses that 
have been linked to suicide risk (progressive, neurodegenerative or autoimmune 
conditions, and pain diagnosis were included).  Finally, an aggregated smoking indicator 
was included in this category.  Tobacco dependence is recognized as being 
underdiagnosed in VHA administrative/clinical coding, so we constructed a “recent 
smoking” variable which assumed a value of “1” if a patient had any of the three in the 
past year: a diagnosis of Tobacco Dependence, at least one visit to a smoking cessation 
clinic, or prescription of nicotine replacement therapy or varenicline. 
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Comorbid Substance Abuse Diagnoses: Seven categories of legal/illicit substance use 
(alcohol, amphetamine, cocaine, marijuana, opioids, sedatives, other substances) were 
coded as four different indicators reflecting diagnoses received in the last year: 
dependence on that particular substance, abuse of that particular substance, remission 
from dependence of that substance and remission from abuse of that substance.  The 
eighth category, hallucinogens, was coded as only 3 indicators (dependence, abuse, and 
remission from dependence) because there were insufficient numbers of patients (≤ 5 in 
one of the treatment groups) diagnosed with remission from hallucinogen abuse in the 
past year.  In addition, indicators were included for combined substance dependence and 
remission from combined substance dependence, including separate indicators denoting 
whether this combined dependence included opioids or not.  Two indicators were also 
included for “unspecified” substance dependence.  Lastly, indicators were included in 
this category for alcohol intoxication (both a narrow and broad definition) and alcohol or 
drug psychoses.   
 
Recent Nonfatal Suicidal Behavior Diagnoses:  Episodes of nonfatal suicidal behavior, 
especially those occurring recently, are among the strongest documented risk factors for 
suicide,65, 132 however there are concerns that diagnoses may incompletely capture actual 
episodes of nonfatal suicidal behavior.133  There are also concerns that outpatient suicidal 
behavior diagnoses may reflect a history of more remote suicidal behavior rather than 
behavior necessarily occurring close to the time the diagnoses were entered.  To address 
these concerns a hierarchy was imposed to avoid double-counting of nonfatal suicide 
behavior episodes between diagnoses recorded during nonmental health hospitalizations, 
mental health hospitalizations, or during outpatient encounters.  Indicator variables were 
developed reflecting the occurrence of a diagnosis of an episode of nonfatal suicidal 
behavior over the last 30 days, days 31 to 180 and days 181 to 365 prior to 
lithium/valproate start.  This approach is expected to result in only an approximate 
indicator of recently diagnosed episodes of suicidal behavior, since a patient could have 
two separate attempts within a time period that were diagnosed in different settings, and 
this occurrence would not be reflected in our coding scheme.  In addition, the same 
attempt, if a diagnosis occurred close to the end of a time interval in one setting (e.g., 
during a non-MH hospitalization), may have been re-diagnosed in a second setting in the 
next time interval.  Thus this single behavior episode would appear as two distinct 
episodes in our coding scheme, not one.  Some imprecision of this type is likely 
unavoidable.   
Despite such uncertainties, given the extreme importance of nonfatal suicidal 
behavior to predicting suicide risk, we felt it was important to incorporate this 
information when available in our extensive propensity score.  Similarly, it was 
considered important to maintain this distinction concerning the setting of the nonfatal 
suicidal behavior diagnosis, since an episode diagnosed in a non-mental health 
hospitalization is likely to be, on average, considerably more serious than diagnoses 
simply recorded as outpatient diagnoses.  It should be recognized that in general 
diagnoses of nonfatal suicidal behavior are specific but very insensitive, 133 although this 
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sensitivity is expected to increase for inpatient diagnoses compared with outpatient 
(another reason that we made this distinction).   
 
MEDICATIONS 
 
Current and Recent Mental Health Medications:  Mental health medication 
prescriptions active at the time of lithium/valproate start or recently filled (within the last 
180 days) were designated into general classes by 24 indicator variables, using a 
classification system previously developed.  This system already uses multiple categories 
to index antidepressants; for this study we also classified second generation 
antipsychotics into individual medications (clozapine, olanzapine, 
risperidone/paliperidone, quetiapine, aripiprazole, ziprasidone).  Such an enhanced 
classification was important given the differential impacts of these medications on both 
suicide and other mortality risk.  An identical number of indicator variables were used to 
reflect recent but not current prescriptions of medications from these same classes, 
designating receipt of one or more prescription of that type of medication in the last 180 
days in the absence of a prescription whose days’ supply includes the start date for 
lithium/valproate treatment. 
  For nonmental health medications, a system was developed using medication 
class code information assigned by the VHA by the VHA national formulary.  The VHA 
assigns every medication administered from the pharmacy into one of more than 1000 
classes of medication denoted by the VHA through 5 character “medication class” codes.  
We took advantage of this classification as a method to logically aggregate prescriptions 
for related medications (e.g., different thiazide diuretics were able to be aggregated 
through these codes into a “thiazide diuretic class,” different loop diuretics into a “loop 
diuretic” class, etc.).  In many cases, we condensed this “class code” into a 3 character 
“superclass” code, but in other cases, such as the diuretic example above, in which 
further distinctions concerning different types of diuretics were judged important, the 
entire 5 character class code was used.  This condensed the approximately 1000 VHA 
medication classes used by our cohort down to approximately 225 classes/superclasses.  
Then all revised medication classes present with a prevalence of ≥ 5% in either treatment 
group (reflecting number of patients with at least one prescription in the last 180 days, or 
with a current prescription on start date of lithium/valproate) were included, along with 
any revised medication classes of < 5% prevalence but > 1% prevalence that were judged 
a priori particularly relevant to either suicide or other mortality risk (e.g., warfarin, 
digoxin, etc.).   
Indicators for “Current” medication classes required the patient to have an active 
prescription with days’ supply that included the start date of lithium/valproate, while 
indicators for “Recent” medication classes required the patient to have had at least one 
prescription filled in the last 180 days but no active supply at time of lithium/valproate 
start. 
In the rare cases when fewer than 5 individuals had received medications of a 
particular class currently or recently, this class was either removed from the propensity 
score model or consolidated with other medication classes.  This resulted in small 
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differences, for instance, in the number of classes of current nonmental health 
medications (54 variables) versus recent medications (55 variables). 
 
Prior Mood Stabilizer Treatment History: Although we sought to identify incident 
users through the requirement of a “clean period,” some patients, although a clear 
minority (36% of a treatment group or less), had had past treatment more remotely with 
either mood stabilizers of any type, or specifically with lithium or valproate.  Two 
indicator variables were included, reflecting past history of treatment with mood 
stabilizers in general and past history of treatment with either lithium or valproate.   
 
OTHER 
 
NonMental Health Diagnoses Possibly reflecting suicide attempts, NonMental 
Health Utilization of special relevance to suicide risk, and NonMental Health 
medications of special relevance to suicide risk:  Because injuries may occur that are 
not recognized as representing suicide attempts, we included indicators based on a variety 
of injury diagnosis codes, reflecting occurrence of these codes in the last year.  These 
indicators included general indicators reflecting any acute injury or any fracture, as well 
as very specific injuries of concern, such as blood vessel injury, poisoning, and 
inhalation/drowning/and asphyxiation injury.  We also include indicators designating 
pain clinic use, opiate pain medication use, and designating if patients had received 
activated charcoal, or naloxone or flumazenil in the past year.   
 
Geographic Suicide Risk: Indicator variables were constructed to classify patients into 5 
categories (approximate quintiles) of age-adjusted regional (state-level) suicide risk, 
based on publically available data from the Centers of Disease Control, which was 
available from 2000-2007.134  Because these statistics would include the suicides of 
Veterans occurring in this period, there is a theoretical potential for some bias to be 
introduced by control of this covariate.  However, practically, this bias is expected to be 
exceedingly small, given that >150,000 suicides occurred across these states over eight 
years, and our sample accounted for only 102 suicides over that period (< 0.1%).  A 
geographic suicide risk indicator was included because suicide risk has been found to 
vary substantially from state to state for reasons that are not completely understood but 
that might be also expected to influence suicide risk in Veterans specifically (e.g., access 
to firearms).  
 
NonMental Health Diagnostic Testing:  Clinic stop codes reflecting diagnostic 
procedures over the last 180 days and days 181 to 365 prior to lithium/valproate start 
were used to construct indicators of the frequency of diagnostic tests over the past year: 
X-Rays, CT or MRI scans, EKGs, Ultrasound, Echocardiograms, Endoscopy, Pulmonary 
Function Tests (PFTs), Nuclear Medicine, and Angiograms (for Angiograms, tests were 
divided as occurring within the last 180d days and in days 181 to 365 prior to 
lithium/valproate start). 
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Three additional variables were included to help balance the extensiveness of pharmacy 
records among our recipients: any prior use of VA pharmacy, use > 180 days prior to 
LI/VAL start, and use > 365 days prior to LI/VAL start. 
The Table following this Appendix (Appendix 1-2 Supplementary Table 1) 
illustrates how the extensive propensity score-matching strategy balanced the treatment 
groups on key measured covariates.  Because of the much greater number of valproate 
recipients in our unmatched cohort, the effect of the matching is essentially to select 
those valproate recipients most similar (in measured covariates) to the lithium recipients.  
For instance, the single covariate most imbalanced between treatment groups in the 
unmatched cohort (Bipolar I diagnosis, with a standardized difference of 0.28 between 
treatment groups) is much more closely balanced in the matched sample, with the two 
groups having a highly similar prevalence of Bipolar I diagnosis (45.1% versus 45.7% for 
a standardized difference of 0.011) that are close to the prevalence of Bipolar I diagnosis 
in the original, unmatched sample of lithium recipients.  In this fashion, the extensive 
propensity score matching produced a sample from within the original unmatched cohort 
closely balanced (all standardized differences after matching < 0.018) on all 934 
covariates.*    
 
 
 
 
 
 
 
 
_________________ 
* Note concerning covariate count:  In the manuscript and here, we refer to 934 
covariates because these were the number of separate, unique quantities balanced through 
the extensive propensity score matching.  This includes “0 count” indicators for the 
variables modeled as more than 2 levels (i.e. more than just absent/present).  For 
variables with > 2 levels, but not dichotomous variables, the number of individuals 
lacking any presence of that indicator (e.g., 0 additional psychiatric medications at 
baseline) is a separate quantity, rather than simply another form of the information that 
can be obtained from the count of individuals scoring “1” for the indicator. 
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Appendix 1-2 Supplementary Table 1.  Key Characteristics of Patients Initiating Lithium (Li) and 
Valproate (VAL) both Prior to and After Propensity-Score Matching
a 
 
Characteristic 
UNMATCHED Sample MATCHED Sample 
Li (n=21468) VAL (n=71887) Std. 
Diff.
b 
Li (n=21194) VAL (n=21194) Std. 
Diff.
b n, (%) n, (%) n, (%) n, (%) 
Demographics 
Age 50+c 10353 (48.2) 36435 (50.7) 0.049 10244 (48.3) 10156 (47.9) 0.008 
Sex (Female)d 2978 (13.9) 6750 (9.4) 0.140 2894 (13.7) 2934 (13.8) 0.005 
Race, White 16994 (79.2) 52493 (73.0) 0.144 16748 (79.0) 16793 (79.2) 0.005 
Race, Black 2833 (13.2) 14197 (19.7) 0.177 2825 (13.3) 2770 (13.1) 0.008 
Married 7500 (34.9) 26484 (36.8) 0.040 7416 (35.0) 7298 (34.4) 0.012 
State Suicide 
Rate, 3rd quintile 
3325 (15.5) 14647 (20.4) 0.128 3305 (15.6) 3251 (15.3) 0.007 
Indicating Diagnosis
e (Past 30 days) 
Bipolar I  9737 (45.4) 22811 (31.7) 0.283 9562 (45.1) 9683 (45.7) 0.011 
Bipolar NOS 1686 (7.9) 3630 (5.0) 0.114 1643 (7.8) 1661 (7.8) 0.003 
Depression NOS 4233 (19.7) 21693 (30.2) 0.243 4214 (19.9) 4129 (19.5) 0.010 
Schizophrenia 924 (4.3) 6605 (9.2) 0.196 924 (4.4) 949 (4.5) 0.006 
Other Psychosis 252 (1.2) 1914 (2.7) 0.109 252 (1.2) 255 (1.2) 0.001 
Additional Psychiatric Diagnoses (Past Year) 
PTSD 4894 (22.8) 20011 (27.8) 0.116 4842 (22.8) 4749 (22.4) 0.010 
Alcohol Dep 4499 (21.0) 15713 (21.9) 0.022 4426 (20.9) 4478 (21.1) 0.006 
Suicidal Behavior Diagnoses (Suicide Attempt) (past 30d, by location where diagnosed (Dx)) 
NonMH Hosp Dx 28 (0.13) 122 (0.17) 0.010 28 (0.13) 24 (0.11) 0.005 
MH Hosp Dx 30 (0.14) 129 (0.18) 0.010 30 (0.14) 32 (0.15) 0.002 
Outpatient Dx 145 (0.68) 507 (0.71) 0.004 144 (0.68) 147 (0.69) 0.002 
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Appendix 1-2 Supplementary Table 1.  (continued) 
Suicidal Behavior Diagnoses (Suicide Attempt) (past 31-180d) 
NonMH Hosp Dx  44 (0.20) 89 (0.12) 0.020 43 (0.20) 43 (0.20) 0.000 
MH Hosp Dx 32 (0.15) 87 (0.12) 0.008 31 (0.15) 29 (0.14) 0.003 
Outpatient Dx 91 (0.42) 276 (0.38) 0.006 90 (0.42) 82 (0.39) 0.006 
Possible Suicidal Behavior-Related Diagnoses (past year) 
Any Acute Injury 3950 (18.4) 13569 (18.9) 0.012 3872 (18.3) 3884 (18.3) 0.001 
Psychiatric Hospitalizations 
D/C past 7 days 2260 (10.5) 9821 (13.7) 0.096 2232 (10.5) 2219 (10.5) 0.002 
D/C past 8-30d 879 (4.1) 3469 (4.8) 0.035 863 (4.1) 881 (4.2) 0.004 
D/C Past 31-180d 2062 (9.6) 7293(10.1) 0.018 2024 (9.5) 2063 (9.7) 0.006 
Current Psychiatric Medications  
Other Mood 
Stabilizer(s)  3009 (14.0) 6875 (9.6) 0.138 2891 (13.6) 2854 (13.5) 0.005 
SSRI antidep 7700 (35.9) 28496 (39.6) 0.078 7615 (35.9) 7666 (36.2) 0.005 
SNRI antidep  2046 (9.5) 4993 (6.9) 0.094 1988 (9.4) 2019 (9.5) 0.005 
Past Treatment History  
Prior Mood  
Stabilizer 7680 (35.8) 20795 (28.9) 0.147 7503 (35.4) 7530 (35.5) 0.003 
Diagnoses, Nonpsychiatric (past year) 
Mild Liver Dz 1892 (8.8) 3308 (4.6) 0.169 1747 (8.2) 1719 (8.1) 0.005 
Outpatient Utilization, Nonpsychiatric (past 180d) 
Gastroenterology 
Clinic, 1+ visits 1197 (5.6) 2466 (3.4) 0.104 1102 (5.2) 1077 (5.1) 0.005 
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Appendix 1-2 Supplementary Table 1 (continued) 
Current Medications, Nonpsychiatric 
Thiazide Diuretic  1515 (7.1) 7650 (10.6) 0.126 1499 (7.1) 1492 (7.0) 0.001 
ACE Inhibitor 2784 (13.0) 12320 (17.1) 0.117 2764 (13.0) 2736 (12.9) 0.004 
NSAIDs 3516 (16.4) 14738 (20.5) 0.106 3491(16.5) 3522 (16.6) 0.004 
a A partial version of this Table appears as Manuscript Table 2.  Since the degree of imbalance in these variables occurring 
prior to matching may be of interest to some readers, we present this Table again with 5 extra columns to report the 
prevalence of these covariates in the sample prior to matching, and to show the reduction in imbalance resulting after the 
extensive propensity score matching. 
b Std. Diff. = Standardized Difference. 
c Age presented in this format (<50 years old vs. ≥50 years old) to streamline its presentation within this Table: age was 
actually modeled using 11 indicators reflecting age groups from <35 years old in 5-year intervals to ≥ 80 years old. 
d The proportion of females in the cohort is low because the veteran sample is predominantly male. 
e Percentages for Indicating Diagnoses do not add up to 100% because some diagnoses are not substantially imbalanced 
and therefore not listed in this Table (e.g., Major Depression, Bipolar II Disorder, ≥2 Indicating Diagnoses in past 30 days), 
although they were included in the propensity score and balanced through matching. 
 
ABBREVIATIONS: Dep = Dependence; D/C =Discharge, NonMH Hosp Dx = Diagnosed during a Non-Mental Health 
hospital stay, MH Hosp Dx = Diagnosed during a Non-Mental Health hospital stay, Outpatient Dx = Diagnosed during an 
outpatient visit, SSRI = Serotonin-Specific Reuptake Inhibitor, antidep = antidepressant, SNRI = Serotonin-Norepinephrine 
Reuptake Inhibitor, Dz = Disease. 
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Appendix 1-3.  Mental Health Medication Covariates Included in the Analysis 
Because psychiatric medications are of particular importance in both helping to 
index the severity of various psychiatric diagnoses and also as potential direct influences 
on suicidal behavior (e.g., clozapine), we sought to control for a wide variety of potential 
psychiatric medications that cohort members might be receiving.  We also sought to 
produce, through propensity score-matching, two cohorts that were not only similar in the 
psychiatric medications that patients were currently receiving, but also medications that 
they have recently been receiving (within the last 6 months) but were not receiving 
currently.  Such medications may have been treatments that they or their provider 
deliberately decided to stop, or intended to continue but were not successful in so doing, 
or for which they were experiencing only a brief interruption in treatment that happened 
to occur in proximity to their lithium/valproate treatment initiation date.  An additional 
reason it is important to control for concomitant medications is that a current or recent 
history of receiving a psychiatric medication may also influence the subsequent 
psychiatric medications a patient might receive. 
Table 1 in the manuscript lists only those medications for which a substantial 
initial imbalance occurred between the treatment groups.  Appendix 1-3 Supplementary 
Table 1 below lists all the psychiatric medications or medication classes that were 
controlled in our analysis; each of these categories was balanced between the treatment 
groups to a standardized difference of < 0.018 for each of the time periods.
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Appendix 1-3 Supplementary Table 1.  Listing of Mental Health Medications that were Propensity 
Score-Matched between the Lithium and Valproate Treatment Groups  
(24 medication/medication classes x 2 time periods) 
CURRENT MENTAL HEALTH MEDICATIONS (24 variables) 
(active prescription on LI/VAL start date) 
Other Mood Stabilizers  
   (carbamazepine, lamotrigine, etc.)  
Olanzapine 
Quetiapine   
Risperidone  
Ziprasidone  
Aripiprazole  
Clozapine 
First Generation Antipsychotics  
SSRIs 
SNRIs 
Bupropion 
Mirtazapine 
TCAs 
MAOIs 
Benzodiazepines 
Other Hypnotics 
Buspirone 
Stimulants 
Disulfarim (Antabuse)/Naltrexone 
Buprenorphine  
Methadone  
Antihistamines 
Anticholinergics  
Atypical Dopaminergic medications 
RECENT MENTAL HEALTH MEDICATIONS (24 variables) 
 (active prescription within the last 180 days but no prescribed supply extending to LI/VAL start date)  
Same medications/medication classes as Current Mental Health Medications 
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Appendix Table 1-1.  Rates of Continuation or Discontinuation of Initial Treatment and Other Censoring 
Events, by Treatment
a 
Treatment 
Status 
90-day Follow-up 180-day Follow-up 365-day Follow-up 
Lithium Valproate Lithium Valproate Lithium Valproate 
N (%) N (%) N (%) N (%) N (%) N (%) 
Still 
Receiving 
Initial 
Treatment 
9920 (46.8) 9950 (47.0) 4987 (23.5) 5145 (24.3) 1612 (7.6) 1712 (8.1) 
Discontinued 
Initial 
Treatment 
10455 (49.3) 10858 (51.2) 15146 (71.4) 15532 (73.3) 18344 (86.6) 18873 (89.1) 
Initiated 
opposite 
mood 
stabilizerb 
772 (3.6) 327 (1.5) 992 (4.7) 426 (2.0) 1150 (5.4) 489 (2.3) 
Died from 
Other 
causes 
32 (0.15) 42 (0.20) 52 (0.25) 74 (0.35) 70 (0.33) 99 (0.47) 
Died from 
Suicide 15 (0.07) 17 (0.08) 17 (0.08) 17 (0.08) 18 (0.08) 21 (0.1) 
a
 n= 21194 propensity-score matched pairs. 
b
 Patients may have reinitiated treatment subsequently with the same or different mood stabilizer, but this occurred after being 
censored from the “Still Receiving Initial Treatment” subsample of our Intent-to-Treat cohort due to a gap in treatment. 
c This count provides the number censored due to an immediate switch to the other mood stabilizer.  
.
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Appendix 1-4.  Survival Analysis of Suicide Risk by Treatment over 0-90 days, 91-
180 days, and 181-365 days 
 
Survival analysis was performed on the intent-to-treat sample using standard Cox 
regression techniques, but its interpretation was complicated by the fact that 
“nonproportional hazards” over the 0-365 day time period were observed.  The 
observation of “nonproportional hazards,” as evidenced by the crossing of the survival 
curves at approximately 90 days (Manuscript Figure 1) and a statistically significant 
time*treatment interaction term (p = 0.03) means that an important assumption of the 
Cox model was not met.  As a response to the observation of nonproportional hazards, we 
adopted one of several established approaches to addressing nonproportional hazards: 
segregating follow-up time into periods over which proportional hazards were 
observed.135 
However, this segregation of time has an important ramification.  Some of the 
follow-up periods have initiation dates after the actual treatment initiation date, which 
means the close balancing of the treatment groups in the propensity score covariates at 
day 0 can no longer be presumed to necessarily hold for later time periods.  This is a 
substantial limitation.  However, it should be noted that for readers interested in 
examining the differences in suicide risk associated with lithium and valproate treatment 
that accounts for differences in amounts of follow-up time (usually a key function of 
survival analysis), such results are, for practical purposes, already provided in Tables 3 
and 4 of the manuscript.  This is because the extensively propensity-score matched 
treatment groups exhibited highly similar rates of treatment discontinuation for the 0-365 
day and briefer time period analyses.  For instance, for the primary (intent-to-treat 
analysis) over 0-365 follow-up time was 7,699, 086 person-days for the lithium treatment 
group and 7,690,014 person-days for the valproate treatment group (a difference of 
0.1%).  Thus, analyses that focus on events and patients (logistic regression) provide very 
similar results to analyses which formally incorporate person-days of exposure, as the 
very close agreement between the logistic regression and rate ratio results provided in 
Manuscript Tables 3 and 4 demonstrates.   
Given these considerations, we present the logistic regression in the manuscript 
and the survival analysis results here (Appendix 1-4 Supplementary Table 1).  The 
survival analysis segregated follow-up time into periods 0-90 days, 91-180 days, and 
181-365 days after medication initiation to account for nonproportional hazards.  
Significantly increased risks of suicide death were observed among all patients initiating 
lithium, but only for the 91-180 day time period (Hazard Ratio (HR) = 3.50, 95% CI 
1.41, 8.66; Appendix 1-4 Supplementary Table 1).  Similar to the 0-180 day logistic 
regression results reported in the manuscript, virtually all elevated suicide risk among 
patients initiated on lithium during this time period occurred among patients who had 
stopped or modified lithium treatment (19 out of 21 suicides, HR = 3.14, 95% CI 1.25, 
7.85).  Risks among patients stopping/modifying lithium treatment were less pronounced 
over other time periods, especially after completion of the first 180 days of follow-up 
(181-365 HR (after stopping/modifying treatment) = 0.93, 95% CI 0.47, 1.80).  This lack 
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of increased risks among patients stopping/ modifying treatment over 181-365 days 
occurred in conjunction with distinctly, although nonsignificantly, reduced risks among 
patients still receiving initial lithium treatment (HR = 0.26, 95% CI 0.03, 2.34, p = 0.23).  
Although based on extremely few suicides (1 versus 4), these results for active treatment 
with lithium after 180 days may be consistent with the suggestion that lithium will reduce 
suicide over longer durations.  Such an association could be becoming apparent in our 
analyses over this period either due to an increasing protective effect of lithium over time 
or due to diminishment of time-varying confounding in our analyses biasing against 
lithium.   
Given the unusual size of our cohort, to benefit future research we explored 
whether the nonsignificant association of active lithium treatment after 180 days 
strengthened if we lengthened follow-up further.  Interestingly, the association of lithium 
with reduced suicide risk among patients still receiving initial treatment strengthened and 
reached borderline statistical significance from 181–730 days (1 suicide among lithium-
treated and 6 suicides among valproate-treated patients, HR = 0.18, 95% CI 0.02, 1.45, p 
= 0.11), but not from 181 days until the end of the study period (up to 10+ years for some 
patients) (8 suicides among lithium-treated and 8 suicides among valproate-treated 
patients, HR = 1.09, 95% CI 0.41, 2.89).  As follow-up time progressively lengthens, the 
lack of reweighting over time would be expected to be an increasingly strong limitation 
(that is, the small fraction of patients still receiving lithium after several years of 
treatment might be considerably different than the fraction of patients continuing to 
receive valproate).  Clearly, still larger cohorts or cohorts with substantially greater rates 
of treatment persistence will be needed to reliably examine the associations between 
lithium and valproate treatment and suicide risks over follow-up times longer than 365 
days.  In addition, alternative designs could be considered to facilitate examinations of 
longer follow-up times, such as examining the more selectively reported but numerous 
outcome of nonfatal suicidal behavior and using marginal structural models to reweight 
patient samples during follow-up. 
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Appendix 1-4 Supplementary Table 1.  Cox Regression Survival Analysis 
by Time Period since Medication Initiation 
Intent-to-Treat Cohort 
Time Period Hazard Ratio (95% CI) 
0-90 days 0.95 (0.60-1.50)a 
91-180 days 3.50 (1.41-8.66)b 
181-365 days 0.81 (0.43-1.53) 
Stratified by Treatment Status 
Time Period Hazard Ratio (95% CI) 
 
During Exposure to 
Initial Treatment 
After 
Stopping/Modifying 
Initial Treatment 
0-90 days 0.93 (0.54-1.58) 1.43 (0.24-8.36) 
91-180 days NCc 3.14 (1.25 – 7.85)d  
181-365 days 0.26 (0.03-2.35)e 0.93 (0.47-1.84)f 
a Based on Stratified Cox regression (stratified on matched pairs), all other Hazard 
Ratios non-stratified. 
b p = 0.007. Other Intent-to-Treat comparisons (0-90 days and 181-365 days were not 
significant at 0.05 level). 
c NC = “Not calculable.” A hazard ratio cannot be calculated because of 0 suicides in the 
valproate subcohort still receiving initial treatment over this period (2 in lithium subcohort 
still receiving initial treatment).   
d p = 0.015. Other comparisons during exposure to initial treatment and after 
stopping/modifying initial treatment not significant at the 0.05 level.    
e Based on 5 suicides (1 in lithium and 4 in valproate subcohorts still receiving initial 
treatment). 
f Based on 33 suicides (16 in lithium and 17 in valproate subcohorts 
discontinuing/modifying treatment).  
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Appendix 1-5.  A Potential Integration of Key Study Findings  
 
Because this study is distinct in its size compared to past studies, it is worthwhile 
to extract as much information from this study as feasible that may helpfully inform 
judgments concerning its clinical and research implications.  The sections below are 
intended to provide a succinct summary of the reasons why the study results appear, in a 
strict sense, to be compatible with four different scenarios: 1) general equivalency 
between the treatments, 2) increased suicide risks associated with lithium discontinuation, 
3) decreased suicide risks associated with active lithium treatment, 4) and, in what we 
suspect to be the most likely scenario, a combination of some degree of decreased risks 
during active treatment and some degree of increased risks upon lithium discontinuation.  
Such a scenario would also appear to be consistent with substantial past literature, given 
that many nonrandomized studies reporting associations between lithium treatment and 
reduced risks of suicide were restricted to patients receiving active treatment, and several 
studies have documented dramatically increased risk of suicide or suicidal behavior 
shortly after the discontinuation of lithium.13, 20, 21, 23, 136  Nevertheless, it is not clear how 
much more likely this interpretation is to be true than an interpretation that posits little or 
no change upon active treatment but distinct risks upon discontinuation, or an 
interpretation that posits substantial decreases in risk during active treatment and 
generally equivalent risks upon discontinuation.  The final possibility, equivalency 
between the treatments, both during active treatment and after discontinuation appears the 
least likely, given the significant risks observed over the 0-180 and 91-180 days periods 
virtually exclusively associated with lithium discontinuation, and the significant 
differences in diagnostically-coded suicidal ideation.  
Nevertheless, because this synthesis requires integration of both statistically 
significant, borderline significant, and (at some points) clearly nonsignificant results, the 
level of confidence to be placed in this interpretation is highly uncertain.  This material 
should be viewed as a qualitative and nondefinitive synthesis of the overall study 
findings.  It is intended to inform interpretations about the most likely clinical and 
research implications of this study, without attempting to quantitatively estimate the 
degree to which these interpretations are more likely than the specific alternatives that are 
discussed.  
 
Appendix 1-5A.  Implications of Observed High Treatment Discontinuation Rates 
 
The rates of treatment discontinuation observed in the study cohort are quite 
substantial.  In general, the rates of treatment impersistence in this study appear to equal 
or exceed those reported previously.  However, many of these reports do not investigate 
comprehensive incident cohort samples.97, 109, 110, 137  Three exceptions are the Johnson 
and McFarland study113 examining all patients initiating lithium in an HMO, the Kessing 
et al. study114 examining all patients initiating lithium in Denmark, and the Licht et al. 
lithium clinic study.138  Johnson & McFarland113 found discontinuation rates slightly 
greater than our study (median time to discontinuation 72 days, rather than approximately 
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90 days in our cohort), whereas Kessing et al.114 found rates slightly lower rates (82% 
discontinuation in one year rather than the approximately 92% discontinuation in a year 
observed in our study).  Both these studies used estimates of prescription length based on 
number of pills, rather than using the actual prescription directions to calculate a days’ 
supply as done in this study.  In addition, Kessing et al.114 mentioned their sample might 
have had lower than average illness severity given that a majority of prescriptions were 
provided by general practitioners, not psychiatrists.  Also, treatment discontinuation rates 
may be higher in our Veteran sample than other samples, given the high rates of 
comorbidities, substance use disorders 139, and homelessness.  Licht et al.138 reported only 
a 19% discontinuation rate for lithium treatment over 2 years; however, their sample was 
from a specialized lithium clinic and their definition of discontinuation was not provided.   
 Despite the fact that quite substantial rates of treatment discontinuation are 
observed, the observed rates are highly similar between the two treatments.  For example, 
at 90 days 46.8% of patients initiating lithium and 47.0% of patients initiating valproate 
remained on initial treatment, at 180 days 23.5% versus 24.3% patients respectively, and 
at 365 days 7.6% versus 8.1% of patients, respectively.  The fact that rates of 
discontinuation were highly similar between the two treatment arms is reassuring in one 
important sense.  Given the initial close balance in measured factors, if substantially 
different treatment discontinuation rates between the treatment groups had been observed 
instead, this would immediately suggest that the patients remaining on initial treatment in 
each treatment group differed more substantially on measured suicide risk factors than at 
initiation.  However, while the similarity in rates is reassuring, confirmation that the 
reasons for discontinuation are similar is necessary to firmly conclude that treatment 
discontinuation occurring during follow-up did not substantially affect the covariate 
balance between the treatment groups.48  Such information is often not available,48 
especially if selection to discontinue may relate to poorly measured or unmeasured 
factors (e.g., information about suicidal planning, symptoms such as hopelessness, etc.).  
Nevertheless, concomitant psychiatric medications are one class of measured 
factors which could potentially exert some degree of influence on this study’s findings.  
Given that this study’s objective was to characterize whether a comparative difference 
existed in the suicide risk associated with lithium and valproate in their associations with 
suicide risk among Veterans receiving usual VHA treatment, the study cohort was not 
restricted to individuals receiving strict monotherapy.  Differences between the treatment 
groups in concomitant psychiatric medications could arise after lithium or valproate 
initiation, for instance if a tendency existed for patients in one group to be more likely to 
add medications during treatment or after initial treatment discontinuation.  Because other 
psychiatric medications may have their own relationship to suicide risk, rigorous 
examination of these possibilities would ultimately be desirable, and we recommend this 
be a focus of future research.  However, approaches such as marginal structural models 
which periodically reweight samples based on measured factors to keep the treatment 
groups closely comparable may potentially be susceptible to the same amplification of 
the effects of unmeasured factors as baseline confounding; therefore, explorations of the 
effects of concomitant psychiatric medications may need to combine or contrast findings 
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from marginal structural models with approaches that restrict samples to individuals not 
receiving any concomitant psychiatric medications, or certain psychiatric medications, at 
any point during follow-up.  Because such restrictions reduce sample size, such efforts 
ideally would involve even larger samples than the one we had available.  
It should be recognized that close balancing was achieved of the patient groups on 
an extensive set of medications psychiatric present at the time of lithium or valproate 
initiation (Appendix 1-3), and also on wide variety of other factors.  Thus, at least for a 
substantial portion of the follow-up period (the earlier months), concomitant medications 
between the groups are likely to be highly similar.  In addition, the balance achieved 
between the treatment groups also included a number of fixed factors (e.g., age) and 
slowly time-varying factors (e.g., additional psychiatric diagnoses) that might influence 
prescribing of concomitant medications.  Furthermore, a distinct aspect of this study was 
that not only were current concomitant psychiatric medications controlled, but also the 
use of psychiatric medications within the last 6 months that were no longer being 
currently prescribed.  To the extent that recent receipt of particular classes of medications 
might plausibly influence choice concerning what subsequent medications should be 
initiated, these influences were tightly balanced at baseline.  As mentioned above, a 
design that rebalances the sample during follow-up with respect to concomitant 
medications is the ideal and should certainly be a future research priority, especially if 
efforts are made to examine longer periods of follow-up.  This study did incorporate 
design features which likely limited the impact of selection during follow-up compared to 
some other designs.  However, since we did not formally attempt to control the impacts 
of selection during follow-up, this limitation should be borne in mind when interpreting 
this study.   
While our study did not attempt a formal analysis incorporating changes 
occurring during follow-up, some aspects of our study serve to diminish concerns that 
differences between the treatment groups in the selection of patients to continue or 
discontinue treatment during follow-up explain all or most of our findings.  Specifically, 
differences in selection during treatment alone would not be expected to create the 
(marginally significant) differences in intent-to-treat estimates measured from treatment 
initiation.  Intent-to-treat estimates continue to incorporate outcomes from all treatment 
initiators, regardless of a patient’s status of still receiving or having discontinued initial 
treatment.  In a sense, patients are not selected out of an intent-to-treat cohort during 
follow-up.  This is especially for an outcome such as suicide, which is comprehensively 
documented nationwide, regardless of whether patients continue to receive care from the 
Veterans Health Administration. 
Differences in selection during follow-up would certainly be expected bias the 
treatment effect estimates observed for patients during active treatment (the only type of 
treatment effect estimate reported in virtually all of the earlier nonrandomized studies of 
lithium) or after treatment discontinuation.  However, such selection would not bias the 
intent-to-treat estimates (in the absence of genuine treatment effects).  Thus, the 
marginally statistically significant intent-to-treat results observed associated with lithium 
treatment after discontinuation over 0-180 days, and the significant risks result over 91-
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180 days (Appendix 1-4), are very important observations since they help restrict the 
potential explanations for the significantly elevated risk observed in patients 
discontinuing lithium over 0-180 days.  
The high rates of discontinuation also suggest the possibility that discontinuation 
decisions may have been made largely by patients rather than providers, and these 
decision may have plausibly related much more to concerns such as stigma, side effects, 
and a lack of perceived efficacy than suicide risk directly.  Thus, it is possible that the 
high rates of discontinuation, while quite sizable, may have had relatively little impact on 
the treatment effect estimates.  In addition, any early provider-based selection that 
occurred should probably most likely be suspected of occurring in the direction of initial 
confounding, rather than against it.  Initial confounding appears to bias to some degree 
towards higher risks observed with lithium, based on the risks observed in the unmatched 
cohort and the greater prevalence of diagnostically-coded suicidal ideation among 
patients initiating lithium in the matched cohort.  If providers on average selected higher 
risk patients to initiate lithium at Day 0, it seems somewhat unlikely that they would 
reverse this tendency in treatment very shortly after treatment started.  Selection in the 
direction of more often retaining higher-risk individuals on lithium than valproate would 
be in the opposite direction of what would be needed to explain the significantly elevated 
risks in patients discontinuing lithium over 0-180 days.   
As a side note, if selection during follow-up did occur in the direction of retaining 
higher-risk individuals on lithium, this would represent a likely third process, along with 
residual baseline confounding and the likelihood, discussed in the manuscript that some 
suicides attributed as occurring “during initial treatment” actually occurred after 
treatment discontinuation, that would be expected to lead to an underestimate of the 
benefit of lithium during active treatment.   
 
Appendix 1-5B.  Likelihood of Substantial Residual Confounding Amplification  
 
Propensity score designs, especially when studying rare or infrequent outcomes, 
permit inclusion of far more covariates than some alternative approaches.  We sought to 
take advantage of this capability to thoroughly control for numerous suicide risk factors 
and potential suicide risk factors in this study’s design by including a large variety of 
covariates and flexibly modeling their distribution, frequency and timing.  We recognized 
that several potential suicide risk factors (suicidal ideation, planning, etc.) would remain 
unmeasured.  If unmeasured confounding remains uncontrolled in a propensity score 
analysis, it has recently become appreciated that the effect estimates produced may 
include an additional source of balance: amplification of whatever confounding remains 
uncontrolled after application of the propensity score methods.43-46  This problematic 
effect occurs if the propensity score includes covariates with a substantial or strong 
association with treatment exposure in the absence of an association with outcome.  We 
took steps that limit the amount of potential amplification of residual confounding that 
application of our propensity score approach might produce.  All variables were 
evaluated to determine their relationship with both treatment and outcome.  Covariates 
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with particularly substantial relationships with exposure to one or the other treatment 
were then evaluated individually to assess their plausibility as confounders.  (Of note, 
none of the many covariates in the model had what might be considered a particularly 
“strong” association with treatment exposure by some definitions.  That is, no covariates 
had an odds ratio for treatment exposure to lithium versus valproate, of even 3.0 or 0.33).  
Nevertheless, given the large number of covariates included in the model, it is possible 
that some degree of amplification of residual confounding was produced by our design.   
However, even if the design created the potential for some amplification of 
residual confounding, the actual quantitative bias that would result would depend heavily 
on how much residual confounding was present after application of the propensity score.  
If little or no residual confounding exists, amplification of this confounding would have 
to exist on a very pronounced scale (e.g., 2-fold, 3-fold, etc.) to substantially bias the 
overall findings (assuming a reasonably-sized treatment effect estimate exists).  
Importantly, with a c statistic of just 0.69, our propensity score is in the lower portion of 
the range of exposure prediction.  A recent simulation, although using R2 rather than the c 
statistics, found that propensity scores in the lower portion of the range of exposure 
prediction should be expected to amplify confounding somewhat modestly (i.e., < 2-
fold).47  In addition, in our study it remains possible that even the initial confounding may 
have been fairly minimal, given the generally close balance (standardized difference < 
0.1) observed initially for over 98% of the covariates examined.   
Nevertheless, we did observe a significant difference in the non-matched 
covariate denoting the presence of diagnostically-coded suicidal ideation, although the 
imbalance between treatment groups was only OR = 1.30.  Due to the low prevalence of 
diagnostically-coded suicidal ideation, this corresponds to a standardized difference of 
only 0.04, which is still greater than any standardized difference for any variable included 
in the propensity score (< 0.018).  Very little is known about the degree to which 
diagnostic codes for suicidal ideation underestimates actual suicidal ideation, but 
underestimation almost certainly occurs.  However, sensitivity analyses proportionally 
boosting the prevalence of suicidal ideation indicates that only when the rates for 
diagnosed-coded suicidal ideation are multiplied ≥ 6-fold to reflect possible overall 
suicidal ideation rates (i.e., including ideation that is both coded and which was not 
recorded with the diagnostic code) does a standardized difference of ≥ 0.10 occur.  
Nevertheless, this would correspond with suicidal ideation rates in the past 30 days of  
15-19%.  Such a rate conceivably is plausible, albeit perhaps at the upper limit of what 
might be expected.  This sensitivity exercise also presumes that the same difference in 
suicidal ideation occurs between the treatment groups for the non-coded suicidal ideation 
rates as for the diagnostically-coded rates. 
The possibility that standardized differences even in an important covariate not 
included in the propensity score may remain generally modest (e.g., standardized 
difference < 0.10) is important.  As pointed out above, the influence of confounding 
amplification on the results is proportional to the amount of residual confounding that 
remains.  If residual confounding is modest, the added effect of residual confounding 
amplification is likely to be still more modest, at least in this range of exposure 
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prediction.47  However, just as clearly, if a substantial degree of residual confounding 
persists (in this study such confounding might result from the known suicide risk factors 
not able to be incorporated in the model), then amplification of residual confounding 
could potentially increase overall residual confounding.  In a sense, amplification of 
residual confounding would be expected to operate similar to amplification in other 
systems:  if residual confounding is minimal, most levels of amplification will not 
produce a level of confounding that is much different quantitatively.  However, if 
residual confounding is substantial, then amplification of residual confounding can serve 
to substantially further increase the degree to which the effect estimate reflects 
confounding.  
Perhaps this study’s most important observation regarding the degree of concern 
that should exist regarding possible amplification of residual confounding amplification 
is the observation that regardless of possible amplification of residual confounding, the 
propensity score matching methodology appears to have effectively reduced the overall 
confounding observed between the treatment groups.  At each time point studied, the 
odds ratios obtained prior to matching were further from the null than after matching.  
For instance, over 0-90 days, when the highest proportion of patients were receiving 
active treatment, matching on measured factors reduced the central estimate of the intent-
to-treat association from 1.10 to 0.95.  Over 0-180 days, movement in the intent-to-treat 
odds ratio estimate from 1.70 to 1.56 was observed after the propensity score matching.  
Over 0-365 days, the analysis which was informed by the largest number of outcomes, 
the intent-to-treat odds ratio prior to matching had a central estimate of 1.45, while after 
matching a central estimate of 1.22 was obtained.  Given that the number of past findings 
suggesting that active lithium treatment is associated with either a reduction or at least a 
neutral association with suicide risk,12, 15 such movement in the estimate away from more 
extreme increased risks being associated with lithium treatment suggests that overall 
confounding has been reduced, not amplified.   
The observation that overall confounding appears to have been reduced by the 
propensity score matching methodology does not mean confounding amplification 
resulting from our methodology does not exist, nor that no confounding exists.  Rather, 
this data suggests that any confounding amplification introduced by our propensity score 
matching methodology, when added to the remaining confounding already present, is not 
sufficient to negate the effectiveness of the methodology in improving our reported 
results by beneficially reducing overall confounding.  Of course, if substantial residual 
confounding amplification is present, this implies that a more optimal control of overall 
confounding is possible.  However, the path to achieving that more optimal state is not 
necessarily obvious.  Removal of variables from the propensity score would certainly be 
expected to reduce residual confounding amplification, but ironically may increase the 
amount of residual confounding (if the removed variables actually had a recognized or 
unrecognized association with outcome), so that overall confounding might actually 
increase.  
The risks of suicide by treatment from the unmatched cohort are important to 
examine for a second reason.  They indicate that the general pattern of intent-to-treat risk 
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observed in the matched analysis closely parallels the pattern observed prior to the 
propensity score matching.  That is, the pattern of generally similar intent-to-treat risks 
over 0- 90 days, changing to substantially increased risks with lithium treatment at 0-180 
days due to a prominence of risks among patients discontinuing lithium, followed by a 
lessening of this increased risk at 0-365 days, is not a product of some artefact produced 
by the propensity score matching.  It is a pattern observed even prior to any matching, 
and thus does not appear to result from the actions of any residual confounding 
amplification.  
Another important observation relevant to judgments about confounding 
amplification results from the sensitivity analysis in which approximately half of the 
propensity score variables were removed (Appendix 1-6).  This modification resulted in 
only a modest change to the effect estimate.  Given that removal of these variables were 
associated with only a modest change in the treatment effect estimate, the corollary is 
inclusion of these covariates, despite the fact they exhibited only minimal univariate 
association with outcome, likely produced only modest confounding amplification.  
Stated another way, the observation that large risks that continue to be associated with 
lithium treatment discontinuation despite removal of all covariates lacking a substantial 
association with outcome (+/- 20%) suggests that either risks associated with lithium 
discontinuation, nonamplified residual confounding, or possibly selection during 
treatment is largely responsible for those significantly increased risks, rather than 
amplification of residual confounding.  As we discuss below, this finding does not 
necessarily mean that overall residual confounding was modest, since we were unable to 
control for some important risk factors, only that amplification of any residual 
confounding amplification appears to be modest in effect.   
In the future, there are certainly alternative approaches which can be considered 
when employing an extensive propensity score in a study of suicide risk to potentially 
optimize confounding control while further limiting confounding amplification.  One 
approach would be to apply an outcome-based selection criteria from the beginning of the 
study (e.g., such as requiring included covariates have at least a +/-20% association with 
suicide).  In some cases, the lack of a univariate association with outcome does not 
necessarily indicate that variable is not a genuine confounder.  Associations with 
correlated variables with differing associations with suicide risk could conceal the actual 
relationship between the variable and the outcome.  Alternative approaches might be to 
adopt the 20% restriction for variables judged particularly unlikely to be associated with 
suicide risk (e.g., the nonmental health covariates with the least established association 
with suicide risk), or apply the 20% restriction just to those covariates with the strongest 
association with treatment, or select the variables on the basis of highly multivariate 
regression associations.  However, the approach which thus far has been demonstrated to 
apparently minimize confounding thus far in two patient cohorts is a blanket requirement 
that all covariates have at least a +/- 20% association with outcome,102 although the 
generalizability of this observation is uncertain.  Another decision point to be explored is 
how to handle multilevel variables.  We retained multilevel covariates in which any strata 
had at least a 20% association with suicide, but alternatives can be readily envisioned of 
136 
 
 
 
requiring that a majority of strata have at least a 20% association, or all strata have such 
an association.   
Clearly, further research in this area is of particular importance.  In sum, however, 
it does not appear that amplification of residual confounding was likely a major influence 
upon our findings.  This tentative conclusion is suggested by the observations that our 
overall propensity score approach appeared to result in a substantial reduction in 
confounding, did not alter the basic pattern of risks over time and by treatment status 
observed between patients initiating lithium and valproate, and the observation that the 
removal of almost half of our propensity score covariates had only a modest effect on the 
treatment effect estimates. 
 
Appendix 1-5C.  Likelihood of Some Residual Confounding Persisting in the 
Analysis 
 
Although any amplification of residual confounding may be modest, at least three 
lines of evidence that suggests that some degree of residual confounding may persist in 
the analysis.  The first and simplest line of evidence is that rates of suicidal ideation (as 
reflected by diagnostic codes received by member of the cohort from 2005-2008) were 
statistically different between the treatment groups.  The difference in prevalence in 
diagnostically-coded suicidal ideation is modest (OR = 1.30, 95% CI 1.09, 1.54), and 
patients who express suicidal ideation are not necessarily those at the highest risk of 
suicide.140  However, such patients are almost certainly at higher risk for suicide than 
many other patients in the cohort, thus this data strongly suggests the presence of at least 
some degree of baseline confounding biasing against lithium.  While it is easy to 
appreciate how the imbalance between the treatment groups in diagnostically-coded 
suicidal ideation could potentially lead to residual confounding biasing against lithium, 
estimating the potential quantitative size of this effect is much more difficult.  
Nevertheless, such estimates, even if somewhat qualitative, are of considerable 
importance, given that any degree of residual confounding biasing against lithium 
suggests that a stronger protective association between lithium treatment and suicide risks 
exists (to a similar degree) than estimated from logistic regression.  
For instance, Kim et al. found that, from VHA charts of patients receiving 
treatment for depression, suicidal ideation in the past year in the absence of an attempt 
was associated with suicide with an odds ratio of approximately 3.0.141  If the sensitivity 
assumption that diagnostically-coded suicidal ideation underestimates actual suicidal 
ideation by up to a factor of 6, then the observed imbalance in diagnostically-coded 
suicidal ideation rates would imply that the overall imbalance in suicidal ideation might 
account for a bias of up to approximately 0.3 on the observed odds ratio.  The impact of 
this imbalance would be less than this amount if it is assumed that diagnostically-coded 
suicidal ideation rates underestimate genuine suicidal ideation by a factor less extreme 
than 6-fold; however, the impact of this imbalance could be greater than approximately 
0.3 if it is assumed that some of this suicidal ideation was also associated with suicidal 
planning or preparatory actions acquiring access to means, both of which are more 
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strongly associated with suicide risk.141  Thus, it is plausible that the imbalance in 
suicidal ideation could account for approximately 60% of the increased risk observed 
among patients stopping/modifying treatment over 365 days (central estimate OR=1.51), 
although certainly the impact of suicidal ideation, depending on its prevalence and 
severity, on observed risk could also be less or more than this amount.  Of particular 
relevance, an impact of this magnitude upon residual confounding resulting from the 
imbalance of suicidal ideation would imply a central estimate odds ratio during active 
treatment over 0-365 days of approximately cOR=0.68, rather than the cOR=0.86 that 
was observed.   
The second line of evidence is the fact that central effect estimates did change, 
albeit modestly, during the modified propensity score sensitivity analysis in which almost 
half the covariates were removed (Appendix 1-6).  This suggests that some degree of 
confounding amplification may exist, which by extension then implies the presence of 
some degree of residual confounding still persisting after the propensity score matching.  
(Some residual confounding must exist for residual confounding amplification to have 
any noticeable quantitative effect).  
The third line of evidence is the least definitive and straightforward, but relates to 
the observation of increased risks among patients stopping or modifying initial treatment 
over 0-180 days.  Of note, these observed risks both strengthened and remained 
significant when only patients stopping, rather than modifying or resuming treatment 
were considered (Table 2-4, Footnote i), when risks were examined among patients 
stopping or modifying treatment over 91-180 days (Appendix1-4), and among all patients 
initiating lithium compared to valproate over 91-180 days (Appendix 1-4).  Residual 
confounding is one of several possible explanations for the observation of increased risk 
in patients discontinuing one treatment compared to discontinuing another treatment48, 49  
However, this conclusion is far from definitive because several other processes can 
influence risk among patients who have stopped initial treatment.  In the strictest sense, 
for risks in “former users” to most directly reflect baseline confounding, such 
confounding must not vary substantially over time, substantial differences must not exist 
in the rates or reasons for discontinuing treatment between treatment groups,48 any effects  
from active treatment must not persist into the period after discontinuation, and/or 
discontinuation of one medication cannot generate different risks (e.g., “rebound” effects) 
than discontinuing the comparison medication.  
In Appendix 1-5D, we discuss the evidence from the time course of risk in 
patients discontinuing treatment that suggests to us that at least some of the risk observed 
in patients who have discontinued treatment is attributable to risks results from 
discontinuation (or selection), not from confounding.  However, in Appendix 1-5E we 
will discuss an integrative synthesis that includes a consideration of the associations 
observed in the intent-to-treat sample and among patients still receiving initial treatment 
from 181-365 days.  These associations suggest not only that an association between 
active lithium treatment and reduced suicide risk is possible, but also that it may be 
sizable.  
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Appendix 1-5D.  Likelihood of Differential Suicide Risk Associated with Lithium 
versus Valproate Discontinuation  
 
Several lines of evidence appear to support the possibility that differential risk of 
suicide may be associated the discontinuation of lithium compared to valproate.  If so, 
such differences could explain (along with residual confounding and possibly some 
contribution from differences in selection during follow-up) part or all of the statistically 
significant increased risks associated with patients discontinuing lithium compared to 
valproate over 0-180 days and, in the survival analysis, over 91-180 days.   
The most important line of evidence is that the time course of risk appears to 
more straightforwardly support the possibility of differential risks upon lithium versus 
valproate discontinuation than residual confounding.  If residual confounding was 
primarily responsible, the general expectation would be that the time-varying pattern of 
suicide risk over time among patients discontinuing lithium treatment would decrease 
progressively from a peak in the first 90 days.  A pattern of risk consistent with this 
possibility has been observed in relation to antidepressant initiation,17, 122 although the 
possibility cannot be excluded that antidepressants may increase suicidal behavior risk 
early in treatment in some sensitive individuals, especially of younger age.142   
If initiation of a medication is viewed as a clinical event that likely serves as a 
marker of a patient sufficiently symptomatic to be at higher than usual risk, 18 then it may 
be relevant to consider the time course of risk concerning other, even more dramatic 
clinical events which may serve to identify patients as being at particularly high risk 
(such as suicide attempts and hospital discharges).  In these instances, highly time-limited 
periods (7-30 days) of extreme risk have been observed (i.e., risks of suicide 10-20X 
greater than what is observed much later  
(e.g., 6 months - 1 year subsequently).63, 65, 66  Thus, the general expectation would be that 
residual confounding, if present, would be the greatest over 0-90 days and decrease in 
subsequent periods.  
Instead, the difference in risk observed among patients discontinuing lithium 
compared to valproate is less evident in the first time period (0-90 days) and then 
becomes much more evident in the subsequent 90 days.  This pattern appears more 
compatible with a developing risk, i.e., a risk that is not initially present but then becomes 
increasingly present over the first 180 days of treatment.  Such an emerging risk fits 
closely what would be expected from risks among patients discontinuing treatment, in 
that patients do not start treatment in the status of no longer receiving treatment.  Rather, 
this status must develop over time.  Furthermore, the period of highest risk (0-180 days, 
or more precisely, as the survival analysis suggests, 91-180 days) would incorporate the 
period of time in which the majority of patients in the cohort would have been 
discontinued from their treatment for 1-5 months.  Interestingly, this corresponds closely 
to the period previously observed to be of highest risk for mood episode relapse in 
patients rapidly discontinuing lithium treatment (median time 4.0 +/- 0.7 months), 
although this information was gathered from patients who had been on lithium 
maintenance treatment.80  Although the time course of the development of risk in the 
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patients discontinuing initial treatment appears very compatible with an emerging risk 
such as risk associated with discontinuation itself, some caution in interpretation is 
warranted.  The more modest risks observed from 0-90 days in patients discontinuing 
initial treatment are based only on 5 total suicides, meaning this estimate (which suggests 
a lower difference in risk among patients discontinuing treatment over the first 90 days 
than over days 91-180 days) is particularly uncertain. 
A second, related line of evidence supports the presence of some degree of 
differential risk being associated with lithium, compared to valproate, discontinuation.  It 
is important to note that between 0-90 days and 0-180 days the movement in the estimate 
of risk among patients still receiving initial treatment is modest.  A central estimate cOR 
of 0.87 exists over 0-90 days, compared to a cOR of 1.0 over 0-180 days. (Since there 
were no suicides in the valproate group on current treatment from 91-180 days, a hazard 
ratio for this period among patients receiving initial treatment unfortunately is not 
available.  Therefore, comparisons must be made between the nested 0-90 and 0-180 day 
periods).  If confounding was the primary or exclusive explanation for why risks in 
patients discontinuing treatment increased from 1.49 (central estimate) over 0-90 days to 
2.72 over 0-180 days, quite a sizeable increase, then risks associated with active 
treatment would be expected to rise considerably unless the treatment effect strengthened 
quickly.  Some minor increase in risk associated with active treatment does occur, but 
nothing similar in size to the increase occurring among patients discontinuing treatment.  
This suggests that the increase in patients discontinuing lithium treatment most likely not 
due primarily to increases in confounding.  This pattern also suggests the elevated risks 
are not the product of selection during follow-up favoring the highest risk individuals 
being discontinued from lithium.  While such selection would produce increased risk of 
suicide being observed in conjunction lithium, rather than valproate, discontinuation, it 
would also be expected to result in a compensatory decrease in risk in patients still 
receiving active treatment.  Instead, the risk increases slightly (from cOR = 0.87 to cOR 
= 1.0).  Thus, the relative stability observed in the estimate of suicide risk associated with 
the two treatments among patients still receiving initial treatment between 0-90 and 0-180 
days suggests that the differing risks of suicide observed upon lithium, compared to 
valproate, is most easily explained by a process that would be restricted just to the 
patients discontinuing initial treatment.  The two other candidates to influence this effect 
estimate, confounding and selection during treatment, both would be expected to 
substantially affect the treatment effect estimate for patients still receiving active 
treatment as well.  Thus, by process of elimination, this data most easily supports the 
existence of risks being associated directly with the discontinuation of lithium, compared 
to valproate.  However, how much more likely this possibility is than the alternatives of 
confounding and selection during treatment cannot be determined, and complex 
combinations of two or three of these processes occurring simultaneously cannot be 
excluded.    
The third line of evidence is that the risk appears to completely resolve by  
181-365 days (although random variation could contribute to this finding).  If 
confounding increased over 91-180 days compared to 0-90 days, it seems appear less 
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plausible this confounding would virtually completely resolve by 181-365 days.  
However, a rapid resolution of risk is more plausible if the peak risks directly associated 
with lithium discontinuation were highly time-limited (as has been somewhat observed 
for the risk of mood episode relapse).80  As discussed in Appendix 1-4, very few suicides 
occurred in patients “newly discontinuing” over 181-365 days, thus the risk estimate for 
patients stopping/modifying initial treatment are particularly influenced by the risk 
observed among the large majority of patients are counted as having stopped/modified 
treatment: those who initially discontinued months ago (i.e., over 0-180 days).  Previous 
studies of suicide risks after discontinuation of lithium maintenance treatment have found 
the increased risk to be clearly time-limited, although the analyses do not address whether 
the time-limited period of risk is confined to any time period shorter than the first year 
after discontinuation.20  However, it is especially notable that the Goodwin et al. 2003 
cohort study,16 which, like this one examined risks starting at the point of treatment 
initiation, noted that 32% of all the suicides occurring after treatment discontinuation 
occurred within the first month after discontinuation.  Unfortunately, the Goodwin et al 
study16 did not report whether this suicide risk differed between lithium, valproate, and/or 
carbamazepine (perhaps because the low numbers likely would have prevented any 
statistical significance findings).  Nor did their report describe whether these risks 
occurred in conjunction with discontinuation occurring early or late in treatment.  
One caution for this interpretation is that the two previous studies by Yerevanian 
and colleagues which compared risk of discontinuing lithium and valproate found 
discontinuation of both medications to be associated with similar and substantial 
increased risks of suicidal events (attempts or hospitalization for suicidal ideation).22, 23  
One major potential difference between the studies, however, is that our study was 
focused exclusively on risks observed within one year of initiation, while the Yerevanian 
studies typically examined lengthy courses of treatment, on average.  For example, 
average follow-up in the 2007 study was approximately 38 months per patient, of which 
approximately > 90% of this time was accounted for by time receiving medication.  This 
longer follow-up time, including more time on medication further from medication 
initiation, might have served to strengthen the association of both medications with 
relatively low rates of suicide during treatment.  This in turn may have produced a larger 
contrast upon discontinuation, especially if the discontinuation is associated with 
decompensation prompting either the patient or provider to discontinuation treatment. 
 
Appendix 1-5E.  Summary and Integration of Key Findings 
 
Although our data initially appears most straightforwardly consistent with an 
interpretation that lithium treatment either is associated with similar suicide risks or 
increased suicide risks compared to valproate in this Veterans cohort over the first 365 
days of treatment, several important complexities present themselves.  The first 
complexity is that any increased risk associated with lithium treatment appears to be 
entirely or almost entirely associated with risks observed after treatment discontinuation, 
not during active treatment.  This suggests that, in contrast to most comparative 
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effectiveness studies, the degree to which the medications may differ in effectiveness 
relates substantially to what is observed after treatment discontinuation, rather than 
during treatment.   
The second major complexity is the highly time-varying pattern of the intent-to-
treat risks, going from a central estimate hazard ratio of 0.95 at 0-90 days to 3.50 at 91-
180 days to 0.81 at 181-365 days, with the 91-180 day hazard ratio being statistically 
significant.  This pattern, although it could reflect a large contribution from random 
variation, appears suggestive of a substantial emergent risk developing after 90 days of 
treatment in those discontinuing treatment.  In general, baseline confounding occurring 
after a marker of high risk such as treatment initiation18 would be expected to diminish 
steadily, with the highest risk being observed shortly after treatment initiation (Appendix 
1-5D).  Therefore, residual confounding does not appear to be a good candidate to 
explain this emergent risk, nor does another possibility, selection during follow-up.  In 
theory, selection of patients during follow-up could certainly produce such an emergent 
risk in patients discontinuing lithium, if the patients being discontinued from lithium 
were those at particularly high risk for suicide.  However, in the absence of a genuine 
medication effect, selection during follow-up in two treatment groups with similar 
discontinuation rates would not be expected to alter intent-to-treat risks measured from 
treatment initiation (Appendix 1-5A).  Although we observe only marginally significant 
intent-to-treat risks from initiation over 180 days, it also should be noted that if selection 
was occurring in the direction to explain the elevated risks among patients discontinuing 
lithium at 180 days, this selection should also engender a reduction in risk among patients 
remaining on initial treatment (since the highest risk individuals are being removed from 
this patient group).  This is not what is observed, instead, the central estimate of the risk 
among patients still receiving initial treatment stays essentially the same (to be precise, 
increases slightly, rather than decreases).  If confounding or selection during follow-up is 
not accounting for this sharply increased risk at 91-180 days, then the emergent risk that 
is suggested is suicide risk that is associated with the discontinuation of lithium early 
during lithium treatment.  Furthermore, it would appear that such risk is somewhat 
limited to a relatively brief period after lithium discontinuation, seemingly similar to the 
timing of risks for mood episode recurrences previously noted for others after rapid 
discontinuation of lithium treatment.80  
 The third major complexity is that intent-to-treat risks do not remain substantially 
elevated in the final time period, but rather decrease to such an extent that an intent-to-
treat estimate is in the direction of lower suicide risk associated with lithium for 181-365 
days (albeit this finding is clearly nonsignificant, and thus potentially being the result of 
chance).  Although the role of chance limits the weight that can be placed on this finding, 
this is potentially a very important observation, given that both any residual confounding 
and risks associated with discontinuation appear clearly to be most likely associated in 
the direction of greater suicide risk observed with lithium.  If both these important 
components to an intent-to-treat estimate would be expected to be in the direction of 
increased risk being associated with lithium treatment, then an obvious candidate that 
remains to account for a reduction in suicide risks is an active medication effect among 
142 
 
 
 
the patients still receiving initial treatment.  The observed risks over 181-365 days also 
suggest that both any confounding and the effects of risk from discontinuation for the 
bulk of the cohort have resolved, a conclusion consistent with the risk of OR = 0.93 
observed among patients who have discontinued treatment.   
 The opportunity to examine risks from this period (181-365 days after initiation) 
are of particular interest, not only because of the possibility for observing relatively 
unconfounded estimates of lithium’s treatment effect that the data somewhat suggests, 
but also because of the potential size of that possible effect.  The reduced risk estimated 
by the central estimate of the intent-to-treat hazard ratio for this time period (0.81) is not 
clinically insubstantial, although it must be kept in mind that this association does not 
achieve statistical significant and part of this reduction appears accounted for by the 
slightly reduced risk of suicide in patients who have discontinued lithium, compared to 
valproate, treatment (the large majority of which would now would be separated by 
months from their discontinuation event).  Nevertheless, this observation suggests there is 
at least a reasonable possibility that active lithium treatment is serving to reduce suicide 
risks of the fraction of patients still receiving lithium within this time period.  Given that 
active treatment now only represents about 16% of the total follow-up time contributing 
to the intent-to-treat estimate within this time period, to the extent that the effects of 
active treatment are contributing to this intent-to-treat effect estimate, the association 
between active lithium treatment and reduced suicide risk could be rather sizeable.  
Consistent with this inference, a sizable association (cOR = 0.26, 95% CI 0.03, 2.35) is 
what is observed among patients still receiving their initial treatment, although it does not 
reach statistical significance (p = 0.23), is informed by just 5 suicides total (1 in lithium 
recipients and 4 in valproate recipients), and may also reflect contributions from any 
effects of differential selection during follow-up.  Thus, despite the overall 
nonsignificance of our primary analysis over 0-365 days, and the significant associations 
observed between lithium discontinuation and increased suicide risk over the first 180 
days, our data also suggests, although with much less confidence, that a clinically 
meaningful reduction in suicide risk may be associated with active lithium treatment after 
just 181 days of treatment.  In this context, it is noteworthy that when the analysis of 
individuals still receiving initial treatment is continued to 730 days, this association 
strengthens (cOR = 0.18) and almost achieves marginal statistical significance (p = 0.11) 
(Appendix 1-4), although this relationship does not persist until the end of follow-up.  
It should also be noted that, because of the direction of any residual confounding 
apparently biases against lithium, it is plausible that similar reductions in suicide risk 
exist over 0-180 days, but this reduction is simply concealed by confounding.  In 
addition, as mentioned in Appendix 1-5A, it is plausible that if selection early during 
treatment paralleled initial confounding, then selection during follow-up may have also 
biased against finding associations between lithium and reduced suicide risk during 
active treatment.  In a sense, this study may provide a useful contrast to earlier literature 
in which baseline confounding was expected to be in the direction of finding an 
association between lithium and decreased suicide risk.14  If selection during follow-up 
generally paralleled initial confounding in this early literature, associations between 
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lithium and suicide risk would be expected to overstate lithium’s benefits.  The extra 
significance of the direction of baseline confounding in predicting both the direction of 
bias to the effect estimates from confounding, but also potentially from selection during 
treatment, reinforces the value of identifying cohorts that appear to have minimal 
confounding in future nonrandomized studies of lithium and suicide risk.  
Given that the likely direction of any residual confounding, and potentially 
selection during follow-up, biases against observing any association between lithium and 
reduced suicide risk, this study is more likely to underestimate than overestimate the 
benefits of active lithium treatment.  This aspect of this study should be kept in mind 
when comparing this study to other literature.  
 
Appendix 1-5F.  Recommendations for Clinical Practice Emerging from This 
Study’s Results 
 
This qualitative integration of the evidence from our study supports a number of 
important clinical and research recommendations.  First, the clearest findings from our 
study related to the statistically significantly increased risk of suicide among patients 
discontinuing lithium over the first 180 days of the study.  Although these risks are in the 
likely direction of any residual confounding, the distinct time course of their emergence 
strongly suggest the presence of at least some degree of increased risk being associated 
with lithium, compared to valproate, discontinuation.  These findings indicate that 
patients should be warned about the possibility of experiencing an increased risk for 
suicide should they choose to discontinue their treatment, and that providers should also 
be educated concerning this possible unintended consequence of lithium treatment.  In 
general, persistence with lithium treatment once initiated should be maximized if possible 
and clinically appropriate.  Maximizing persistence may have the dual benefit of 
maximizing any beneficial associations of active lithium treatment with reduced suicide 
risk and minimizing the risks associated with lithium discontinuation.  Useful reviews of 
evidence-based approaches to maximize adherence to mood stabilizers have been 
published.116  Providers should also be educated that, should discontinuation prove 
necessary, gradual, rather than rapid, discontinuation of lithium should be implemented 
when clinically appropriate.  Gradual discontinuation appears to substantially reduce the 
risk of mood episode relapse79, 80 and thus plausibly may also decrease any associated 
suicide risk.  (However, the possibilities that this difference in risk may relate all or in 
part to the characteristics of patients able to discontinue gradually versus those not able to 
discontinue gradually cannot be currently ruled out).  Patients who do discontinue 
treatment should also be educated to monitor themselves closely, and providers should 
monitor such patients closely when feasible.  Such monitoring is already recommended in 
general after mood stabilizer discontinuation.78 
In addition, this study provides several important research recommendations, 
which are discussed further in Appendix 1-7.  
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Appendix 1-6.  Modified Propensity Score Analysis 
As part of the evolution of propensity score methods, concerns have been raised 
that inclusion of variables that are not strongly related to outcome may actually increase 
the impact of confounders not included in the analysis.46, 59  Processes for handling this 
possibility have been debated, but one approach that has been evaluated in the literature 
has been to restrict the propensity score simply to variables with a strong association with 
outcome (e.g. +/-20 %).143  We applied this approach to our data in an exploratory 
analysis focused on the time period with the most statistically significant findings (0-180 
days).  All covariates associated with a univariate OR with suicide of between 0.83-1.19 
were removed from the propensity score (approximately 50% of the total number of 
covariates).  Because of the interest in risk in patients stopping treatment entirely, rather 
than simply modifying treatment, for this exploratory analysis we removed patients who 
modified or resumed their treatment to obtain a “no longer exposed” sample of follow-up 
time from patients restricted to those who discontinued treatment.  The following results 
were obtained, compared to the results for this analysis for the full propensity score 
(given in Table 4, Footnote i, and below). 
Full Propensity Score Analysis:  
Patients Still Receiving Initial Treatment: Conditional Odds Ratio (cOR) = 1.00,  
95% CI 0.5, 1.96; Rate Ratio = 1.01 
Patients No Longer Exposed (i.e., removing patients who modify or discontinue and 
subsequently resume treatment): Odds Ratio = 3.61, 95% CI 1.34-9.73, Rate Ratio = 3.60 
 
Modified Propensity Score Analysis (removing variables not associated with a +/-20% 
change in the odds of suicide from the propensity score): 
Patients Still Receiving Initial Treatment: 0-180 days: cOR = 1.00; 95% CI 0.58, 1.72;  
Rate Ratio = 1.22 
Patients No Longer Exposed:  0-180 days: OR = 3.00; 95% CI 1.19, 7.55; Rate Ratio = 
2.98 
This analysis provides suggestive evidence that the overall contribution of any 
amplification of confounding to the effect estimates may be relatively modest (given that 
only a 24% change in risks among patients discontinuing treatment is observed after this 
substantial change in the propensity score was executed).  Such a finding appears 
consistent with other lines of evidence suggesting that residual confounding amplification 
does not overly impair this analysis (Appendix 1-5B).  The development of methodology 
for assessing the possibility of confounding amplification, however, is still embryonic.  
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That consideration, plus the large role that may be played by statistical uncertainty given 
the wide confidence intervals in this study, means definitive conclusions about the 
amount of residual confounding amplification cannot be reached.  Since propensity score 
methods are specifically sensitive to this potential effect, the possibility of residual 
confounding amplification should be kept in mind in the interpretation of this study’s 
results and during comparisons to previous findings.  
Appendix 1-7.  Suggestions Concerning Future Research  
Despite this study’s unprecedented size, one fundamental conclusion of the study 
is that further research concerning the associations between lithium and suicide risk needs 
to be vigorously conducted.  Even without this study, differences between recent and past 
randomized and nonrandomized research suggest that questions remain concerning the 
degree to which lithium treatment may be associated with reduction in suicide and 
suicidal behavior risk.  Furthermore, there is an increasing awareness among healthcare 
researchers that nonrandomized studies may easily contain confounding bias related to 
the characteristics of those patients, even within specific diagnostic categories, that are 
chosen to initiate one medication compared to another, despite efforts to rigorously 
control for measurable patient differences.  Mental health research may be particularly 
sensitive to this potential confounding.  As we indicate, despite the extensiveness of our 
covariates, like virtually all of its predecessors this study lacks extensive information 
concerning several potential confounders such as suicidal ideation, planning and means, 
psychiatric symptoms, and recent stressors.   
Nevertheless, our study, through its inclusion of intent-to-treat and post-
discontinuation risk estimates, will hopefully serve to help focus future mental health 
research into the question of lithium and suicide risk.  First, this study has indicated that 
increased investigative focus should be placed on examining the possibility that lithium 
treatment, in cohorts with very high discontinuation rates, might actually increase overall 
(intent-to-treat) risks of suicide in the short term, if it is determined that lithium 
discontinuation does indeed pose greater acute suicide risks than valproate 
discontinuation.  Second, however, our results remain compatible with the possibility that 
active treatment with lithium may be associated with substantial reductions in suicide 
risk.  This also should be the focus of energetic follow-up research, especially since 
relatively few effective interventions against suicides are known, including among 
medications.  Consider, for instance, that if sufficient residual confounding and/or 
selection during follow-up biasing against lithium persists in our analysis to conceal a 
protective association of lithium with suicide even on par with that of clozapine (HR = 
0.76) for suicidal events, lithium would likely be a much more valuable intervention.  
This potential value arises from lithium’s potential impacts on suicide mortality (not 
observed for clozapine28), use across a broader range of psychiatric diagnoses, and much 
less burdensome monitoring requirements. 
This study has reemphasized the need to become even more rigorous about 
attempting to control for confounding at baseline, given that imbalances appear to persist 
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in the factors (e.g., diagnostically-coded suicidal ideation) not able to be included in the 
propensity score (despite very tight balance being achieved in numerous other 
covariates).  Such additional research could take several forms.  Randomized trials, 
although challenging to execute, would undoubtedly provide the most rigorous, 
unconfounded answer regarding the effectiveness of lithium and comparison medications 
against suicidal behavior, if such trials can be conducted practically (numerous 
participants would be needed), safely (recommendations how to do so have been 
advanced),28, 144 and ethically (i.e., through comparisons with genuine equipoise).  
Instrumental variables such as prescriber preference variables129 may also be valuable to 
investigate, given the potential capability of instrumental variables to balance 
unmeasured factors.  Not all the assumptions underlying instrumental variable analysis, 
however, can be rigorously tested.  Nevertheless, in other treatment studies in which 
unmeasured confounding was suspected, instrumental variables produce effect estimates 
closer to those obtained by randomized trials than propensity score methods.145  Chart 
review study designs,146 potentially combined with marginal structural models to address 
medication, risk factor, and suicidal ideation changes during follow-up, would likely 
constitute a useful enhancement in cohorts with substantial discontinuation of treatment.  
Addressing factors such as suicidal ideation, planning, and means, recent 
stressors, and recent or current psychiatric symptoms will not be simple, and likely will 
entail potentially laborious manual chart reviews unless effective automated methods to 
identify these factors can be developed.  It seems likely that case-control or case-cohort 
designs may need to be adopted to reduce the total number of charts to be reviewed to a 
feasible number. 
In addition, research is needed into how to optimize selection strategies for 
variables in propensity scores to maximize their benefits in reducing confounding while 
minimizing potential confounding amplification.  This would be especially valuable for 
studies of suicide risk, since suicide risk is sufficiently multifactorial that approaches 
such as propensity scores using extensive covariates will likely continue to be desirable.  
Finally, our study has illustrated the importance of subsequent research adopting 
methodology such as marginal structural models* that will help facilitate examination of  
_________________ 
*Because marginal structural models allow a sample to be periodically rebalanced in risk 
factor composition over time, they may also prove valuable for investigating one further 
finding from our study.  Although not statistically significant and therefore potentially 
incidental, the finding of consistently lower suicide rates in the valproate cohort after 
discontinuation of valproate than during valproate treatment (Table 2-3, 0-365 day results 
for the period after stopping/modifying initial treatment, and Table 4, 0-180 day results 
for the period after stopping/modifying initial treatment) deserves further investigation 
given the US FDA labeling warning concerning the possibility of increased suicidal 
ideation or behavior during anticonvulsant treatment (primarily on the basis of data 
compiled from patients with epilepsy).  Another explanation may be that some of the 
patients subsequently switched treatment to lithium.  If this were the case, it would be 
another suggestive finding of some association between lithium and reduced suicide risk.   
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outcomes over longer follow-up periods.  Studies over longer follow-up could prove  
any time-varying components to this risk may have largely resolved by that point.  
Rebalancing on measured factors at that point (i.e., 6 months or one year after initiation) 
and starting follow-up might be one approach to particularly limit confounding in  
useful for two reasons.  First, it is possible that the associations between lithium or 
comparison medications and suicide risk strengthen or weaken over time.  Second, if 
baseline confounding is substantially time-varying, periods later in follow-up may have 
less confounding, as some of our findings suggest. 
 However, while chart review approaches might provide improved information 
about suicidal ideation, psychiatric symptoms, and stressors, such information would 
almost certainly be still incomplete.  For this reason, among nonrandomized studies either 
instrumental variable analysis (as mentioned above) is likely to be particularly valuable, 
or cohort studies or nested case control studies from cohorts large enough and with 
sufficient adherence that substantial numbers of patients continue to receive initial 
treatment for more than just 6 months - 1 year after initiation.  It is plausible that if 
patients were directed to one medication or the other on the basis of suicide risk initially, 
nonrandomized studies of lithium and comparison medications.  The advantages of a 
patient sample that might be largely devoid of confounding might outweigh concerns that 
the results would be the most strictly generalizable for the rather select population of 
patients who are adherent to the medications for 6 months or more.  
Large cohort studies may also provide also valuable information for other reasons 
besides simply whichever methodological enhancements may be applied.  Cohorts with 
greater adherence in general would provide greater power to detect any reductions in 
suicide risk associated with active lithium treatment (although power to examine risks in 
patients discontinuing lithium would then be lessened).48  Research in some international 
settings for which lithium treatment remains more routine also may potentially yield 
lower levels of baseline confounding than studies in the United States, in which only a 
decided minority of patients receive lithium.  As studies become more sophisticated and 
as sample sizes continue to increase, consideration should be given to incorporating 
information both about dose and compliance based on additional information besides 
prescription records (e.g., serum blood levels).  Regarding dose, one approach might be 
requiring a minimum dose for study entry (similar to how we excluded “as needed” use 
of lithium or valproate, use of lithium or comparison medications below a certain 
threshold dose might be excluded).  More useful might be categorizing doses into a “high 
dose” (i.e., equal or above the median dose) and “low dose” strata.  Such determinations 
may become complicated as patients shift from one status to another over time, although 
perhaps this could be reflected in marginal structural models or similar approaches.  
Ideally, judgments concerning dose should take into account a patients’ age (and possibly 
weight), since lower doses are routinely and appropriately used in older patients.  As an 
extreme, formulas exist to calculate expected lithium serum levels based on renal 
function and other factors, but it is uncertain how valuable this level of precision may be, 
given that patient fidelity with dosing recommendations usually cannot be ascertained.  
Serum blood levels can reflect adherence at certain points, but it is unclear how often that 
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determination will be made close to a point of clinical interest (i.e., an outcome such as 
suicide or suicidal behavior).  Such a determination may often occur close to at least 
some of the decisions to modify dose, however.  Serum blood level information may have 
to be used more qualitatively to determine whether patients appear to have histories of 
good or poor treatment persistence in the study, or perhaps examined most closely in 
subsamples in which the information is available close to a point of clinical interest.   
Given the possibility that lithium may increase suicide risks upon discontinuation 
for some period of time, nonrandomized research should also strive to incorporate an 
intent-to-treat perspective that ascertains outcomes for individuals both receiving and no 
longer receiving their initiated treatment.  Such an approach will also help facilitate 
comparisons to randomized research. 
It is hoped that the study reported here will help contribute to continued 
improvements in the investigation of the associations of lithium, and other psychiatric 
medications, with either decreases or increases in suicide risk.  This treatment question is 
clearly of the utmost importance to patients and providers alike. 
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(Additional information of particular relevance to Chapter 3) 
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Appendix 2-2.  Diagnostic Codes Included in the Cohort  
 
The databases used in this study were initially developed for use in tracking 
delivered care to a broad collection of VHA patient with depressive or psychotic 
disorders.  Because of this, a considerable range of diagnostic codes were included during 
database construction.  To maximize power and because existing literature suggested than 
any mortality advantages for lithium might span a variety of diagnoses,12, 84, 86, 90  we 
decided to retain this broad group of included diagnoses.  Virtually all cohort members 
had received a diagnosis of bipolar I, II, NOS, Depression NOS, major depressive 
disorder, schizophrenia, schizoaffective disorder, or “other psychoses” within the past 30 
days.  Furthermore, the prevalence of these diagnostic categories were highly similar 
between the two matched treatment groups (i.e., within a standardized difference of < 
0.019).  Specifically, however, patients could enter the cohort if they had received any 
one of the following ICD-9 codes in the 30 days prior to lithium or valproate initiation:  
(more common) 296.0-296.99, 311, and 295.0-295.9, (less common): 297.0-297.3, 297.8-
297.9, 298.0-298.4, 298.8, 300.4, 301.12, 309.0-309.1, and 293.83.  For more details the 
interested reader is referred to Appendix 1-1. 
 
 
Appendix 2-3.  Components of Former User Risk  
Former user risks have been proposed as a potential indicator of confounding49 or 
selection (if confounding has been adequately addressed).48  However, in actuality 
differences in former user risks between treatment groups have the potential to be 
composed of a complex combination of residual confounding, differential selection 
during treatment, differential discontinuation-associated risks, and any difference in 
persistent effects from treatment.  How often all of these components substantively 
contribute to former user risk is unclear. 
Stated another way, a former user risk (e.g., odds ratio, hazards ratio) of 1.0 is 
compatible with an absence of confounding, but does not establish this.  Similar former 
user risks cannot establish an absence of confounding if substantial selection during 
follow-up, discontinuation-associated risks, or persistent effects from active treatment are 
present.  However, former user risks can still have considerable investigative value.  As 
former user risks gets further from a null value (1.0), it is clear that the presence of 
confounding, selection, and/or persistence and discontinuation effects becomes 
increasingly likely, while analyses that achieve former user risks of close to 1.0 may or 
may not have these substantial effects or biases.  However, since two or more strong 
biases or effects can potentially co-occur in opposite directions even if the former user 
risk approximates 1.0, a lack of strong biases can never be definitively concluded on the 
basis of former user risks alone.  
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Appendix 2-4.  Aspects of the High-Dimensional Propensity Score Implementation 
Our approach generally followed the original high-dimensional propensity score 
(hdPS) method used by Schneeweiss and colleagues,41 with the following exceptions: 
1) No automated variable construction or selection based on a combined measure of 
association with exposure and outcome was performed.  Instead initial variables 
were constructed from most entries in a category (e.g., clinic visits, medications, 
etc.), except those that were the least common (see below).  Selection was later 
imposed for the outcome-focused propensity score based solely on associations 
with outcome, not with exposure.  A few variables were also removed, as 
described in Appendix 2-6, relating to very specific measures of past mood 
stabilizer use which appeared likely to potentially act as instrumental variables. 
2) Although limited screening for covariate prevalence was done (few variables were 
included if present in <1% of the sample), no limitation was placed on whether 
that a covariate needed to be present in 5% of the patient sample as in the original 
hdPS method.41  This was because mortality is an infrequent outcome affecting 
only a small subsample of the cohort, thus even a covariate of low overall 
prevalence may contribute to a substantial portion of deaths.  Some important 
covariates judged particularly important a priori (e.g., current warfarin 
prescription, cardiac catheterization in the last 180 days, or age ≥ 80 years old) 
were included even if present in an overall prevalence of 1% or less.  
3) For clearly important variables, a more detailed coding of frequency of 
occurrence was undertaken than just the absence, presence at < median frequency, 
presence at greater > median frequency, and presence at > 75th percentile 
frequency used in the original hdPS method. 
4) Greater temporal detail than in the original hdPS method was included for some 
variables by coding several different time periods for hospitalizations, total 
provider visits, and other general utilization variables, as well coding frequency in 
two time periods for specific clinic visits (0-180 days and 181-365 days) and 
medications (current prescriptions and recent, but not current, prescriptions [last 
days supply ending within the last 180 days]).  This strategy was implemented to 
make information about recent care that might contribute baseline mortality risk 
less dependent on the exact relationship of the medication initiation date to receipt 
of medications or services.  In addition, this approach might include more detailed 
information that may be relevant to recent adherence behavior.   
 
 
Appendix 2-5.  Summary of Variables  
The following Table summarizes the variables in the initial high-dimensional 
propensity score:
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Appendix 2-5 Supplementary Table 1.  Summary of Variables Included in the Initial High-
Dimensional Propensity Score (forming the basis of those variables selected for the Outcome-
Focused Propensity Score) 
Type of Patient 
Characteristic Covariates  
General Covariates 
Demographics 
 
10 Covariates (49 indicators) including age (11 5-year categories), sex, self-
reported Race (6), ethnicity, marital status (4), income(6), Disability Status(4), 
distance to VA facility (4), urban/rural hospital location, and fiscal year of 
medication start (11)  
Presenting 
Diagnosis 
 9 Covariates denoting psychiatric diagnosis in the past 30 days: Bipolar I, Bipolar 
II, Bipolar NOS, Major Depression, Depression NOS, Schizophrenia, 
Schizoaffective Disorder, Other Psychoses, and ≥ 2 of these diagnoses 
NonMental Health Covariates 
General Utilization Total number of current prescriptions, possibly discontinued prescriptions (expired 
in last 30 days) and recently discontinued prescriptions (expired from 31-180 
days), Total number of Provider, Specialist, Surgical, ER Visits, and Inpatient 
Stays (over from 1- 3 different time periods), number of lab visits in last year, 
receipt of a flu shot in last year 
 Diagnoses 
 
 41 Variables (44 indicators) relating to diagnoses in the past year, including Total 
Charlson Comorbidity (CCM) conditions (4 levels), 13 individual CCM Categories 
(MI, CHF, PVD, CEVD, COPD, Conn Tissue Dz, Peptic Ulcer, Mild Liver Dz, 
Mod/Sev Liver Dz, DM w/o complications, DM w/ complications, Renal Dz, 
AIDS/HIV), 11 individual Elixhauser comorbidity categories nonredundant with 
CCM categories (Arrhythmia ,Weight Loss, Coagulopathy, Pulmonary Circulation 
Dz, HTN, Valve Dz, Neurodegenerative Dz, Hypothyroid, Obesity, Anemia from 
Blood Loss, Deficiency Anemia), and 16 additional diagnostic categories (e.g. any 
fracture, hip fracture, neuropathic pain, back pain, internal injuries, open wounds, 
etc.), and a Recent Smoking indicator combining Tobacco Dependence diagnosis 
or treatment)  
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Appendix 2-5 Supplementary Table 1.  (continued) 
Current Medications 54 covariates representing current prescriptions for specific medications or 
medication classes, including antiarrhythmic, several antibiotics and 
antihypertensive classes, warfarin, antiplatelet agents, statins, oral diabetes 
medications, HepC medications, opiate pain medications, low and high dose 
aspirin, NSAIDS, acetaminophen, inhalers, GI protectants, and other medications  
Recent Medications 55 Covariates representing medication/medication classes prescribed in last 180 
days but not active on initiation date.  Includes 52 of the 54 the current medication 
classes, plus vancomycin, antinausea medications, and bandages.  
Hospitalizations 
 
41 Covariates denoting both the presence of specific types of VHA discharges in 
the last two years (e.g., Medical ICU, Surgical ICU, Cardiology, Cardiac 
Stepdown, Telemetry, General Medicine, 8 types of surgical hospitalizations, etc.).  
An additional set of variables were constructed to indicate the specific type of 
discharge which constituted the most recent VHA discharge.  Additional 
covariates addressed how recently the latest VHA hospitalization preceded 
medication initiation and the presence of any discharges against medical advice in 
the past year.  
Outpatient Providers 
Visited 
156 Covariates (300 indicators) denoting frequency (typically 0/1/2+ visits) of a 
large variety of outpatient clinics visited in the last 180 days and in days 181-365 
prior to initiation.  These include specific medical specialties, specific surgical 
specialties, anticoagulation clinic, outpatient pharmacy consultation, physical 
therapy, pacemaker and cardiac catheterization clinics, weight loss clinics, and 
nonmedical specialty services such work therapy and chaplain visits.  
Diagnostic Tests 9 covariates (16 indicators) for frequency of tests in prior year, including X-Ray 
(3), CT/MRI(3), EKG (3), Echocardiogram, Ultrasound, Endoscopy, Nuclear 
Medicine, PFT, and Angiogram.  
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Appendix 2-5 Supplementary Table 1.  (continued) 
Substance Abuse 
Diagnoses 
41 variables diagnoses in the past year of alcohol, amphetamine, cannabis, 
cocaine, opioid, sedative, stimulant, hallucinogen, and other/unspecified 
substance categories abuse or dependence.  For each substance, 4 variables 
were constructed reflecting the diagnoses categories of abuse, dependence, 
remission from abuse, and remission from dependence.  In addition, variables 
were constructed to reflect combined drug dependence (with or without opioids), 
alcohol intoxication, and alcohol psychosis. 
Substance Abuse 
Treatment 
11 variables (19 covariates), including frequency of individual or group substance 
abuse treatment in last 180 days or days 181-365 prior to initiation, and current or 
recent prescription of disulfarim, naltrexone, buprenorphine, or methadone.]  
Other Psychiatric 
Covariates  
Numerous covariates including General Mental Health Utilization variables, 
comorbid psychiatric diagnoses, current psychiatric medications, recent 
psychiatric medications, number, type and timing of recent psychiatric 
hospitalizations, recent diagnosed suicide attempts, and types of psychiatric 
outpatient clinic utilization (e.g., psychiatry, psychotherapy, PTSD-focused, etc.) 
Aggregate Mortality 5 indicators denoting age and sex-adjusted state mortality risk, derived from CDC 
data, grouped into 5 categories (approximate quintiles). 
VHA Hospital 
Network Mortality/ 
Quality of Care 
6 indicators denoting categories of rate of risk-adjusted mortality for the VA 
Integrated Service Network (VISN) where patient received care.  (Categorization 
based on data reported in Reference 16). 
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Appendix 2-6.  Derivation Process for Variables  
This appendix is provided to document for interested readers how the additional 
covariates in the nonsuicide mortality high-dimensional propensity score were derived 
(the state all-cause mortality rate variables and the VHA VISN risk-adjusted mortality 
variables).  For the remainder of the variables, the reader is directed to Appendix 1-2.  
These variables form the basis from which the 523 covariates in the outcome-focused 
propensity score were selected.  The selection process for the outcome-focused 
propensity score variables is also described.   
 
Geographic All-Cause Mortality Risk: Indicator variables were constructed to classify 
patients into 5 categories (approximate quintiles) of age-adjusted regional (state-level) 
mortality risk, based on publically available data from the Centers of Disease Control for 
the years 2000 and 2007.134  Because these statistics would include the deaths of Veterans 
occurring in this period, there is the potential for control for “predictors” that include 
outcome-related information, but this bias is expected to be exceedingly small, given the 
large number of deaths that occurred across these states over eight years, and our sample 
accounted for less than 600 nonsuicide deaths over that period.  A geographic all-cause 
mortality indicator was included to guard against the possibility of regional differences in 
prescribing patterns creating a spurious association between treatment and mortality.  
 
VHA Hospital System (VISN) Mortality Risk:  Indicator Variables were used to 
classify patients into 6 categories of risk-adjusted (age, gender, Charlson Comorbidity 
Index, perceived physical health, and perceived mental health) all-cause mortality risk, 
using information from VA surveys administered in 1998 and 1999.100  Although this 
information is most accurate for the very beginning of the study period (mid-1999), it 
was judged that having some indicator of both mortality variation among VA Hospital 
Systems would be helpful.  While the relationship between all-cause mortality and 
quality of care is controversial, such variables might help limit possible spurious 
associations between a treatment and mortality due to general tendency for hospitals 
providing higher- or lower- quality care to have providers who favored one or the other 
treatment.   
 
Selection of Covariates for the Outcome-Focused Propensity Score: Covariates were 
selected with an association with mortality of +/- 20 percent (odds ratio of ≥ 1.2 or ≤ 
0.83), as has been done previously.102  Determining whether a dichotomous variable has a 
20% association with mortality is generally straightforward, however for covariates with 
more than two possible levels (e.g., age), determining which variables are included or 
excluded becomes more of a matter of judgment.  Either highly restrictive (requiring all 
categories of the variable to have an association with mortality of ≥ 20%) or highly 
permissive criteria (requiring only 1 category of the multilevel variable to have an 
association of ≥ 20%) could be envisioned.  We adopted a compromise approach in 
which multilevel variables were included in the outcome-focused propensity score only if 
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a majority of level of that variable had a +/- 20% odds ratio association with nonsuicide 
mortality, except for a very few limited exceptions.    
 
 
Appendix 2-7.  Initial Propensity Score Results 
Matching upon the initial propensity score produced results that appear to be 
consistent with some degree of “amplified confounding.” 46, 59  For this reason we chose 
to report the outcome-focused propensity score results throughout the manuscript as 
likely more unbiased.  However, for completeness, we report the initial propensity score 
results here and compare these results to Tables 3 and 4 of the manuscript. 
Comparing the former user values between the initial and outcome-focused 
propensity score-matched analyses suggests that the outcome-focused propensity score is 
less confounded than the initial propensity score: At 90 and 365 days the former user 
hazard ratios are closer to 1.0 for the outcome-focused propensity score than the initial 
propensity score (central estimate HRs 0-90 day: 0.88 (outcome-focused score) versus 
0.67 (initial score); 0-365 days: 1.02 (outcome-focused score) versus 0.84 (initial score).  
This pattern does not hold for 0-180 days, but in this case the results are consistent with 
potential discontinuation risks being attenuated by the presence of greater confounding 
for the initial propensity-score matched cohort in the direction of better outcomes for 
lithium (central estimate HR = 1.19 versus 1.54 for the outcome-focused score).  In 
addition, the initial propensity score intent-to-treat and former user hazard ratios over 0-
90 and 0-365 days are more similar than the outcome-focused propensity score hazard 
ratios to the hazard ratios observed prior to propensity score matching (Appendix 2-9).  
This suggests greater residual confounding for the initial propensity score matched 
cohorts.  Since this analysis includes more covariates, this suggests a greater 
amplification of unmeasured/incompletely measured confounding as some have 
suggested can occur with control of measured covariates not substantially associated with 
outcome.46, 101  Interestingly, the as-treated initial propensity score results are not closer 
to the unmatched results than the outcome-focused results, a finding that suggests some 
contribution from random error or that the effects of amplified confounding/less 
important covariates may warrant more theoretical or empirical investigation.  
Also of note, the former user risks of HR = 0.84 over 0-365 days actually exceeds 
in magnitude the intent-to-treat risk estimate.  This same pattern is observed over 0-90 
days.  This pattern of risk suggests that the initial propensity score intent-to-treat risks 
may be largely or even initially explained by confounding, and that the former user risks 
is made up of substantial confounding combined with an additional element (e.g., random 
error). 
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APPENDIX 2-7 SUPPLEMENTARY TABLE 1.  Risk of Nonsuicide Mortality  
(Intent-to-Treat Cohort, Initial Propensity Score-Matched) 
Time Period 
Hazard Ratio (Lithium/Valproate) 
Intent-to-Treat 
During Initial 
Exposure 
(As-Treated) 
Subsequent 
Nonexposure 
(Former User) 
0-90 Days 0.72
a 
(0.55-0.95) 
0.81 
(0.57-1.14) 
0.67 
(0.35-1.25) 
0-180 Days 0.97
b 
(0.82-1.15) 
0.83 
(0.61-1.12) 
 
1.19 
( 0.80-1.77 ) 
 
0-365 Days 
0.87c 
(0.77-0.97) 
0.77 
(0.57-1.03) 
 
0.84 
(0.65-1.07) 
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Appendix 2-8.  Propensity Score Matching Details 
 Our propensity score matching was performed using greedy-matching involving 
freely available SAS code from the Mayo Foundation for Medical Education and 
Research99 as well as SAS code from Fairies et al., Chapter 3 of the SAS Press book 
“Analysis of Observational Health Care Data Using SAS.”61  
Because it is not part of this published code, we did not trim our propensity score 
cohorts to a “Common Support Area” prior to matching.  Perhaps due to the large 
preponderance of patients initiating valproate compared to lithium and the wide, 
overlapping propensity score distribution for both medications, very few patients fell 
outside the “Common Support Area.”  This is reflected by the fact that use of fairly 
standard 0.2 propensity score logit calipers resulted in a narrow propensity score range 
while including virtually all lithium-treated patients.  We more precisely established this 
for our highly similar analysis of suicide mortality.  This analysis also involved nearly 
complete matching of lithium-treated patients, and these patients were matched using a 
propensity score that included 98% of the covariates included in the initial propensity 
score for this study.  For this similar analysis, we established that exceedingly few 
patients fell outside of a Common Support Area (only 0.05% [lithium-treated patients] to 
0.12% [valproate-treated patients] of the entire unmatched cohort).   
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Appendix 2-9.  Mortality by Treatment in the Unmatched Cohort and Implications for Confounding 
Appendix 2-9 Supplementary Table 1.  Risk of Nonsuicide Mortality over 365 days, by Treatment 
Analysis 
(incident Users) 
Hazard Ratio (Lithium Versus Valproate) 
(95% Confidence Interval) 
Intent-to-Treat 
Sample 
Stratified by Exposure Status 
During Initial 
Exposure 
(As-Treated) 
During 
Subsequent 
Nonexposure 
(Former Users) 
Unmatched Cohort 
0.74a 
(0.65-0.84) 
0.58a 
( 0.45-0.74) 
0.77a 
(0.63-0.94) 
Outcome-Focused High-Dimensional 
Propensity-Score Matched Cohort 
0.92a 
(0.82-1.04) 
0.59a 
(0.53-0.97)  
1.02a 
(0.79-1.32) 
a P values are: p<0.0001 (Intent-to-Treat), p<0.0001 (Current Users); p=0.011 (Former Users) 
b P values are: p=0.173 (Intent-to-Treat); p=.028 (Current Users); p=0.888 (Former Users) 
 
Of note, for each effect estimate the outcome-focused high-dimensional propensity-score matched cohort produced 
estimates in the direction of reducing the effect sizes from the unmatched analysis each of which indicated a stronger 
association with worsened outcomes among patients initiating valproate.  (However, this change in estimates between the 
unmatched and matched analyses was minimal for the as-treated effect estimate).  These findings suggest confounding in the 
overall cohort is in the direction of patients who are less medically ill preferentially receiving lithium (i.e., patients having less 
risk of nonsuicide mortality at baseline, prior to treatment initiation).  As a result, the unmatched associations show stronger 
effect sizes favoring lithium treatment than the matched analysis.
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Appendix 2-10.  Persistence with Treatment at 90, 180, and 365 days 
Appendix 2-10 Supplementary Table 1.  Censoring of Patient Cohorts at 90, 180 and 365 days  
(Outcome-focused Propensity Score Matched Cohort) 
Treatment 
Status 
0-90 Day Follow-up 0-180 Day Follow-up 0-365 Day Follow-up 
Lithium Valproate Lithium Valproate Lithium Valproate 
N (%) N (%) N (%) N (%) N (%) N (%) 
Still 
Receiving 
Initial 
Treatment 
9967 46.8 9852 46.3 5012 23.5 5086 23.9 1621 7.6 1723 8.1 
Discontinued 
Initial 
Treatment 
10501 48.7 11046 51.3 15220 71.5 15699 73.8 18445 86.7 18974 89.1 
Initiated 
opposite 
mood 
stabilizerb 
773 3.6 321 1.5 987 4.6 415 2.0 1133 
 
5.3 
 
470 2.2 
Suicide 
Mortality  15 0.07 15 0.07 17 0.08 16 0.08 18 0.08 20 0.09 
Nonsuicide 
Mortalityc 32 0.15 54 0.25 52 0.24 72 0.34 71 0.33 101 0.47 
 
a n= 21288 propensity-score matched pairs 
b i.e., switched directly from lithium to valproate or directly from valproate to lithium  
c Because this Table row reflect patients censored due to nonsuicide death occurring before  any treatment impersistence, they are equivalent to the “as-
treated” counts. 
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Appendix 2-11.  Numerical Illustration Concerning Possible Residual Confounding 
As an example, at 180 days the intent-to-treat HR (central estimate) of 0.97 
suggests that residual confounding of only approximately 3-4% lower baseline hazard of 
mortality at baseline (prior to medication initiation) among patients initiating lithium 
would be sufficient to yield a central estimate of increased, rather than decreased, 
mortality risk among all lithium initiators over the first 180 days of treatment.  Slightly 
more confounding would be necessary to yield a central estimate of increased risk over 0-
365 days.  Statically, the confidence intervals already preclude definitive conclusions 
concerning net harms or benefits of lithium compared to valproate for these periods.  
Notably, the intent-to-treat associations over 0-180 days includes the period of strong, 
statistical significant intent-to-treat associations between lithium initiation and lower 
mortality risks from 0-90 days. 
 
 
Appendix 2-12.  Expected Decrease over Time of Intent-to-Treat Effect Sizes 
Perhaps nonintuitively, if a genuine medication effect exists during active 
treatment, it can be generally expected that intent-to-treat estimates will predictably 
weaken over time in a well-controlled analysis.  This is because an increasing number of 
“as-treated” individuals can be expected to discontinue medication treatment over time.  
As a result individuals “no longer exposed” to the study intervention constitute a greater 
and greater percentage of total follow-up time.   
However, an important point is worth noting.  First, as more and more cohort 
members become nonexposed, their risk actually converges on an intent-to-treat estimate 
that reflects confounding (as well as any discontinuation-associated risks and random 
error), not necessarily a true null value (HR=1.0).  For this reason, intent-to-treat 
estimates may not always weaken over time as treatment persistence decreases (for 
example, in this study, the 0-365-day HR = 0.92, 95% CI 0.82, 1.04]) is further from 1.0 
than the 0-180-day HR = 0.97, 95% CI 0.82, 1.15).  Thus, the possibility of residual 
confounding should be considered whenever a pattern of weakening intent-to-treat 
estimates over time is not observed.  While the differences observed in this study are 
within the realm of random error, it should be remembered that the two hazard ratios are 
not estimating the same quantity; because, proportionally, considerably less as-treated 
and considerably more former user follow-up time is present over 0-365 days than 0-180 
days.  Thus, the expectation would be that the 0-365 day intent-to-treat central estimate 
effect size would show even a smaller association favoring lithium, not a slightly large 
one.  The fact that this effect estimate reverses in direction from the 0-180 day central 
estimate, even though substantial random error is present in the comparison, may be 
notable.  
From a related perspective, the rapid increase in central estimate of the hazard 
ratio from 0-90 days to 0-180 days implies an actual increased risk among patients who 
previously initiated lithium during the period of 91-180 days.  Interestingly, this is the 
163 
 
 
 
general pattern of risk we observed in a related study of suicide mortality drawn from the 
same unmatched cohort (Chapter 2).  Our secondary analysis of former user risk suggests 
a possible reason for this increased risk associated with lithium initiation: a sufficient 
number of former users experiencing some substantial risk associated with lithium 
discontinuation to potentially outweigh any benefits experienced by the minority of 
patients who remain on initial lithium treatment during this period.  
 
Appendix 2-13.  Evidence for and against Selection During Treatment 
On theoretical grounds, selection during treatment could plausibly explain the 
reduced risks in as treated patients and enhanced risk among patients discontinuing 
lithium.  This would occur if a greater number of medically ill patients had their lithium 
treatment stopped because of their deteriorating condition than medically ill patients 
receiving valproate.  In essence, this differential selection would serve to transfer a 
greater number of high-risk patients receiving lithium treatment than receiving valproate 
treatment to the category of individuals having discontinued treatment.  That is, a greater 
number of lithium-treated patients change status from being counted as “as-treated” 
individuals to being counted as “former users.” 
 However, this phenomenon, unless the selection was based primarily on adverse 
medical risks caused by the medications themselves, would not easily explain the 
changes in intent-to-treat risks, nor the consistency of the as-treated risks observed. 
Finally, this possibility is also rendered less likely by the very similar rates of medication 
discontinuation observed between the treatment groups receiving the two medications 
over time.  However, as others have pointed out, this line of reasoning is not firmly 
conclusive since patients may discontinue medications at the same rate but for different 
reasons.48  
Furthermore, a simple model combining confounding and selection (i.e., positing 
no medication effects on either risks during active treatment or after discontinuation) 
does not appear sufficient, since in such a model, in order to explain the intent-to-treat 
findings, confounding would have to change direction from 0-90 and 91-180 days, and 
then change direction again, to explain the 0-90, 0-180, and 0-365 day intent-to-treat 
estimates observed.    
It is possible, of course, that random variation does contribute to the 90, 180 and 
365 day estimates and perhaps enhances the differences between them, producing 
spurious changes in direction of the estimates.  However, the probability random error 
explains the difference between the 0-90, 0-180, and the 0-365 day intent-to-treat 
estimates entirely (i.e., in the absence of residual confounding or genuine medication 
effects during treatment or upon discontinuation), or to the differences between the 0-90, 
0-180 and 0-365 day former user risks entirely, would be considerably less than 50%.   
Thus, the simplest consistent interpretation of the outcome-focused results is that 
some level of overall residual confounding biasing against valproate persists in the 0-365 
day analyses, although it is not the only contributor to the risk estimates.  When 
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dissociation-associated risks and/or (less likely) selection effects weaken from 0-180 days 
to 0-365 days, any confounding might then serve to “pull” the former user risk much 
closer to the null over a relatively short period, and make the intent-to-treat estimates 
more negative.  
 
 
Appendix 2-14.  The Value of Lithium Treatment Persistence 
A corollary exists to the interpretation given above that some level of residual 
confounding is likely in the analysis is biasing towards lower mortality risk among 
patients initiating lithium.  That corollary is that the assessment of whether patients 
initiating lithium are at greater or lesser mortality risk when all associations (active 
treatment and dissociation-associated) are considered is made more complicated.  This is 
especially true because the margin of beneficial association observed at 0-180 and 0-365 
days is generally small.  That is, as pointed out in Appendix 2-11, even small to relatively 
small levels of residual confounding (for the 0-180 day and 0-365 day analyses, 
respectively) would be sufficient to conceal any overall hazardous treatment effects 
associated with lithium compared to valproate.  For this reason, we note in the manuscript 
that further research is clearly needed and caution should be exercised regarding any 
judgments of whether greater or lesser lithium use would be desirable. 
However, the recommendation for increasing persistence with lithium treatment is 
clearly indicated by the data, regardless of this uncertainty.  Whether lithium is reducing 
mortality risks (relative to valproate) during active treatment, or increasing mortality risks 
upon discontinuation, or both, in any of these scenarios increasing persistence with 
lithium treatment should result in mortality benefits.  Put another way, regardless of 
whether the net impact of lithium over the entire follow-up period leads to lesser or 
greater mortality risks than initiation of valproate, once the decisions has been made to 
initiate lithium, boosting persistence with lithium would be indicated and beneficial.*  
This is because the study suggests that lithium has at worst a neutral effect during active 
treatment and potentially a beneficial effect, whereas any hazards from lithium treatment 
relative to valproate appear to occur upon discontinuation.  Emphasizing treatment 
persistence would have the effect of increasing any benefits experienced during active 
treatment and reducing any risks resulting from discontinuation.  Regardless of which  
 
 
_________________ 
 
* One possible exception to this principle exists.  If confounding biasing against 
valproate is so great that a net hazard is associated with even active lithium treatment, 
then depending on this magnitude of this hazard, it may be worth even in the short term 
the patient discontinuing lithium and suffering potential short-term discontinuation 
hazards.  While our data, being observational (nonrandomized) cannot exclude this 
possibility, it is not substantially supported from the study findings.   
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risk predominates, once a decision is made to initiate lithium, efforts to boost treatment 
persistence when feasible appear likely to benefit the patient.  
 
Appendix 2-15.  Challenges in Completely Modeling Important Risk Factors 
 
It is important to recognize there is inherent difficult in capturing a fully desirable 
amount of information concerning some types of variables.  Hospitalizations prior to 
medication initiation are an example.  We chose to model these hospitalizations in three 
ways: multiple indicators for the overall number of recent nonmental health 
hospitalizations, whether any hospitalization of a particular type (e.g., ICU, cardiac, etc.) 
had occurred in the past 2 years, and what type of hospitalization had occurred most 
recently prior to medication initiation.  However, it can be easily conceptualized that 
near-complete modeling of hospitalizations experienced by the patient in the last two 
years might have included the timing and number of days preceding medication initiation 
for every hospitalization type, and potentially length of stay as well.  Furthermore, 
indicators concerning whether multiple hospitalizations of the same type had occurred 
and how separated in time the repeat admission were might be desirable.  And of course, 
as pointed out in the manuscript, hospitalizations may occur outside the VHA system for 
which we have no information.  For these types of variables, at some point practical 
decisions must be made concerning what detail in modeling is appropriate, along with the 
realization that incorporation into the model of complete information likely can never be 
achieved.  
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